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Staphylococcus aureus (Sau) is frequently identified to colonize the mucosa and skin 
compartments in humans. Invasive Sau infection induces acute episodes of inflammatory 
diseases, such as pneumonia, bacteremia and skin abscesses. In asymptomatic Sau carriers, 
superantigenic Sau (SAg-Sau) infection has been closely associated with several autoimmune 
diseases, including Wegner’s granulomatosis (WG), multiple sclerosis (MS) and rheumatoid 
arthritis (RS). 
SAg-Sau induces polyclonal T cell activation and activates pro-inflammatory responses 
leading to inflammatory pathologies. IL-17A-producing CD4+ T cells (Th17) are identified as a 
major pro-inflammatory T cell subset causing autoimmune pathogenesis, which can also be 
activated by SAg-Sau stimulation. T cell-mediated immune tolerance is well appreciated for 
controlling inflammations and avoiding inappropriate activation of pathogenic T cells. How 
SAg-Sau modulates T cell-mediated immune regulation, and whether these modulations are 
contributing to SAg-Sau-activated pro-inflammatory T cell responses remains unclarified. 
In this study, I examined the CD4+ T cell activation in human nasopharynx-associated 
lymphoid tissue (NALT) in response to extracted Sau antigens, and how SAg-Sau-activated 
Th17 responses are regulated by CD4+ T cell-mediated immune controls, including 
Foxp3+CD4+ T cells (Tregs), IL-10 and IL-35.  
SAg-Sau activated a potent Th17 response which was markedly higher than Streptococcus 
pneumoniae (Spn) and other commonly identified bacterial colonizers in human nasopharynx. 
The Foxp3+ Treg population was largely expanded by SAg-Sau, although it failed to suppress 
the Th17 activation. The cell surface expression of CD39 on expanded Tregs was 
downregulated which may account for their lack of suppression on Th17 activation. 
SAg-Sau also enhanced IL-10 expression, primarily in Foxp3-CD4+ T cells. Interestingly, the 
Th17 responses were not altered by neutralizing IL-10 in SAg-Sau stimulated tonsillar 
mononuclear cells (MNCs), although a significantly enhanced Th1 activation was observed. 
Furthermore, addition of recombinant IL-10 suppressed the Th1 activation but promoted SAg-
Sau-activated Th17 responses. 
In contrast to upregulated IL-10, the expression of IL-35 in tonsillar CD4+ T cells was 
significantly downregulated by SAg-Sau. Treating MNCs with recombinant IL-35 was able to 
suppress SAg-Sau-activated high Th17 responses without affecting those low Th17 
responders. In SAg-Sau-induced Th17 differentiation, IL-35 downregulated RORgt expression 
in CD4+ T cells and inhibited IL-17A production. Further, it was confirmed in an in vivo murine 
model that nasopharyngeal infection of SAg-Sau markedly enhanced Th17 response in the 
cervical lymph nodes (CLNs), which was accompanied with reduced expression of IL-35 in 
the CD4+ T cells. 
The results suggest SAg-Sau downregulates CD4+ T cell-mediated immune controls in the 
nasopharynx, thus allowing activation of over-reactive Th17 responses. Immune suppressive 
cytokines IL-10 and IL-35 play differential role in SAg-Sau-activated inflammatory Th1 and 
Th17 responses which should be further evaluated to inform cytokine-based immune 
therapies for inflammatory/autoimmune conditions. The results also suggest that IL-35 has 
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1.1 Nasopharyngeal colonisation of Staphylococcus aureus 
The nasopharynx is part of the upper respiratory tract, which hosts a diverse community of 
microbes. Streptococcus pneumoniae (Spn) and Staphylococcus aureus (Sau) are both 
frequent colonisers of the human nasopharyngeal niche and occasionally cause infectious 
diseases. Whilst Spn carriage is more common in children, the frequency of Sau colonisation 
increases with age and Sau rarely co-colonises with Spn1-3. Interestingly, this negative 
correlation of Spn and Sau carriage is not found in HIV-positive individuals, which suggests 
that host immunity, especially CD4+ T cells, could play an important role in regulating bacterial 
colonization in nasopharynx4,5. 
The spectrum of diseases caused by Sau overlaps with Spn, including pneumonia, sinusitis 
and bacteremia. Apart from upper respiratory tract, Sau is also frequently found on the skin 
and contributes to skin infection. Some Sau-related diseases, such as food poisoning and 
toxic shock syndrome6, are not caused by direct infection but through the toxins produced and 
released by Sau. 
In human nasopharynx, Sau has an overall carriage rate of 30%7,8. Whilst a large proportion 
of the population (± 60%) harbours Sau intermittently, only a minority of people (± 20%) almost 
never carry it7. Sau carriage may lead to an invasive infection contributing to inflammatory 
diseases e.g. pneumonia, and in rare conditions, causing bacteremia and sepsis. Some Sau 
isolates are known to be superantigenic due to their ability to produce various superantigens 
(SAgs), including toxic shock syndrome toxin (TSST) and staphylococcal enterotoxins (SEA, 
SEB, SEC, SED and SEE)9,10. SAgs are mostly encoded by mobile genetic elements, such as 
prophages and staphylococcal pathogenicity islands, and the distribution of SAg genes is 
strain-dependent11,12.  
Although most of Sau carriers are asymptomatic, carriage of enterotoxin-producing Sau 
induces activation of Th17 cells, a CD4+ T cell subset, and relates to a higher relapse rate in 
patients with Wegener’s granulomatosis (WG), an autoimmune vasculitis, which has raised 
concerns that it may present as a major risk factor for genetically predisposed individuals 
developing autoimmune diseases10,13-15.  
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1.2 Mechanisms of infection-induced autoimmunity 
Autoimmune diseases are characterised by aberrant immune responses in the host that attack 
and damage self-tissues. In healthy subjects, most auto-reactive T cells are deleted through 
negative selection in the thymus, those that escape are tightly controlled by peripheral 
tolerance mechanisms. Genetic and environmental factors that break the immune tolerance 
may lead to the activation of self-antigen specific T and B cells and cause autoimmune 
pathogenesis either organ-specifically or systemically. The immune responses are commonly 
triggered by the invasion of exogeneous pathogens, and these infection-induced inflammatory 
responses could sometimes override tolerogenic signals on auto-reactive immune cells. 
Infection is therefore considered as a major causative factor for autoimmune development16-
18. Proposed mechanisms of infection-induced autoimmunity include molecular mimicry 
(cross-reactivity), epitope spreading and bystander activation19. 
The molecular mimicry theory is based on the possibility of sequence similarity between self-
peptides and pathogen-derived foreign peptides, thereby enabling those pathogen-activated 
immune cells to cross-react with self-tissues. Pharyngeal carriage of group C and G 
streptococci may cause rheumatic fever with evidence showing that antibodies against group 
C and G streptococci isolated from throat swabs of asymptomatic Aboriginal children cross-
react with human heart myosin20. 
Epitope spreading has been seen in a murine model of experimental autoimmune 
encephalomyelitis (EAE) induced by proteolipid protein (PLP) epitopes. In this model, the 
immunodominant PLP epitope, PLP139-151, was used to prime the SJL mice. PLP139-151-specific 
CD4+ T cells were initially induced and maintained throughout the disease course, however 
PLP178-191 and myelin basic protein (MBP84-104)-specific CD4+ T cells were identified during the 
first and second relapses respectively21. Tissue damage allows the sequestered auto-antigens 
to be exposed and presented to antigen-presenting cells (APC), and subsequently activates 
adaptive immune responses19,22. In infection caused tissue damage, the invading pathogens 
induce potent inflammatory responses that enhance the antigen presentation and T cell 
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priming not only for microbe-derived antigens but also for those previously concealed auto-
antigens via mechanisms of bystander activation. 
 
1.3 The link between SAg-Sau infection and autoimmune conditions 
Up to half of the Sau isolates were shown to produce various enterotoxins9,10, which are highly 
virulent and function as superantigens that stimulate poly-clonal T cell activation via cross-
linking the major histocompatibility complex (MHC) Class II of APC and T cell receptor (TCR) 
Vb chain23,24. Thus, most studies addressing the relationship between Sau and autoimmune 
disorders focus on the role of enterotoxins. It has also been demonstrated that memory Th17 
cells, a CD4+ T cell subset that contributes greatly to autoimmunity, can be activated by 
superantigenic Sau (SAg-Sau) (Sau strain that produces these enterotoxins)14. With evidence 
showing that staphylococcal superantigens have the ability to induce autoimmune pathologies, 
as well as its potential in activating pro-inflammatory Th17 cells, it is plausible to suggest that 
SAg-Sau infection may contribute to autoimmune development. Here, I reviewed studies 
revealing the link between Sau infection and chronic inflammatory/autoimmune diseases and 
explored how it may associate with a potential pathological Th17 activation. 
It was first reported in a rat arthritis model demonstrating the capability of staphylococcal 
superantigens to promote inflammatory pathologies25. The joint inflammation was induced by 
peptidoglycan-polysaccharide, and intravenous (i.v.) injection of staphylococcal TSST-1 was 
able to reactivate it repeatedly following each injection. The limitation of this study was that 
the arthritis was induced by complexes isolated from streptococci cell wall, but not self-
antigens, thus the inflammatory responses and tissue pathologies presented may be different 
from an autoimmune arthritis. Nevertheless, it demonstrated that systemic administration of 
staphylococcal TSST-1 could reactivate T cells in the joint that have been primed by other 
antigens, resulting in arthritis flare-ups. 
Shortly following the arthritis study, 2 parallel studies were carried out to investigate the effects 
of staphylococcal enterotoxins (SEs) on the development of multiple sclerosis (MS) using a 
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murine model of EAE26,27. In one study, (PL/J ́  SJL) F1, PL/J and SJL/J mice were immunized 
with MBP peptide AC1-11 or spinal cord homogenate, and then treated with staphylococcal 
enterotoxin B (SEB) or enterotoxin A (SEA) intraperitoneally (i.p.). SEB treatment significantly 
increased relapses and was able to exacerbate sub-clinical EAE. SEA-treated mice showed 
an increase in relapses, although it was not statistically significant26. Both SEA and SEB were 
demonstrated to be effective in inducing relapses in another study. Furthermore, it was shown 
that the EAE could be re-induced multiple times with each incident occurring after an SEB 
injection, which was similar to the effect of TSST-1 shown in the arthritis model mentioned 
above27. However, both studies failed to show EAE induction by SEs without prior antigen 
challenge. Therefore, SAg-Sau/SEs appears to affect EAE development when auto-antigens 
or auto-reactive T cells are presented. It is notable that pre-treating mice with SEB has been 
shown to reduce T cell activation and ameliorate Ac1-11-induced EAE, which can be 
explained by SEB-induced anergy in naïve T cells bearing Vb8 receptors28,29. This 
contradicted observation could be explained by the timing of SEs administration. While SEB 
stimulation is able to cause clonal deletion and unresponsiveness in naïve T cells, antigen-
experienced T cells are protected from the induction of anergy and could be further 
activated27,30. Hence, SAg-Sau infection that happens at different stages of an autoimmune 
disease may have differential effects on disease development. 
Although SEB pre-treatment protected the PL/J mice from EAE induction by rat MBP, 
administration of SEA was able to overcome the T cell anergy and induced an initial episode 
of EAE31. This indicates that encephalitogenic MBP-specific T cells are not restricted to the 
Vb8+ T cells that specifically reactivates with SEB, and those non-Vb8+ T cells primed by MBP 
could be activated by other superantigens leading to accelerated onset of disease. Further, 
SEA pre-treated mice developed EAE and were susceptible to relapse induced by SEB31. It is 
common that a SAg-Sau strain can be positive in more than one enterotoxin, and different 
SAg-Sau strains produce various enterotoxins32,33, SAg-Sau colonization/infection is therefore 
a major risk factor for the development of multiple sclerosis which should not be 
underestimated. 
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The effects of SEs for promoting autoimmune pathogenesis have also been reported in other 
autoimmune disease models34,35.  In an experimental model of autoimmune uveoretinitis, mice 
were immunized with human interphotoreceptor retinoid binding protein (IRBP) peptide, and 
SEB was given on day 10 or day 24 post immunization. While SEB treatment during disease 
progression enhanced the severity of clinical symptoms, administrating SEB after resolution 
of clinical signs was able to induce a disease relapse. The promoted proliferation of IRBP-
specific T cells by SEB was accompanied with enhanced production of IFNg and IL-17A34. 
This study further confirms that SEs are able to reactivate auto-reactive T cells via initiating 
poly-clonal T cell activation regardless of antigen-specificity. 
In above described studies, a prior auto-antigen challenge to prime a population of auto-
reactive T cells is essential for SAg-Sau/SEs to play a role in later autoimmune development. 
It is well documented that auto-reactive T and B cells exist even in healthy individuals36. 
Therefore, is it possible for SAg-Sau/SEs to initiate autoimmunity with naturally occurred auto-
reactive T cells? One study addressed this question using HLA-DQ8 transgenic mice that 
were chronically exposed to SEB35. The HLA-DQ8 transgenic mice express human MHC class 
II, thus the activation of auto-reactive T cells by the SEs resembles the autoimmune events 
which may happen in humans. Extremely small non-lethal amounts of SEB were administrated 
subcutaneously (s.c.) with mini-osmotic pumps for 4 weeks without any exogenous antigen 
challenge. Interestingly, the SEB-treated mice developed systemic inflammatory disease 
manifested by elevated levels of anti-nuclear antibodies, mononuclear cell infiltration in kidney, 
lung and liver, accompanied with pathological changes in these organs, which were very 
similar to human systemic lupus erythematosus (SLE). It further demonstrated that this SEB-
induced multi-system autoimmune pathologies were CD4+ T cell/CD28-dependent and IFNg-
producing Th1 cell-mediated. While the importance of Th1 cells in an autoimmune disease 
mimicking human lupus was shown in this study, it only compared the STAT4- and STAT6-
deficient mice to demonstrate Th1, rather than Th2, was involved in disease development. 
The role of STAT3-dependent pathway and IL-17A-producing Th17 cells in this autoimmune 
disease model was not investigated. Recent studies have provided a large body of evidence 
demonstrating a more critical role of Th17 cells in the aetiology and pathology of autoimmune 
diseases37. 
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To establish the role of SAg-Sau/SEs in autoimmune disease development, only experimental 
evidence from murine studies is not sufficient. By identifying bacterial species isolated from 
the nasopharynx in patients with autoimmune diseases, the association between SAg-Sau 
nasal colonization and certain autoimmune diseases has been established10,15,32,38-42. 
Wegener’s granulomatosis is an autoimmune vasculitis that has been consistently found to 
be closely related to SAg-Sau colonization10,15,43. In an observational cohort study for patients 
with biopsy-proven WG, chronic nasal carriage of Sau was identified as an independent risk 
factor (relative risk, 7.16) for disease relapse, and the carriage rate was about three times 
higher than it was in healthy subjects15. Further investigations revealed that Sau stains that 
produce SEA, TSST-1, SEC and exfoliative toxin A (ETA) were most frequently found in WG 
patients, and carriage of TSST-1-positive Sau correlated with the occurrence of relapses 
(relative risk, 13.3)10,44. 
Significantly higher carriage rate of Sau has also been reported in patients with MS32. However, 
another study examining the association between MS patients and colonization of Sau that 
harbour superantigens did not find increased Sau carriage in those patients. Nevertheless, 
they did show that SEA-producing Sau was more prevalent in patients who suffered a relapse 
within 30 days of study recruitment for those individuals carrying Sau39. SLE is a systemic 
autoimmune disease that affects multi-organs. Although Sau carriage rate in patients with SLE 
was similar to that reported in healthy subjects, investigation into the organ involvement of 
these patients showed a higher frequency of renal and skin manifestations in Sau-positive 
patients45. These Sau-positive patients also had an increased production of auto-antibodies, 
such as anti-double stranded DNA (dsDNA), anti-Smith (Sm) and anti-ribonucleoprotein 
(RNP). It suggests that Sau colonization is associated with a specific phenotype of SLE. It is 
possible that certain organs may be more susceptible to Sau-induced bystander activation of 
auto-reactive T cells. Rheumatoid arthritis (RA) is another commonly seen autoimmune 
disorder that primarily affects joints. A study compared staphylococci carriage rates between 
patients with RA, healthy adults and elderly volunteers, and reported that RA patients had the 
highest carriage rate of Sau whereas the carriage of staphylococcus epidermidis was 
comparable among three groups38. Report from another study also demonstrated that patients 
with RA more often carried Sau in their nasal vestibule, and had increased antibody titres to 
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TSST-1, suggesting a distinct subpopulation of Sau that produces TSST-1 superantigen is 
involved in the pathogenesis of rheumatoid arthritis42. However, an increased Sau carriage 
rate in RA patients is not consistently found46, and the association between Sau carriage and 
RA development remains inconclusive.  
It has been proved difficult though to track down a particular infectious agent that induces or 
promotes autoimmune diseases, as the responsible microbe could have been cleared at the 
time the disease is diagnosed. Sau carriage appears to be intermittent in most individuals and 
can be affected if patients are treated with antibiotics or immune-suppressive drugs. Thus, to 
establish SAg-Sau infection as an initiative event for the patient to develop autoimmune 
disorder would require a regular check-up of nasal carriage status in longitudinal studies that 
follow up the patients from disease onset to remissions and relapses. In addition, future 
epidemiological studies should also consider divergent individual responses to Sau infection 
when evaluating the resulting impact of Sau carriage on autoimmune development. 
Approaches to identify individuals who are genetically susceptible to autoimmunity are yet to 
be established. It is likely multiple infectious events are contributing to the aetiology of 
autoimmune disease, thus making it extremely difficult to establish causative relationship of a 
particular pathogen infection and an on-going autoimmune condition in clinical patients. 
Previous evidence from murine models of autoimmune diseases strongly suggest SAg-
Sau/SEs is a key player in the development of autoimmune pathogenesis. However, the 
impact of chronic or intermittent colonization of SAg-Sau in disease onset and progression 
has not been clarified. It is equally important to elucidate how Sau infection shapes the 
immune environment to favour the activation of auto-reactive immune responses in order to 
better understand the relationship between infections and autoimmune disorders and provide 
new strategies for clinical treatment. 
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1.4 Th17 cells as key pro-inflammatory T cell subset for autoimmunity 
It is plausible that superantigen-activated non-specific T cell responses are the principal 
mechanism for SAg-Sau-related autoimmunity. I propose two possible ways by which SAg-
Sau nasal colonization may induce potential autoimmune responses. First, SAg-Sau infection 
happens in the presence of auto-reactive T cells and is able to activate these cells via 
polyclonal T cell activation. Activated auto-reactive T cells escape peripheral immune 
surveillance and approach the target organ to attack self-tissue. Second, SAg-Sau 
colonization activates a population of pro-inflammatory T cells that cannot be suppressed by 
regulatory networks. These pro-inflammatory T cells then travel to susceptible organs to cause 
an initial tissue damage, followed by the exposure of sequestered auto-antigens to prime auto-
reactive immune cells. In the inflammatory microenvironment created by SAg-Sau-activated 
T cells, these auto-reactive immune cells are polarised to pro-inflammatory phenotypes 
leading to self-destruction. The gut-residing segmented filamentous bacteria (SFB), which 
induce IL-17A-producing Th17 cells, are able to drive autoimmune arthritis and 
encephalomyelitis, suggesting that locally activated Th17 cells could enter the circulation and 
cause autoimmune pathogenesis at a distal site47,48. In light of these intriguing findings, it will 
be interesting to know whether SAg-Sau colonization can activate Th17 cells that are resistant 
to regulations and have the potential to initiate autoimmunity. Before this, how have Th17 cells 
come to the centre of autoimmunity? 
CD4+ T cells can differentiate into either pro-inflammatory subsets, Th1 and Th17 cells, or 
anti-inflammatory subsets e.g. Foxp3+ regulatory T cells (Tregs) in response to various 
microbial infections. Th1 cell activation was deemed as a key contributor for the development 
of autoimmune diseases until it was found that Th1 related gene mutations, such as ifng, ifngr 
and T-bet, led to more severe disease manifestations in murine models of EAE and 
experimental autoimmune myocarditis (EAM). From these experiments, it was concluded that 
IL-17-producing Th17 cells rather than IFNg-producing Th1 cells were the major players in 
autoimmune disease development49-51. It is now known that although Th17 cells are important 
in host immune defence against bacterial and fungal infections52,53, they are critically involved 
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in the development of autoimmune diseases including MS, RA, psoriasis and inflammatory 
bowel disease (IBD)37,50,54.  
The initial study suggesting that IL-17 drives pathological changes was described in collagen-
induced arthritis (CIA), which showed blocking endogenous IL-17 with soluble IL-17 receptor 
protein dose-dependently suppressed the incidence of arthritis, whereas systemically 
increased expression of IL-17 enhanced CIA55. The effect of IL-17 in promoting CIA 
development was later confirmed by Nakae et al. using IL-17-deficient mice56. They further 
demonstrated that mice with IL-17 deficiency were also more resistant to the induction of EAE, 
exhibiting delayed disease onset and improved clinical scores associated with significantly 
reduced mononuclear cell infiltration within the spinal cords57.  
Another line of evidence delineating the role of IL-17-producing CD4+ T cells in autoimmunity 
came from studies using IL23-/- and Rorg-/- mice58-60. IL-23 is a heterodimeric cytokine 
belonging to IL-12 family. IL-23 is shown both in vitro and in vivo to drive Th17 cell activation, 
while IL-12 is known to activate IFNg-producing Th1 cells. IL-23-deficient mice were EAE 
resistant, although the number of immune cells including IFNg+ cells that invaded the central 
nervous system in IL23-/- mice were comparable to wild type mice. However, a lack of IL-17 
expression was observed in these infiltrating T cells indicating Th17 deficiency abrogated 
autoantigen-induced neural inflammation. Indeed, primed with PLP autoantigens, it was the 
IL-23-expanded Th17 cells but not IL-12-expanded Th1 cells that induced EAE pathology 
following adoptive transfer in the recipient mice58. Th17 cells as a distinct Th cell lineage are 
induced via signalling pathways independent of those required for the development of Th1 
and Th2 cells. The orphan nuclear receptor, RORgt, is the key transcription factor to induce 
Th17-related gene expression. Mice lacking RORgt were deficient in generating Th17 cells, 
and in turn they had attenuated autoimmune disease59.  
Besides autoimmune diseases, Th17 cells are also implicated in a wide range of inflammatory 
conditions, such as contact hypersensitivity, asthma and atopic dermatitis61-64. 
Hypersensitivity pneumonitis (HP) is an allergic pulmonary disorder mediated by inflammatory 
T cell responses. In the experimental model of HP induced by repeated intranasal 
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administration of S. rectivirgula, depleting IL-17 via genetic deletion or immunoneutralization 
resulted in less inflammation along with a significantly lower count of mononuclear cells that 
infiltrated the lungs65. Asthma, characterised by airway hyperresponsiveness (AHR), was 
largely thought to be Th2-driven chronic inflammatory disease. However, the aetiology of 
asthma is heterogeneous which involves Th17-mediated pathologies61,66. Asthma patients 
with a Th17-dominant inflammatory response have been found by assessing the gene 
expression profile of endobronchial biopsies62. Neutralizing Th2-type cytokines, IL-4 and IL-
13, in murine model of allergic asthma induced Th17 responses and neutrophilic inflammation, 
suggesting that targeting Th2 cytokines in clinical treatment may promote Th17-dependent 
airway inflammation62,67. 
Several signature molecules, such as IL-23R, GM-CSF and CCR6, are suggested to 
contribute to the pathogenicity of Th17 cells from murine studies68-70. However, IL-17A, the 
hallmark cytokine of Th17 cells, has been shown to be a highly effective target in clinical 
studies treating autoimmune diseases including psoriasis, MS and RA37. Th17 cells also 
produce IL-17F and IL-22, but clinical studies targeting these cytokines have provided 
evidence suggesting that IL-17A is the primary effector cytokine leading to the clinical 
manifestation of most autoimmune diseases associated with Th17 activation37. It has been 
reported that IL-17A contributes to autoimmunity by inducing chemokine expression, recruiting 
neutrophils, macrophages and auto-reactive T cells, and promoting germinal centre formation 
to produce auto-antibodies47,48. Given the critical role of IL-17A-producing Th17 cells in 
mediating inflammatory pathologies, pathogens that are able to activate a strong Th17/IL-17A 
responses would therefore pose potential risk to the development of inflammatory and 
autoimmune diseases. 
Staphylococcal superantigens activate CD4+ T cell dominant-inflammatory responses, and it 
has been shown that they mainly trigger Th1 and Th17 responses characterised by a massive 
production of pro-inflammatory cytokines, such as IFNg, IL-17A and TNF-a71. In humans, the 
capacity of SAg-Sau in activating Th17 responses is associated with the abundance of 
memory T cell repertoire14. Sitting at the entrance of upper respiratory tract, the nasopharynx-
associated lymphoid tissue (NALT) is constantly exposed to inhaled foreign antigens and 
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thereby containing a substantial proportion of antigen-experienced effector and memory cells. 
Hence, it could be postulated that nasopharyngeal infection of SAg-Sau could lead to a potent 
Th17 activation in the nasopharynx and NALT. It has been reviewed above that SAg-Sau 
infection is related to the pathogenesis of various autoimmune diseases, including MS, WG 
and RA, and in all these diseases Th17 has been shown to play an indispensable role as 
demonstrated in both animal disease models and clinical studies37,56,57,72. However, how 
superantigenic Th17 responses may affect the disease development is yet to be illustrated. It 
is also unknown as to how SAg-Sau-activated Th17 responses are regulated, which may well 
underlie the aetiology of autoimmunity.  
 
1.5 T cell-mediated regulation of Th17 responses 
 In the periphery, Foxp3+ Tregs are a major cell population to regulate over-activated 
inflammatory responses and maintain immune tolerance. Tregs regulate effector T cell 
responses through cell contact and by producing immune suppressive cytokines, such as 
TGF-b1 and IL-10. Animal studies have demonstrated the importance of Tregs for protecting 
the host from developing autoimmune disorders by suppressing effector T cell responses73,74. 
Th1-type responses are effectively controlled by Tregs, but Th17 responses appear to be less 
susceptible to Treg-mediated suppression. In a spontaneous autoimmune gastritis (AIG) 
model, transfer of polyclonal Tregs markedly suppressed the induction and progression of AIG 
mediated by Th1 effectors, whereas the Th17-driven inflammation was more aggressive but 
could only be modestly suppressed at the initial stage75. Interestingly however, Tregs with 
TCRs recognizing the specific autoantigen exhibited higher suppressive activity against the 
pathological Th17 cells than natural Tregs (nTregs) and TGF-b-induced polyclonal Tregs. By 
transferring the autoantigen-specific Tregs, the mice were protected from the Th17 cell-
mediated tissue destruction76. This suggests that Tregs may suppress Th1 and Th17 effectors 
through divergent pathways, and Treg-mediated suppression of Th17 cells may to some 
extent depend on TCR specificity. 
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Another interesting study dissecting the intracellular signalling pathways that endow Tregs 
with the ability to suppress pathological Th17 cells suggests that Tregs require the activation 
of signal transducer and activator of transcription 3 (STAT3) to induce a subset of suppressor 
molecules specialized for Th17 suppression. Treg-specific deletion of STAT3 resulted in the 
development of Th17-driven colitis, despite these Stat3-/- Tregs had unaffected in vitro 
suppressor capacity with regard to controlling effector T cell proliferation77. Both IL-6 and IL-
10 are known to activate STAT3 signalling but give rise to distinct outcomes. In Tregs, the 
activation of STAT3-mediated suppressor program against Th17 responses is dependent on 
IL-10 signalling. Ablation of IL-10 receptor (IL-10R) in Tregs led to the dysregulation of 
pathological Th17 activation similarly as it was shown by Tregs harbouring STAT3 deficiency78. 
Collectively in mice, Tregs may be less efficient in suppressing Th17 activation, they are 
capable of restraining overreactive Th17 responses via pathways differentiated from those 
commonly used to suppress cell proliferation and Th1-type responses. 
In humans, IL-17 expression and proliferation of Th17 clones are poorly suppressed by Foxp3+ 
Tregs79,80. However, a subpopulation of human Tregs that express CD39 has been shown to 
inhibit IL-17 production via cell contact81. CD39 is an ectonucleotidase expressed by B cell, 
dendritic cells (DCs) and Tregs. It mediates immune suppression through catalysing 
extracellular ATP, which has multiple pro-inflammatory effects, to suppressive adenosine82,83. 
Notably, the number of CD39+ Tregs were markedly reduced in patients with MS, suggesting 
this Treg subset may have specific role in the control of the disease and its reduction was 
likely concerning an impaired suppression of pathological Th17 responses81,84. Whilst the 
suppression mechanism of CD39+ Treg requires further investigation, it remains controversial 
whether human Th17 cells can be controlled by the Tregs. It is therefore of interest to examine 
the role of Tregs in the control of SAg-Sau-activated Th17 responses and how it may relate 
to the specific CD39+ Treg subset. 
Unlike Tregs, immune suppressive cytokine IL-10 has a well-defined role in regulating Th17 
responses. IL-10 activates STAT3 signalling in the Tregs to mediate their suppression against 
Th17 cells as has been mentioned above78. Besides, it has been reported by Huber et al. that 
IL-17A-producing CD4+ T cells expressed IL-10R and their proliferation was controlled by IL-
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10 signalling. T cell-specific deletion of IL-10R disrupted the IL-10 signalling in CD4+ T cells 
and thereby abrogated the suppression of pathological Th17 cells by Foxp3+ Tregs and Foxp3-
CD4+ IL-10-producing regulatory T cells (Type 1 regulatory T cells, Tr1)85. Moreover, some 
Th17 cells were shown to co-express IL-10 and these IL-10+ Th17 cells upregulated an array 
of immunoregulatory molecules, such as TGF-b and CTLA4, as well as molecules involved in 
the suppressive function of Tregs, thereby directing the Th17 cells towards a non-pathogenic 
phenotype. When co-cultured with monocytes, the IL-10+ Th17 cells drove anti-inflammatory 
M2 macrophages leading to tissue repair, rather than the pro-inflammatory M1 macrophages 
which could be polarised by IL-10- Th17 cells 86.  
By suppressing pathological Th17 responses, as well as other inflammatory immune 
responses, IL-10 and IL-10-producing T cells are of significant importance in the control of 
autoimmunity. IL-10 or IL-10 receptor (IL-10R) knockout mice are prone to the development 
of autoimmune disorders, such as IBD and EAE87. Loss of function mutations in IL-10 and IL-
10R in humans has been linked to an early-onset of IBD88-90. Nevertheless, attempts to utilise 
recombinant IL-10 clinically for treating autoimmune diseases have been unsuccessful91. It is 
therefore intriguing to explore whether IL-10 is able to regulate the pro-inflammatory T cell 
responses, especially the Th17 responses, in all immunological settings, including that in the 
context of SAg-Sau-infected nasopharynx. IL-10 has been shown to suppress Th17 induction 
in mice with systemic infection of Sau, but the superantigenicity of the Sau strain used in the 
study was not indicated, nor whether the Sau-activated effector and memory Th17 responses 
were affected by the increased level of IL-10 in the system92. 
IL-35 is a recently identified immune regulatory cytokine, which may play a protective role in 
the development of autoimmune disorders93. IL-35 belongs to the IL-12 cytokine family, and 
is made of two shared subunits, IL-12A and EBI3. Unlike most of the other pro-inflammatory 
cytokines in the IL-12 family, IL-35 has been shown to suppress Th17 cell activation in 
autoimmune diseases and inflammatory disorders in animal models94-96. Treatment with 
soluble tumor necrosis factor receptor (TNFR) has been proven to be highly effective for 
patients with RA. CIA is an animal model of RA, in which IL-35 exhibited comparable 
therapeutic effects to TNFR in protecting the mice from developing severe joint inflammation, 
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and this protection was associated with IL-35-mediated suppression of Th17 responses95. The 
suppressive effect of IL-35 on Th1 responses was not consistent though which was dependent 
of the stimulation conditions95. In mice, IL-35 is primarily produced by Foxp3+ Tregs and acts 
as an indispensable suppressive cytokine contributing to the regulatory activity of Tregs97. 
Another CD4+ T cell subset that has been identified as a major source of IL-35 is the inducible 
IL-35-produing regulatory T cells (iTr35s)94. Derived from conventional T cells (Tconvs), iTr35s 
had potent regulatory control over effector T cells and were able to suppress autoimmune 
development in mice with induced EAE and IBD. Additionally, iTr35s have been reported to 
promote tumor growth as well, suggesting an overall suppressive role of iTr35s in the host 
immunity94.  
A recent report demonstrates that the IL-12A subunit of IL-35 ameliorated autoimmune uveitis 
in mice by antagonizing Th17 responses which was through inducing IL-10- and IL-35-
expressing B cells98. IL-35+ B cells have been shown by previous studies to control 
autoimmune pathologies similarly as iTr35s, but the effect of IL-35+ B cells is suggested to be 
dependent on IL-10 while iTr35s mediate suppression via IL-35 but not IL-10 or TGF-b94,99,100. 
However, whether iTr35s also exist in humans and have similar immune regulatory effects is 
still debated94,101. Expression of the EBI3 subunit in CD4+ T cells isolated from human 
peripheral blood mononuclear cells (PBMCs) was detectable only after stimulation with anti-
CD3/anti-CD28 or phytohemagglutinin (PHA), while the IL-12A subunit was expressed 
constitutively101. It is still unclear if activated human CD4+ T cell produce heterodimeric IL-35 
protein. Current data on the role of IL-35 in human diseases is limited, although a reduced 
level of IL-35 in the circulation has been shown to be associated with several autoimmune 
disorders102-104.  
Sau carriage in human nasopharynx is common. Considering the potential of Sau, and SAg-
Sau in particular, to induce strong pro-inflammatory T cell responses in human NALT which 
may contribute to inflammatory/autoimmune conditions, it will be valuable to examine how the 
pro-inflammatory responses (e.g. Th17 and Th1) are regulated by the regulatory T cells and 
cytokines. Such information will add to our understanding of Sau- and superantigen-related 
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inflammatory diseases and on new strategies in the management of inflammatory conditions 
such as autoimmune diseases. 
In this PhD study, in order to delineate T cell-mediated regulation of Th17 responses in the 
context of SAg-Sau infection, I propose to study: 
1. Whether Sau and SAg-Sau are able to activate Th17 responses in human NALT, and 
to what extent. 
2. The effect of SAg-Sau on the response of Foxp3+ Tregs, and how they may regulate 
the Th17 activation. 
3. Whether IL-10 and IL-10-producing Tr1 cells are activated by SAg-Sau in NALT, and 
the IL-10-mediated regulation of SAg-Sau-activated Th1 and Th17 responses. 
4. The effect of SAg-Sau on IL-35-producing CD4+ T cells, and the role of IL-35 in SAg-
Sau-activated pro-inflammatory T cell responses in human NALT. 
5. Whether in vivo nasopharyngeal infection of SAg-Sau in mice could elicit T cell 









Materials and Methods  
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2.1 Prepare bacterial stocks 
For the handling of bacterial culture, all operations were performed in a biosafety cabinet or 
next to a Bunsen burner to avoid contamination. 
 
2.1.1 Blood agar plates (blood agar base + 5% v/v Horse blood) 
40 g of blood agar, base (BAB) (Sigma-Aldrich) was suspended in 1 L of distilled water and 
then autoclaved at 15 psi for 20 min to completely dissolve the BAB and sterilize the media. 
After autoclaving, the BAB media was allowed to cool to 56°C approximately, followed by 
adding 50 ml of sterile defibrinated horse blood to the media. The blood was evenly mixed 
before pouring culture dishes. The dishes were left in the biosafety cabinet to allow the agar 
to set. The BAB plates can be used straight away once set or stored upside down at 4°C. 
 
2.1.2 Todd Hewitt Broth media (Todd Hewitt Broth + 0.5% w/v yeast extract) 
37 g of Todd Hewitt Broth (THB) and 5 g of yeast extract was dissolved in 1 L of distilled water 
and then autoclaved at 15 psi for 20 min to sterilize the media. The media was stored at 4°C 
for later use. 
 
2.1.3 BAB plate inoculation 
The bacterial stocks were removed from -80°C freezer and left at room temperature (RT) to 
thaw. All culture dishes were properly labelled before inoculation. 20 μl of stock culture were 
added onto the BAB plate and streaked using a sterile loop. For bead stocks, a single bead 
was transferred onto the plate and streaked. The inoculated plates were kept overnight at 
37°C for staphylococcus. Spn strains were cultured at 37°C with 5% CO2.  
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To prepare a bead stock, several single colonies were transferred into cryopreservative fluid 
using a sterile loop. Bacterial stocks were stored at -80°C freezer. 
 
2.1.4 Bacterial liquid stocks 
Several single colonies were picked up from the culture plate and dispersed into 3 ml of THB 
media. The bacteria were cultured overnight at 37°C. In the next morning, the bacteria cultures 
were taken out of the warm room and checked for turbidity. The culture appeared cloudy if the 
bacteria were growing.  
To expand the culture, 1-2 ml of the overnight culture was transferred into 20 ml of fresh THB 
media, followed by culturing in a shaking incubator with the temperature set at 37°C and the 
shaking speed set at 250 rpm/min. The culture turbidity was checked hourly. Once the culture 
started to appear cloudy, 1 ml of the culture was transferred to a plastic cuvette for the 
measurement of optical density (OD) at a wavelength of 600 nm. The OD value of the culture 
was read every 30 min. The culture was terminated once the OD value reached 0.5, which 
meant that the bacterial growth had entered exponential phase. The bacterial cultures were 
then mixed with equal amount of 30% sterile glycerol before aliquoting into 500 μl aliquots. 
Bacterial liquid stocks were kept in -80°C freezer. 
 
2.2 Preparation of bacterial culture supernatant 
All bacterial strains used for producing concentrated culture supernatant (CCS) are listed in 
Table 2.1. 
Bacterial liquid stock was removed from the -80°C freezer and left at RT to defrost. 20 μl of 
stock bacteria was inoculated to 3 ml of THB in a Bijou container, and cultured overnight at 
37°C. The bacterial culture was expanded as describe in 2.1.4. 200 μl of the culture was left 
out for the measurement of colony forming units (CFU) later. 
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The expanded bacterial culture was transferred to a 50 ml conical centrifuge tube, followed by 
centrifuging at 3000 g for 30 min with the temperature set at 4°C. For Spn strains, the 
centrifuging speed was set at 3500 g to ensure proper pelleting of the bacteria. After 
centrifugation, the supernatant was collected and filtered through a 0.45 μm syringe filter using 
a 20 ml syringe, followed by filtering through a 0.2 μm syringe filter. 
The Vivaspin 20 concentrator (5,000 MWCO) was rinsed with 10 ml of phosphate buffered 
saline (PBS) before used for concentrating the filtered supernatant. The supernatant was 
transferred to the concentrator and centrifuged at 3000 g for 30 min with a temperature of 4°C. 
A maximum of 15 ml sample can be loaded to the concentrator. If the sample volume exceeds 
15 ml, remaining sample can be loaded later in the same concentrator. The flow-through was 
discarded after each centrifugation. The aim is to concentrate the supernatant 10 times (10´), 
thus if starting from 20 ml, the sample should be centrifuged until 2 ml of liquid was left above 
the membrane of the concentrator. Several centrifugations were usually required to 
concentrate the culture supernatant to desired amount.  
Once the sample was fully concentrated, it was aliquoted into 500 μl aliquots for long-term 
storage at -80°C. The CCS was further aliquoted to 50 μl aliquots and stored at -20°C for cell 
stimulation. 









Table 2.1 Bacterial strains 





Positive for mec (subtype II); negative for 




Positive for tsst, sea, sec and see; negative 
for mecA.  
BEI Resources 
C1 Carriage strain isolated from nasal swab Clinical isolates1 
C2 Carriage strain isolated from nasal swab Clinical isolates1 






C4 Carriage strain isolated from nasal swab Clinical isolates1 
C5 Carriage strain isolated from nasal swab Clinical isolates1 
Streptococcus 
pneumoniae 
D39WT Standard encapsulated serotype 2 
Kindly provided 
by Prof. James 
C Paton4 
TIGR4 Virulent serotype 4 
Kindly provided 
by Dr. Michelle 
Barocchi5 
C6 Carriage strain isolated from nasal swab Clinical isolates2 
C7 Carriage strain isolated from nasal swab Clinical isolates2 
C8 Carriage strain isolated from nasal swab Clinical isolates2 
C9 Carriage strain isolated from nasal swab Clinical isolates2 
Moraxella 
catarrhalis C10 Carriage strain isolated from nasal swab
 Clinical isolates2 
1 These carriage strains were isolated and tested by Lualuaa Zaki 
2 These carriage strains were isolated and tested by Dr. Qibo Zhang 
3 SE level shown in Figure 3.3 d 
4 University of Adelaide, Australia 
5 Novartis, Siena, Italy 
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2.3 Viable count (The Miles and Misra Methods) 
The bacterial suspension was serially diluted in a 96-well round-bottom microplate by adding 
20 μl of sample into wells containing 180 μl of sterile PBS. Serial dilutions were made to 1:108. 
The BAB plates were equally divided into 8 sectors and labelled with dilutions for these sectors. 
3 ´ 20 μl of the appropriate dilution were dropped onto each sector. The inoculated plates 
were then left open in the biosafety cabinet to allow the drops to dry into the agar. Avoid 
touching the agar surface with the pipette when inoculating plates. The plates were inverted 
and cultured at 37°C for 16 to 24 hours. 
Each sector was observed for bacterial growth, and colonies were counted in the sector where 
the highest number of full-size discrete colonies were seen. The number of CFU per ml from 
the original sample was calculated using the following equation: 
           CFU per ml = Number of colonies in the sector/60 ´ dilution factor ´ 1000 
 
2.4 Detection of staphylococcal enterotoxins (SEs) 
To identify if the Sau strains isolated from patient nasal swabs are capable of producing SE 
(A-E), the RIDASCREEN@ SET Total kit (r-biopharm, Germany) was used to detect the SEs 
in the bacterial culture supernatant. 
The 10´ wash buffer was incubated in a 37°C to completely dissolve any visible crystals and 
then diluted with sterile distilled water. Pre-coated wells were inserted into the microwell holder, 
followed by adding 1:10 diluted CCS samples. The positive and negative controls provided 
were also added accordingly. The wells were sealed and incubated for 1 hour at 37°C. 
Following the incubation, samples were discarded, and liquid residues were removed by blot 
the wells on tissue towel. The wells were washed with 300 μl of 1´ wash buffer for 5 times. 
Then, 100 μl/well of green-stained conjugate 1 was added, and the wells were incubated for 
1 hour at 37°C. The wells were washed again followed by adding 100μl/well of blue-stained 
conjugate 2 and incubating for 30 min at 37°C. After washing, the wells were incubated with 
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100 μl/well of red-stained substrate/chromogen at 37°C for a further 15 min. The microwells 
were gently tapped to make the colour evenly distributed before adding 100 μl/well of stop 
solution. The wells were read for OD values at 450 and 620 nm using ELISA microplate reader. 
The (OD450 – OD620) was calculated for each sample. The assay is deemed valid only when 
the calculated OD value for the positive control is over 1.0 and the negative control is less 
than 0.2. 
 
2.5 Isolation of mononuclear cells from human tonsils 
The adenotonsillar tissues were obtained from immunocompetent patients undergoing 
adenoidectomy and/or tonsillectomy due to upper-airway obstructions at Alder Hey children’s 
Hospital, and Royal Liverpool and Broadgreen University Hospitals. Patients with known 
immunodeficiency or who had been prescribed antibiotics within 3 weeks before surgery were 
excluded. The study was approved by the National Research Ethics Committee and written 
consent was obtained in all cases. 
Isolation procedure was carried out in a biosafety cabinet and guidelines of aseptic technique 
were followed to ensure sterile handling of clinical samples. 
Tonsillar samples were collected in Hank’s balanced salt solution (HBSS) (Sigma-Aldrich) 
supplemented with 1% of penicillin-streptomycin (10,000 U/ml, Thermo Fisher). Tonsillar 
tissues were washed with HBSS to remove blood attached on the tissue surface and then 
transferred to a 100 mm petri dish containing 15ml of HBSS. Using a sterile scalpel, the tissues 
were loosened to release cells to the media, followed by filtering the cell suspension through 
a 70 μl cell strainer to remove tissue debris and dissociate cells. Filtered single cell suspension 
was collected in a 50 ml conical centrifuge tube. The tissues were rinsed with 10 ml of HBSS 
in order to collect remaining cells. Again, cell suspension was filtered and collected in the 
same tube. 
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Mononuclear cells (MNCs) were isolated by density gradient centrifugation with Ficoll-Paque 
(Sigma-Aldrich). 10-15 ml of the single cell suspension was carefully layered onto 10ml of 
Ficoll-Paque media solution in a 30 ml Universal tube, making sure to not mix the cell 
suspension with the Ficoll-Paque media. After all cell suspensions were properly layered, 
centrifuging at 400 g for 30 min with a temperature of 20°C. The brake of the centrifuge was 
turned off to avoid disturbing the layers during deceleration. Following centrifugation, the 
upper layer containing plasma and platelets was drawn off using a sterile pipette, leaving the 
MNC layer undisturbed at the interface. The layer of MNCs were then carefully collected in a 
50 ml conical centrifuge tube. The volume of total MNCs collected was estimated and at least 
3 volumes of Dulbecco’s phosphate-buffered saline (DPBS) was added to the MNCs to ensure 
a proper washing of the cells. Cells were well-suspended by inverting the tubed for several 
times before centrifuging at 300 g for 10 min. 
After centrifuging, the supernatant was removed and MNCs were resuspended in RPMI 1640 
medium (with L-glutamine and phenol red, Thermo Fisher) supplemented with 10% v/v of fetal 
bovine serum (FBS) (Sigma-Aldrich) and 1% v/v of penicillin-streptomycin (P/S). Cells were 
kept in an ice box before stimulation. 
 
2.6 Isolation of mononuclear cells from human peripheral blood 
Blood was extracted from healthy donors and collected in heparin treated sterile tubes. The 
study was approved by the National Research Ethics Committee and written consent was 
obtained in all cases. 
Isolation procedure was carried out in a biosafety cabinet and guidelines of aseptic technique 
were followed to ensure sterile handling of human samples. 
Equal volume of HBSS was added to the blood and mixed by inverting the tube several times. 
15 ml of diluted blood sample was carefully layered onto 10 ml of Ficoll-Paque. The rest of 
isolation procedure was carried out as described in 2.5. 
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2.7 Primary tonsillar MNCs culture and stimulation 
All procedures were done in a biosafety cabinet and guidelines of aseptic technique were 
strictly followed. 
Complete medium was prepared by supplementing RPMI 1640 medium with 10% v/v of FBS 
and 1% v/v of P/S and used for in vitro culture of primary tonsillar MNCs. 
Following MNC isolation, cells were washed with DPBS by centrifuging at 400 g for 5 min. 
Supernatant was removed, and the cell pellet was loosened by tapping the tube bottom. Cells 
were then resuspended with appropriate amount of cold complete medium. Cell numbers were 
counted using a hemocytometer with properly diluted cell suspension. Cell concentration was 
adjusted to 4 ´ 106/ml before seeding cells in culture plate. For 48-well plate and 96-well plate, 
cells were seed at 500 μl/well and 250 μl/well respectively. 
The protein concentration of bacterial CCS was adjusted to 0.1 mg/ml by diluting with 
complete medium. Cells were stimulated by adding 5 μl of 0.1 mg/ml CCS to each well of cells 
in 48-well plate to make the final concentration of CCS at 1 μg/ml. 10´ concentrated THB 
media was used to treat control cells. The outer wells of the culture plate were not used for 
cell culture but filled with appropriate amount of sterile water to minimize edge effect. 
Cells were cultured at 37°C with 5% of CO2 for 48 hours to detect memory T cell responses. 
In some experiments, cells were treated with 100 ng/ml of recombinant IL-35 (R&D system) 
and IL-10 (PeproTech) respectively in order to examine the suppressive effects of IL-35 and 
IL-10 on memory T cell responses. The lyophilized human IL-35 Fc chimera protein was 
reconstituted at 100 µg/ml in DPBS and then diluted to 10 µg/ml with complete RPMI 1640 
medium. The 10 µg/ml of IL-35 solution was aliquoted into 50 µl aliquots and stored in -70°C 
freezer. To maintain the biological activity of IL-35, it was ensured that all the aliquots used 
had undergone no more than two freeze-thaw cycles. Recombinant human IL-10 was 
reconstituted at 100 µg/ml in DPBS and aliquoted into 5 μl aliquots, stored in -70°C freezer. 
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The 100 µg/ml of IL-10 solution were further diluted to 10 μg/ml with complete medium before 
use.  
Positive control cells were treated with 20 ng/ml of phorbol 12-myristate 13-acetate (PMA) and 
1 μg/ml of Ionomycin for 4 hours before terminating the culture. PMA and Ionomycin both were 
purchased from Sigma-Aldrich. 
 
2.7.1 Treatment of MNCs with IL-35-conditioned medium 
Expression plasmids containing genes encoding human EBI3 (pRP-Neo-hEBI3) and IL-12A 
(pRP-Puro-hIL12A) were constructed by VectorBuilder. Plasmids were introduced into CHO 
cells using Lipofectamine3000 (Invitrogen) cell transfection kit. Successful transfectants were 
selected and expanded via G418 and puromycin double selection. Co-expression of human 
EBI3 and IL-12A in transfected clones was confirmed by Western blotting. The heterodimeric 
EBI3/IL-12A (IL-35) secretion was detected by co-immunoprecipitation and Western blotting. 
IL-35-expressing CHO cell clones and control CHO cells were cultured in a comparable cell 
density. The cell culture medium collected at 48hrs was used as conditioned medium to test 
the biological function of native IL-35 in this study. 
IL-35-conditioned medium was aliquoted into 200 µl aliquots and stored in -70°C freezer. 
When used to treat cells, 5 µl, 10 µl and 50 µl of IL-35-conditioned medium was supplemented 
in 500 µl of cells to make the concentration at 1%, 2% and 10% respectively. Equal volume of 
conditioned medium harvested from control CHO cells were added to another set of cell 




2.7.2 IL-10 neutralization 
In IL-10 neutralization experiment, cells were treated with 1µg/ml of LEAFTM purified anti-
human IL-10 or rat IgG1k isotype ctrl antibody (BioLegend) and stimulated with bacterial CCS 
for 48 hours. 
 
2.8 Magnetic cell sorting 
All antibody-labelled magnetic beads and separation columns were purchased from Miltenyi 
Biotec. 
 
2.8.1 Direct magnetic labelling (CD25, CD45RO and CD4 microbeads) 
The separation buffer was prepared by supplementing DPBS with 0.5% of BSA. 
By calculating separated cells required for the experiment, a starting cell number can be 
estimated taking into account the proportion of intended cell population within total MNCs and 
cell loss during isolation process. MNCs were washed and resuspended in appropriate 
amount of buffer (80 μl of buffer was added per 107 total cells). Cells were labelled by adding 
20 μl of antibody-conjugated magnetic beads per 107 total cells, followed by incubation at 4°C 
for 15 min. 
Following labelling, cells were washed by adding 1-2ml of buffer per 107 total cells and 
centrifuging at 400 g for 5 min. During centrifugation, LS column was set up on a magnetic 
separator and rinsed with 2 ml of buffer. After washing, cells were resuspended in 500 μl of 
buffer for up to 108 cells. For higher cell numbers, the buffer volume was scaled up accordingly. 
The cell suspension was applied onto the column, and unlabelled cells that passed through 
were collected in a Universal tube. The column was washed with 2 ml of buffer for 3 times, 
and the effluent was collected in the same tube. New buffer was added only when the column 
reservoir was empty. 
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To elute magnetically labelled cells, the column was removed from the separator and placed 
in a new Universal tube, followed by pipetting 5 ml of buffer onto the column and pushing the 
plunger into the column to flush out those cells. 
 
2.8.2 Indirect magnetic labelling (CD69 microbead kit II) 
To separated CD69+ cells from the MNCs, cells were first labelled with Biotin-conjugated anti-
CD69 antibody by adding 10 μl of CD69-Biotin to 107 cells suspended in 40 μl of buffer and 
incubating at 4°C for 15 min. Then, 20 μl of Anti-Biotin microbeads and 30 μl of buffer were 
added per 107 cells, followed by a further incubation of 15 min at 4°C. Following the two-steps 
labelling, cells were washed and separated with LS column as described in 2.8.1. 
 
2.9 CFSE cell proliferation assay 
Carboxyfluorescein succinimidyl ester (CFSE) is a fluorescent dye that can be activated by 
488 nm laser and the emissions are detected by the 530/30 filter, the same filter for fluorescein 
isothiocyanate (FITC). CFSE is cell permeable and able to covalently bind to intracellular 
amino acids. Following each cell division, CFSE fluorescence is also halved within daughter 
cells. Thus, each generation of cells is represented by an individual peak on the flow cytometry 











Figure 2.1 The dividing cycles of CFSE-labelled cells  
 CFSE labelled cells were cultured with or without SAg-Sau CCS for 5 days, followed by staining with 
anti-human CD4 antibody and acquiring data on the flow cytometry machine. The histogram plots are 
gated on CD4+ T cells, showing the median fluorescent intensity (MFI) of the CFSE signals. The left plot 
showing one single peak indicates the media control (MC) cells were not proliferated. SAg-Sau 
stimulated CD4+ T cells are shown in the right plot with 4 more separate peaks to the left of the X-axis, 
representing cells that have undergone 1, 2, 3 and 4 dividing cycles, from right to the left, respectively.  
 
Stock CFSE solution was prepared by reconstituting a vial of lyophilized CellTraceTM CFSE 
(Life technologies) with 18 μl of DMSO. The stock solution was stored in -20°C and protected 
from light. 
Cells were washed with DPBS before staining with CFSE. To stain 108 cells, 2.5 μl of the stock 
solution was diluted in 5 ml of DPBS, making the CFSE concentration at 2.5 μM. After washing, 
cells were resuspended in the 5 ml of CFSE solution and incubated at 37°C for 8 min in the 
dark. 
Following incubation, at least 5 volumes of complete RPMI 1640 medium were added to the 
cells to absorb any unbound dye, followed by centrifuging at 400 g for 5 min. Then, 
supernatant was removed, and cells were resuspended in appropriate amount of complete 
medium. 
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CFSE stained cells were cultured and stimulated with bacterial CCS for 5 days, followed by 
harvesting cells for cell surface staining before acquiring on the flow cytometry machine.  
 
2.10 Th17 cell induction 
CD45RO+ memory T cells were removed from tonsillar MNCs by magnetic cell sorting as 
described in 2.8.1. CD45RO+ T cell-depleted MNCs were resuspended in appropriate amount 
of complete medium. Cell numbers were adjusted to 4 ´ 106 cells/ml. 
Polarizing cytokines used to assist Th17 cell differentiation were IL-1b, IL-21 and TGF-b1. All 
three recombinant proteins were purchased from R&D System. Recombinant human IL-1b 
and IL-21 were reconstituted at 50 μg/ml and 100 μg/ml in DPBS respectively. Recombinant 
human TGF-b1 was reconstituted at 20 μg/ml in sterile 4mM HCl containing 1 mg/ml of BSA. 
After reconstitution, recombinant proteins were aliquoted into 5 μl aliquots and stored in -70°C 
freezer. The reconstituted TGF-b1 was further diluted to 2 μg/ml with DPBS. 
1 μl of IL-1b (50 μg/ml), 0.5 μl of IL-21 (100 μg/ml) and 0.5 μl of TGFb1 (2 μg/ml) were added 
per ml of cells. Thus, 50 ng/ml of IL-1b and IL-21, plus 2 ng/ml of TGFb1 were supplemented 
in CD45RO+ T cell-depleted MNCs. Cells were then seeded to 48-well plate and stimulated 
with 50 ng/ml of Sau-CCS for 7 days. In some experiments, cells were treated with 10 ng/ml 
of recombinant IL-35 at day 0 and day 3 in order to examine the suppressive effect of IL-35 
on SAg-Sau-induced Th17 differentiation. 
Cell culture supernatant was collected at day 7. 20 ng/ml of PMA, 1 μg/ml of Ionomycin and 1 
μl/ml of brefeldin A were added to cells in the last 4 hours if cells were harvested for flow 
cytometry staining. 
 
2.11 Flow cytometry staining 
All antibodies used for flow cytometry staining are listed in table 2.2. 
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2.11.1 Cell surface staining 
The staining buffer was prepared by supplementing PBS with 0.02% of bovine serum albumin 
(BSA). 
Cell culture supernatant was collected before harvesting cells for staining. After removing 400 
μl of culture supernatant, 500 μl of staining buffer was added to the cells. Cells were 
suspended by gently drawing them in and out of a pipette tip, and cell suspensions were 
collected in a 1.5 ml Eppendorf tube. 
Cells were pelleted by centrifuging at 400 g for 5 min. The supernatant was discarded, and 
the cell pellet was loosened by a brief vortex before resuspending cells with 500 μl of staining 
buffer and centrifuge again. Supernatant was poured off, followed by briefly blotting the tube 
on paper towel to remove excess liquid, leaving an approximately 20 μl of buffer in the tube 
with the cell pellet. Cells were properly suspended in the remaining buffer before adding 
antibody solutions. 
The concentration of antibodies used are either titrated previously or as per manufacturer’s 
instructions. 30 μl of antibody master mix was added to each sample, e.g. 5 μl of BV421-anti-
human CD4 (Biolegend), 5 μl of Alexa Fluor 647-anti-human CD3 (BD Biosciences) and 20 μl 
of staining buffer was mixed for each sample. Thus, up to 2 ´ 106 cells were stained in 50 μl 
of staining buffer with antibodies at appropriate concentrations. Cells with antibodies were 
incubated at 4°C for 30 min. 
Following staining, cells were washed with 1ml of staining buffer by centrifuging at 400 g for 5 
min. If no further intracellular staining was required, cells were resuspended in 400 μl of 
staining buffer and filtered through nylon mesh to remove cell clumps. Stained cells were 
acquired on a flow cytometry machine. 
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2.11.2 Intracellular cytokine staining 
For intracellular cytokine staining, the cells were treated with 1 μl/ml of brefeldin A 
(eBioscience) for 4 hours before terminating the culture in order to block cytokine secretion. 
Cells were harvested and stained with cell surface antibodies as described in 2.11.1. After 
washing cells with staining buffer, cell pellet was properly loosened before resuspended in 
100 μl of IC fixation buffer (eBioscience). Cells were fixed by incubating at RT for 30 min, in 
the dark.  
The 10´ permeabilization buffer (eBioscience) was diluted with distilled water to make 1´ 
working solution. After fixation, cells were permeabilized by directly adding 1 ml of 1´ 
permeabilization buffer. Permeabilized cells were pelleted by centrifuging at 600 g for 5 min. 
Cells were washed again with 1´ permeabilization buffer before staining with intracellular 
antibodies. An approximately 20 μl of buffer was remained to suspend cells after removing 
supernatant. 
Intracellular antibody master mix was prepared and added to the cells as it was described for 
cell surface antibodies. Cells with antibodies were incubated at RT for 30 min, in the dark. 
Stained cells were washed by topping up with permeabilization buffer and centrifuging. After 
washing, cells were resuspended in 400 μl of staining buffer and filtered before acquiring on 
a flow cytometry machine. 
 
2.11.3 Foxp3/transcription factor staining 
Cells were harvested and stained with cell surface antibodies as described in 2.11.1. 
Fixation/permeabilization buffer was prepared by mixing 1 part concentrate with 3 parts diluent. 
The Foxp3/transcription factor staining buffer set was purchased from eBioscience. 
After washing cells with staining buffer, 350 μl of the fixation/permeabilization buffer was 
added to the cells to fix and permeabilize cells simultaneously, followed by incubation at RT 
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for 30 min in the dark. By doing so, both cell membrane and nuclear membrane were properly 
permeabilized to allow antibodies for transcription factors to enter the nuclear. 
Following fixation and permeabilization, cells were washed by directly adding 1 ml of 1´ 
permeabilization buffer and centrifuged at 1000 g for 5 min. Cells were washed again before 
staining with intracellular antibodies. 
Intracellular antibody master mix was prepared and added to the cells the same as it was 
described for cell surface staining. Cells with antibodies were incubated at RT for 30 min, in 
the dark. 
Stained cells were washed with 1´ permeabilization buffer and then resuspended in 400 μl of 
staining buffer. 
If an intracellular cytokine was stained together with Foxp3/transcription factor, the 
Foxp3/transcription factor staining protocol was followed. 
 
Table 2.2 Fluorescence-activated cell sorting (FACS) antibodies 
FACS antibody Clone Manufacturer Isotype control 
Alexa Fluor 647 mouse anti-
human CD3 UCHT1 
BD 
Biosciences Alexa Fluor 647 mouse IgG1 k 
PE-Cy5 mouse anti-human CD4 RPA-T4 BD Biosciences PE-Cy5 mouse IgG1 k 
Alexa Fluor 488 mouse anti-
human Foxp3 259D/C7 
BD 
Biosciences Alexa Fluor 488 mouse IgG1 k 
PE mouse anti-human IL-17A N49-653 BD Biosciences PE mouse IgG1 k 
PE rat anti-human IL-10 JES3-19F1 
BD 
Biosciences PE rat IgG2a k 
Alexa Fluor 647 mouse anti-
human IL-17A SCPL1362 
BD 
Biosciences Alexa Fluor 647 mouse IgG1 k 
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PE-Cy7 mouse anti-human CD4 SK3 BD Biosciences PE-Cy7 mouse IgG1 k 
Alexa Fluor 647 mouse anti-
human Foxp3 259D/C7 
BD 
Biosciences Alexa Fluor 647 mouse IgG1 k 
BV421 mouse anti-human 
GARP 7B11 
BD 
Biosciences BV421 mouse IgG2b k 
PE anti-human CD4 RPA-T4 BioLegend PE mouse IgG1 k 
BV421 anti-human CD4 RPA-T4 BioLegend BV421 mouse IgG1 k 
PerCP/Cy5.5 anti-human CD4 RPA-T4 BioLegend PerCP/Cy5.5 mouse IgG1k 
PE mouse anti-human CD39 TU66 BD Biosciences PE mouse IgG2b k 
Alexa Fluor 488 mouse anti-
human IL-17A N49-653 
BD 
Biosciences Alexa Fluor 488 mouse IgG1 k 
PE mouse anti-human IL-17A SCPL1362 BD Biosciences PE mouse IgG1 k 
Alexa Fluor 488 anti-human 
IFNg 4S.B3 BioLegend Alexa Fluor 488 mouse IgG1 k 
PE mouse anti-human RORgt Q21-559 BD Biosciences PE mouse IgG2b k 
FITC anti-human CD4 RPA-T4 BioLegend FITC mouse IgG1 k 
Alexa Fluor 488 anti-human Ki-
67 Ki-67 BioLegend Alexa Fluor 488 mouse IgG1 k 
Pacific Blue anti-human CD4 RPA-T4 BioLegend Pacific Blue mouse IgG1 k 
Pacific Blue 488 anti-human 
IFNg 4S.B3 BioLegend Pacific Blue mouse IgG1 k 
Alexa Fluor 488 anti-human 
CD3 OKT3 BioLegend Alexa Fluor 488 mouse IgG2a k 
BV421 rat anti-human GM-CSF BVD2-21C11 
BD 
Biosciences BV421 rat IgG2a k 
BV421 rat anti-human CD210a 
(IL-10RA) 3F9 
BD 
Biosciences BV421 rat IgG2a k 
Human IL-23R APC-conjugated 218213 R&D Systems APC mouse IgG2b 
 53 
 
2.12 Flow cytometry machine setup 
Stained cell samples were acquired using BD FACSCanto II or BD FACSCelesta. 
 
2.12.1 Isotype controls and compensation setup 
To exclude nonspecific staining and justify the gate for the positive cell population, cells were 
stained with the specific antibodies and corresponding isotype control antibodies respectively 
at the first time of staining. 
For a staining panel that contains antibodies conjugating with fluorochromes that have 
overlapped emission spectra, a spillover could occur if the fluorescence emission of one 
fluorochrome is detected by a detector that is designed to detect the signal of another 
fluorochrome. In this circumstance, compensations were set up to correct the spillover and 
ensure accurate interpretation of the data. 
Unstained cells and single colour stained cells were prepared for compensation setup. For the 
staining panel containing antibodies conjugating with FITC, PE, PerCP and APC, 
compensation controls were prepared as listed in Table 2.3. 
 
Table 2.3 Staining for compensation controls 
Tube 1 Unstained cells 
Tube 2 Cells stained with FITC conjugated antibody 
Tube 3 Cells stained with PE conjugated antibody 
Tube 4 Cells stained with PerCP conjugated antibody 
Tube 5 Cells stained with APC conjugated antibody 
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To ensure a proper positive population being presented, antibodies targeting highly expressed 
proteins by the cells were used for the compensation setup.  
To set up compensations in BD FACSDiva software, Create Compensation Controls was 
chosen, and samples were acquired accordingly. The unstained cells were firstly acquired to 
gate out the desired cell population. The gate was then applied to all following compensation 
controls. Forward scatter (FSC) and side scatter (SSC) voltages were adjusted to display the 
cell population properly. Single colour stained cells were acquired accordingly, and voltages 
of all fluorescent parameters were optimized in order to place the negative and positive 
population appropriately in the plot. After recording all compensation control tubes, Calculate 
Compensation was chosen, followed by naming the compensation setup and linking it to the 
experiment’s cytometer settings.        
 
2.12.2 Running samples with BD FACSDiva software 
A new experiment was created and named after logging into the software. In the cytometer 
settings of the experiment, fluorochromes that were not included in the staining panel were 
deleted. A new specimen was created under the named experiment, and tubes were added 
under the specimen. In the Global Work Sheet, appropriate plots were created for previewing 
the data when acquiring samples. 
The flow rate was set to low or medium speed when adjusting settings. The unstained sample 
was first loaded and acquired for a few seconds, followed by adjusting voltages for FSC and 
SSC to make sure cell populations are in scale and displayed appropriately in the plot. The 
desired cell population, e.g. P1, was gated out, followed by setting the stopping gate on P1 
and changing the events to record to a number you desired in the acquisition setup. Then, by 
acquiring a stained sample, voltages for fluorochrome parameters were adjusted to ensure 
that the negative and positive populations were in scale and separated properly. 
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After optimizing voltages for all parameters, samples were recorded accordingly. All recorded 
data was exported and analysed using Flowjo software. 
 
2.13 Enzyme-linked immunosorbent assay (ELISA) 
Cell culture supernatant was collected in 1.5-ml Eppendorf tubes and stored in -20°C before 
measurement of cytokine concentrations by ELISA. 
Capture antibody was diluted in 5 ml of 1´ coating buffer as noted on the Certificate of Analysis 
(C of A) or as labelled on the antibody vial, followed by coating a Corning ELISA plate 
(Appleton Woods) with 50 μl/well of diluted capture antibody using a multichannel pipette. The 
plate was sealed and incubated overnight at 4°C. 
The 5´ ELISA/ELISPOT Diluent was diluted with distilled water to make 1´ working solution. 
The ELISA washing buffer was prepared by supplementing PBS with 0.05% v/v of Tween 20 
(Sigma-Aldrich). 
The capture antibody solution was discarded before washing the plate on a plate washer 
equipped with ELISA washing buffer. The plate was washed for 3 times, followed by adding 
100 μl/well of the 1´ ELISA/ELISPOT Diluent to block unspecific protein bindings in later steps. 
The plate was sealed and incubated for 2 hours at RT. 
Protein standard was reconstituted and diluted as noted on C of A. Cell culture supernatant 
was diluted with 1´ ELISA/ELISPOT Diluent to make the concentration of analyte that by 
estimation is within the range of the standard curve. 
After blocking, the plate was washed for 3 times, and residual buffer was removed by tapping 
the plate on paper towels. 50 μl/well of the standard was added to appropriated wells, and 2-
fold serial dilutions of the top standards was performed to make the standard curve, followed 
by adding 50 μl/well of diluted samples. Both standard and samples were added in duplicate. 
The plate was incubated with samples overnight at 4°C for maximal sensitivity. 
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Detection antibody was diluted in 5 ml of 1´ ELISA/ELISPOT Diluent as noted on C of A. After 
discarding samples, the plate was washed for 5 times before adding 50 μl/well of diluted 
detection antibody using a multichannel pipette. Again, the plate was sealed and incubated 
for 1 hour at RT. 
The plate was washed for 5 times after incubating with detection antibody. The detection 
antibody is biotin conjugated, thus properly diluted Avidin-HRP was added to wells (50 μl/well) 
in order to link horseradish peroxidase (HRP) to specifically captured proteins for later 
detection. The plate was incubated with Avidin-HRP for 30 min at RT. 
Following Avidin-HRP incubation, the plate was washed for at least 5 times to ensure complete 
removing of the reagent. Then, 50 μl/well of 1´ TMB solution was added to each well. 3,3’,5,5’-
Tetramethylbenzidine (TMB) is chromogenic substrate for HRP, which causes the solution to 
take on a blue colour. The plate was incubated in the dark for an approximately 15 min to 
allow colour development. 
50 μl of Stop Solution (2N H2SO4) was added to each well to end colour development, which 
turned TMB to yellow. Plate was then read at 450 nm using ELISA microplate reader. The 
concentrations of the analyte in samples were determined by the standard curve constructed 
from 2-fold serial diluted protein standards. 
 
2.14 Cytometric Beads Array (CBA) 
CBA is a fluorescent bead-based multiplex assay which allows simultaneous quantification of 
multiple target analytes using flow cytometry. The Human Th Cytokine Panel (13-plex) kit was 
purchased from BioLegend. Beads of this kit can be distinguished by size and internal 
fluorescence (Allophycocyanin, APC), thus different bead set can be identified based on FSC, 
SSC and APC. Each set of beads are conjugated with a specific antibody to capture the target 
analyte in samples. By further labelling the captured analyte with biotin-conjugated detection 
antibody and streptavidin-PE, the amount of the analyte can be reflected by the intensity of 
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PE signal. This assay was used to measure cytokine concentrations in the culture supernatant 
of tonsillar MNCs. 
 
2.14.1 Assay procedure 
All reagents were removed from the fridge and allowed to warm to RT before use. The 20´ 
stock solution was diluted in distilled water to make 1´ Wash Buffer. The top standard C7 
(10,000 pg/ml) was defrosted, and 4-fold serial dilution was performed with Assay Buffer 
provided to obtain standards C6 (2500 pg/ml), C5 (625 pg/ml), C4 (156.3 pg/ml), C3 (39.1 
pg/ml), C2 (9.8 pg/ml), C1 (2.4 pg/ml). Assay Buffer only was used as C0 (0 pg/ml). 
The pre-mixed beads were well suspended by vortexing for 1 min. 25 μl of Assay Buffer was 
added into each tube, followed by adding 25 μl/tube of standards or samples respectively. 25 
μl/tube of pre-mixed beads and detection antibodies were added subsequently. The beads 
bottle was shaken intermittently to avoid bead settling. The tubes were then covered with foil 
and incubated on a shaker with the shaking speed set at 1000rpm for 2 hours at RT. Then, 
25 μl/tube of streptavidin-PE was added directly, and tubes were incubated for a further 30 
min at RT. 
Following incubation, tubes were centrifuged at 1000 g for 5 min to pellet beads. Supernatants 
were removed completely, followed by washing the beads with 200 μl of 1´ Wash Buffer. After 
washing, beads were resuspended in 200 μl of 1´ Wash Buffer and acquired on the flow 
cytometry. 
 
2.14.2 Flow cytometry setup on BD FACSCanto II 
After logging into FACSDiva software, a new experiment was created and parameter FSC, 
SSC, FITC, PE and APC was kept in the cytometer setting. The Raw Beads provided in the 
kit were used to set up the PMT settings. 
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The Raw Beads were properly suspended by vortexing for 30 seconds, followed by 
transferring 400 μl of the beads to a FACS tube. The flow rate was set to low, and the Raw 
Beads were acquired. The voltages of FSC and SSC were adjusted to display populations of 
Beads A and Beads B appropriately in the plot as shown in Figure 2.2 a. The voltage for FITC 
parameter was also adjusted to place the majority of beads between 1 ´ 101 to 1 ´ 102 for 
FITC signal (Figure 2.2 b). Then Beads A and Beads B populations were gated out, and two 
dot plots were created with PE for X-axis, APC for Y-axis, and gated on Beads A and Beads 
B respectively. By adjusting voltages for APC and PE, majority of beads were displayed 
between 1 ´ 101 to 1 ´ 102 for PE signal, and 1 ´ 102 to 5 ´ 104 for APC signal (Figure 2.2 c, 
d). After optimizing voltages for all parameters, samples were then recorded accordingly. The 
number of beads recorded was set to about 300 per analyte. 




Figure 2.2 Cytometric settings on Canto II FACSDiva for CBA detection 
The Raw Beads were acquired on the flow cytometry machine. The voltage of parameter FSC-A, SSC-
A, FITC-A, PE-A and APC-A were adjusted as indicated in the above paragraph to put the Beads A and 
Beads B population in the position shown in the dot plots. This figure is cited from the Manual of 







2.15 Quantitative reverse transcription PCR (RT-qPCR) 
2.15.1 mRNA extraction 
The RNeasy Mini Kit was purchased from Qiagen for mRNA extraction. 
1 ´ 106 to 5 ´ 106 of Tonsillar MNCs or isolated CD4+ T cells was pelleted by centrifuging at 
400 g for 5 min, followed by completely removing the supernatant. The RLT lysis buffer was 
freshly supplemented with 1% v/v b-mercaptoethanol (b-ME) to eliminate ribonuclease 
released during cell lysis. Cell pellet was loosened by flicking the tube before adding 350 μl of 
RLT lysis buffer to the cells. Cell lysate was frozen in -70°C before the mRNA extraction. 
Ribonuclease (RNase) can be found in air, most surfaces and dust. To avoid exposing isolated 
RNA to surrounding RNase during isolation and the following reverse transcription procedures, 
the benchtop and surroundings were carefully cleaned with 1% distel, and special precautions 
were taken when processing samples. 
Cell lysates were removed from -70°C freezer and defrosted in 37°C water bath. Once 
defrosted, cell lysates were immediately removed from the water bath and kept in an ice box. 
Cell lysate was homogenized by transferring into a QIAShredder spin column and centrifuging 
at full speed of the microcentrifuge for 2 min. The volume of lysate after homogenization was 
measured, and then 1 volume of 70% ethanol was added to the homogenized lysate and 
mixed well by pipetting. Up to 700 μl of sample was transferred to an RNeasy spin column, 
and centrifuged at ³ 8000 g for 15 seconds. The flow-through was discarded, followed by 
adding 700 μl of RW1 buffer to the column and centrifuging again at ³ 8000 g for 15 seconds. 
The RPE buffer was prepared by adding appropriate amount of ethanol before use. The 
column was then washed twice with 500 μl of RPE buffer and the flow-through was discarded 
following each wash. After washing steps, the column was carefully removed from the old 
collection tube and placed in a new 2 ml collection tube. The column in the new collection tube 
was centrifuged at full speed for 1 min to eliminate any possible carry-over of the RPE buffer. 
Then, the RNeasy spin column was placed in a new 1.5 ml collection tube, and 30 μl of RNase-
free water was added directly to the spin column membrane. The column was centrifuged at 
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³ 8000 g for 1 min to elute the RNA bound to the column membrane. Isolated RNA samples 
were kept in an ice box. 
The concentration and purity of isolated RNA was measured using NanoDrop 
spectrophotometer by dropping 2 μl of the RNA sample onto the pedestal. The OD at 260 nm 
equals 1.0 for a 40 μg/ml RNA solution, thus the RNA concentration in the solution was 
determined by the reading at OD260. Pure RNA has an OD260/OD280 ratio of approximately 2.0. 
 
2.15.2  Reverse transcription 
First-strand cDNA was synthesized from the isolated RNA by reverse transcription using 
Moloney Murine Leukemia Virus Reverse Transcriptase (M-MLV RT) (Promega). All other 
reagents required for the synthesis were also from Promega. RNA samples and all reagents 
were placed on ice throughout the procedure. RNase-free water was used for dilution of 
reagents. 
10 mM dNTPs was prepared by mixing and diluting 50 μl of dATP, dCTP, dGTP and dTTP 
(100 mM) in 300 μl of RNase-free water. 40 u/μl of Recombinant RNasin Ribonuclease 
Inhibitor was diluted to 25 u/μl, and 500 ng/μl of Random Primers was diluted to 50 ng/μl. 
A total 1 μg of RNA was used for the first-strand cDNA synthesis. 1 μl of Random Primers (50 
ng/μl) was added to 1 μg of RNA in a total volume of 15 μl RNase-free water in a PCR 
microtube, followed by heating at 70°C for 5min using a PCR machine. Following the heating, 
samples were cooled down immediately on ice to prevent reforming of secondary structure. 
Volumes of reagents required for a 25 μl reaction was listed in Table 2.4. The reaction master 
mix was prepared by mixing these reagents with volumes required for total reactions intended. 
10 μl of the master mix was added to 15 μl of the pre-heated RNA sample, followed by 
incubating the reaction tube at 37°C for 1 hour in a PCR machine. Synthesized cDNA sample 
was kept in -20°C freezer before used for qPCR reaction later. 
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               Table 2.4 Reagents for RT master mix 
Reagents Volume for one reaction (μl) 
5´ M-MLV Reaction Buffer 5 
dNTPs (10 mM) 1 
RNasin Ribonuclease Inhibitor (25 u/μl) 1 
M-MLV RT (200 u/μl) 1 
RNase-free water 2 
Total 10 
  
2.15.3 Quantitative polymerase chain reaction (qPCR) 
The mRNA expressions of targeted genes were detected by SYBR-based quantitative PCR 
using SYBRÒ Green JumpStartTM Taq ReadyMixTM (Sigma-Aldrich). This 2´ qPCR ReadyMix 
contains Taq polymerase, SYBR Green I and dNTPs in MgCl2 buffer. The SYBR Green I stain 
preferentially binds to double-strand DNA enabling the detection of DNA copies amplified by 
the thermostable Taq polymerase. 
Gene-specific primers were designed using the ‘Primer-Blast’ tool provided on the website of 
National Centre for Biotechnology Information (NCBI) and then synthesized by Sigma-Aldrich. 
All primers used were listed in Table 2.5. The lyophilized primers were reconstituted at 100 
μM in nuclease-free water, and then further diluted to 10 μM. The cDNA samples were 1:10 
diluted in nuclease-free water and used as template in the qPCR reaction. Other components 





Table 2.5 qPCR Primers 






Forward 5’-TGCCTTCACCACTCCCAAAACCTGCTGA-3’ 70.0 
154 
Reverse 5’-ATGGTAAACAGGCCTCCACTGTGCTGGT-3’ 69.6 
Human ebi3 
NM_005755.2 
Forward 5’-AAACTCCACCAGCCCCGTGTCCTTCATT-3’ 69.9 
161 
Reverse 5’-CGGTGACATTGAGCACGTAGGGAGCCAT-3’ 70.1 
Human il23r 
NM_144701.2 
Forward 5’-GGTGGCAGCCTGGCTCTGAAGTGGAATTA-3’ 70.0 
193 
Reverse 5’-GGTTCTACCCAGATGTGGCCAGAGCAGTT-3’ 69.6 
Human il17ra 
NM_014339.6 
Forward 5’-ACCTTAAAGGGTGCTGTCGCCACCAAGT-3’ 70.0 
181 
Reverse 5’-AGCAGGATGGAGATGCCCGTGATGAACC-3’ 70.0 
Human b-actin 
NM_001101.5 
Forward 5’-GCTCACCATGGATGATGATATCGCCGC-3’ 67.7 
199 
Reverse 5’-GATGCCTCTCTTGCTCTGGGCCTCGTC-3’ 70.2 
Mouse il17a 
NM_010552.3 
Forward 5’-CCAGCTGATCAGGACGCGCAAACATGAG-3’ 69.7 
115 
Reverse 5’-TGAGGGATGATCGCTGCTGCCTTCACTG-3’ 70.1 
Mouse il12a 
NM_001159424.2 
Forward 5’-TTCCAGGCCATCAACGCAGCACTTCAGA-3’ 70.2 
196 
Reverse 5’-TGAAGGCGTGAAGCAGGATGCAGAGCTT-3’ 70.3 
Mouse ebi3 
NM_015766.2 
Forward 5’-GCCTCCTAGCCTTTGTGGCTGAGCGAAT-3’ 70.3 
133 
Reverse 5’-GAGAAGATGTCCGGGAAGGGCCAGGAAG-3’ 69.8 
Mouse b-actin 
NM_007393.5 
Forward 5’-TTCTTTGCAGCTCCTTCGTTGCCGGTC-3’ 69.5 
199 





               Table 2.6 Components for qPCR reaction 
Components Volume for one reaction (μl) 
2´ SYBRÒ Green JumpStartTM Taq ReadyMixTM 10 
Forward primer (10 μM) 0.4 
Reverse primer (10 μM) 0.4 
Nuclease-free water 5.2 
Total 16 
 
Depending on total reactions intended for each target gene, volumes of these components 
were calculated and then mixed to make the master mix for qPCR reactions. 16 μl of the 
master mix was added to a 96-well PCR plate. Without touching the master mix down in the 
bottom, 4 μl of 1:10 diluted cDNA sample was added on the inner wall of the well. The plate 
was sealed and briefly centrifuged to mix the cDNA sample with the master mix. All reactions 
were made in duplicate. The PCR plate was run in Bio-Rad CFX ConnectTM Real-Time PCR 
machine with cycling parameters set as following (Table 2.7). 
If only target gene was specifically amplified, a single sharp peak at the melting temperature 
(Tm) of the amplified gene fragments would be shown in the Melting Curve (Appendix 1). The 
quantitative cycle (Cq) is the number of cycle when the accumulated fluorescence from SYBR 
Green bound DNA copies is detected above the base level. The Cq value of the target gene 
was normalized to the Cq of b-actin housekeeping gene and translated into fold changes of 






                           Table 2.7 qPCR step protocol 
Step 1 94°C for 2:00 min 
Step 2 94°C for 0:15 min 
Step 3 63°C for 0:20 min 
Step 4 72°C for 0:20 min + Plate read 
Step 5 GOTO Step 2, 39 more times 
Step 6 Melt Curve 75°C to 95°C, increment 0.5°C 
 0:05 min + Plate read 
Step 7 4°C Hold 
 
2.16 DNA gel electrophoresis 
Amplified DNA fragments from the qPCR reaction were examined by agarose gel 
electrophoresis to ensure the qPCR products are the same size as the predicted gene 
fragment. 
To make a 1.5% agarose gel, 1.05 g of agarose was suspended in 70 ml of TBE buffer in a 
flask followed by microwaving for 1-3 min until the agarose was completely dissolved. The 
agarose solution was cooled to 55°C approximately before adding 7 μl of SYBRÒ Safe DNA 
gel stain (10,000´ concentrated in DMSO) and mixing well by swirling the flask. The SYBR 
safe binds to the DNA and allows it to be visualized using an imager. The agarose solution 
was then poured into a gel tray, and a well comb was inserted immediately. The new poured 
gel was left at room temperature for 20-30 min until it was completely solidified. 
The agarose gel was placed into the gel box (electrophoresis unit), followed by filling the box 
with TBE buffer until the gel was covered. The well comb was removed to expose loading 
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wells. The 100 bp DNA ladder (New England BioLabs) was loaded into the first and last lanes 
of the gel. The rest of wells were loaded with qPCR products mixed with the Loading Buffer. 
By connecting the electrodes of the gel box to a power pack, the gel loaded with DNA samples 
was run at 100 V for 45-60 min. The DNA is negatively charged and runs towards the positive 
electrode. The Loading buffer added to the DNA samples contains visible dye showing the 
migration of DNA in the gel during electrophoresis. It also has a high percentage of glycerol 
that increases the density of the DNA sample, making it settle down to the bottom of the gel 
well. 
The agarose gel could be equally divided into 2 sections by inserting 2 parallel combs. Once 
the DNA samples had run nearly half way through the gel, the power was turned off, and the 
agarose gel was carefully removed from the gel box for DNA imaging using Bio-Rad 
ChemiDocTM XRS+ System. 
The DNA fragments of human Il12a, Ebi3, Il23r, Il17ra, b-actin and mouse Il12a, Ebi3, Il17a, 
b-actin following qPCR are shown in Appendix 1. 
 
2.17 Western Blotting 
2.17.1 Sample preparation 
Tonsillar MNCs with or without stimulation were separated into CD4+ T cells and CD4- MNCs 
by magnetic cell sorting as described in 2.8. The purity of isolated CD4+ T cells (>96%) was 
confirmed by FACS staining with anti-CD3 and anti-CD4 antibodies (Appendix 2). To ensure 
enough amount of protein for later detection, at least 2 ´ 106 of isolated cells were 
resuspended in 50-100 μl of clear lysis buffer (CLB) which was kindly provided by Dr. Ziqi Lin, 
and lysed on ice for 20 min. To prevent protein degradation, the CLB was freshly 
supplemented with protease inhibitor cocktail (Sigma-Aldrich) before use, and lysate samples 
were kept in cold condition for the subsequent processing. The cell lysate was sonicated for 
3 ´ 5 seconds and then centrifuged at 10,000 g for 30 min with a temperature of 4°C to pellet 
cell debris and DNA fragments. Following centrifuging, the supernatant was carefully 
 67 
transferred to a new Eppendorf tube. Samples were stored in -70°C freezer if not used on the 
same day. 
2.5 μl of the protein sample was diluted 10 times in distilled water for the measurement of 
protein concentration using Pierce BCA Protein Assay Kit. 40 μg of each protein sample was 
mixed with 1/3 sample volume of 4´ Laemmli sample buffer (Bio-Rad) before heating at 95°C 
for 5 min. The 4´ Laemmli sample buffer was freshly supplemented with 10% v/v of b-ME 
which helps to break the disulfate bonds in the protein. Following heating, the samples were 
centrifuged at 10,000 g for 1 min. 
 
2.17.2 Polyacrylamide gel electrophoresis (PAGE) and Blotting 
The 4-15% Mini-PROTEANÒ TGXTM Precast Protein Gels and 10´ Tris/Glycine/SDS running 
buffer were purchased from Bio-Rad. 
The precast gel was placed into a gel tank filled with 1´ running buffer, and the well comb was 
removed carefully. Equal amount of protein samples (40 μg) were loaded into the wells. By 
connecting the tank to a power pack, the gel was run at 100 V constantly for 90 min 
approximately. The CLB and running buffer both contain SDS that denatures protein and coats 
the protein with a uniform negative charge. Thus, proteins in the sample run towards the 
positive electrode and separated based on their molecular weight (MW). 
The proteins were transferred from the gel to a PVDF membrane using Trans-Blot Turbo 
Transfer System with Trans-BlotÒ TurboTM Mini PVDF Transfer Pack (Bio-Rad). Once 
completing the electrophoresis, the gel was trimmed appropriately and carefully transferred 
onto the PVDF membrane which is layered on top of the anode stack, followed by placing the 
cathode stack on the gel. Any air bubble in the assembled transfer pack was removed using 
a blot roller. The stack with the gel and membrane was then lifted from the tray and placed in 
the centre of the cassette withdrawn from a Trans-Blot Turbo instrument. The cassette was 
closed firmly before slid back to the instrument. The transfer pack was run under a pre-
programmed ‘Mixed MW’ protocol. 
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2.17.3 Antibody labelling and protein imaging 
The 10´ Tris buffered saline (TBS) was diluted with distilled water and supplemented with 0.1% 
v/v of Tween 20 to make TBST washing buffer.  
Following blotting, the membrane was instantly immersed in 5% w/v skim milk in TBST and 
incubated on an orbital shake (110 revs/min) at RT for 2 hours to block unspecific protein 
bindings in later steps. Then, the membrane was briefly rinsed and incubated in the primary 
antibody solution against target protein on the shake (110 revs/min) at 4°C, overnight. The 
primary antibody was diluted in antibody diluent (Life technologies) accordingly (Table 8). 
On the following day, the membrane was washed with TBST for 5 ´ 5 min with the shaking 
speed set to 150-200 revs/min before incubating with HRP-conjugated secondary antibody 
solution for 1 hour at RT, also on the shaker (110 revs/min). Anti-Rabbit IgG secondary 
antibody or Mouse IgG kappa binding protein (m-IgGκ BP) was used depending on the host 
species used to generate the primary antibody. The secondary antibody was diluted 
accordingly using 5% w/v skim milk in TBST (Table 2.8). After incubation with secondary 
antibody, the membrane was washed again with TBST for 5 ´ 5 min with the shaking speed 
set to 150-200 revs/min. The Clarity Western ECL Substrate (Bio-Rad) was prepared as per 
manufacturer’s instruction and then applied to the membrane, followed by capturing the 








Table 2.8 Western Blot antibodies 
Antibodies Manufacturer Stock concentration Dilution 
Primary 
antibody 
Anti-IL-12/IL-35 p35 antibody 
(Clone 27537) R&D 0.5 mg/ml 1:500 
Anti-IL-27/IL-35 EBI3 antibody 
(Clone A15058A) BioLegend 0.5 mg/ml 1:500 
b-Actin antibody (C4) Santa Cruz 200 μg/ml 1:1000 
Secondary 
antibody 
m-IgGκ BP-HRP Santa Cruz 400 μg/ml 1:5000 
Mouse anti-rabbit IgG-HRP Santa Cruz 400 μg/ml 1:5000 
 
2.18 Co-Immunoprecipitation (Co-IP) 
IL-35 is a heterodimer protein consisting of IL-12p35 and EBI3 subunits. To detect IL-35 
heterodimer, the M-280 sheep anti-mouse IgG Dynabeads (Thermo Fisher) was incubated 
with the protein sample and anti-IL12p35 antibody to capture the target heterodimer protein, 
followed by eluting the target protein from the beads and immunoblotting with anti-EBI3 
antibody. 
 
2.18.1 Co-IP in cell culture supernatant 
The cell culture supernatant was collected and centrifuged at 400 g for 5 min to remove 
residual cells. 1.5 μg of anti-IL-12/IL-35 p35 (Clone 27537) antibody was added to 1 ml of 
culture supernatant and incubated with gentle rotation at 4°C for 1-2 hours. 
Dynabeads in the vial were suspended properly by vortex for 1 min. 50 μl of Dynabeads was 
used for each sample, which contains approximately 3 ´ 107 beads. Appropriate amount of 
Dynabeads were transferred to a 5 ml FACS tube and washed twice with 1 ml RPMI 1640 
medium using EasySepTM Magnet (STEMCELL). The beads were resuspended in the same 
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volume of medium as the initial volume of beads. Then, 50 μl of beads were added to the 
culture supernatant pre-incubated with anti-IL-12/IL-35 p35 antibody and incubated overnight 
with gentle rotation at 4°C. 
On the following day, the culture supernatant with Dynabeads was transferred to a 5 ml FACS 
tube, followed by washing the beads twice with 1 ml of cold DPBS. The beads were then 
resuspended with 30 μl of cold RIPA buffer (Sigma-Aldrich) and transferred to an Eppendorf 
tube. Appropriate amount of 4´ Laemmli sample buffer supplemented with 10% v/v b-ME was 
added to the beads, followed by heating the beads at 100°C for 10 min to elute the target 
protein from the beads. The beads were pelleted by centrifuging at 10,000 g for 5 min with a 
temperature of 4°C, and the supernatant containing eluted protein was carefully collected for 
detection of EBI3 subunit by Western Blot as described in 2.17.2 and 2.17.3. 
 
2.18.2 Co-IP in cell lysate 
The tonsillar MNCs were stimulated with SAg-Sau CCS for 48 hours, and the Brefeldin A was 
added to the cells 4 hours before harvesting cells. 1 ´ 108 cells were harvested for CD4+ T 
cell isolation by magnetic cell sorting as described in 2.8.1. The number of isolated CD4+ T 
cells was counted, and 1 ´ 107 cells were transferred to a new Universal tube and centrifuged 
at 400 g for 5 min. The supernatant was removed completely, and cell pellet was loosened by 
flicking the tube. 1 ml of RIPA buffer without SDS and supplemented with protease inhibitors 
was added to the cells, followed by incubating on ice for 30 min to lyse the cells completely. 
The cell lysates were sonicated for 3 ´ 5 seconds on ice before centrifuging at 10,000 g for 
30 min with a temperature of 4°C to remove cell debris and DNA fragments. Following 
centrifuging, the supernatant was carefully collected for Co-IP. 
The Co-IP procedure described in 2.18.1 was followed for the detection of IL-35 heterodimer 
in the CD4+ T cell lysis. However, RIPA buffer instead of RPMI 1640 medium and DPBS was 
used for Dynabeads calibration and washing. 
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2.19 Luciferase assay for the detection of active TGF-b 
2.19.1 Transformed Mink Lung Cells (TMLCs) 
TMLC is a luciferase-fused TGF-b reporter cell line, which was kindly provided by Dr Mark 
Travis from the University of Manchester. TGF-b is secreted in a latent form which requires 
further processing to release active TGF-b. The TMLCs were transfected with an expression 
construct containing a truncated plasminogen activator inhibitor-1 (PAI-1) promoter fused to 
the firefly luciferase reporter gene. Active TGF-b is able to induce the expression of PAI-1 in 
TMLCs, resulting in dose-dependently enhanced luciferase activity in the cell lysates which 
can be detected as increased relative light units (RLU) in the luciferase assay. 
The TMLCs were revived and cultured with high-glucose Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10% v/v of FBS, 1% v/v of P/S and L-glutamine in a T-75 flask. 
TMLC are adherent cells and requires digestion by trypsin when passaging cells. Cells were 
passaged when reaching 80-90% confluency. The cell culture supernatant was discarded, 
and the cells were washed with DPBS. 2 ml of trypsin-EDTA solution (Sigma-Aldrich) was 
added to the cells, gently tilting the flask to ensure cells were evenly covered with the solution. 
The flask was kept in the incubator at 37°C for 2-10 min until over 90% of cells were detached. 
10 volumes of complete medium was added to the cell to inhibit trypsin activity, and cells were 
pelleted by centrifuging at 400 g for 5 min. Cells were then resuspended in complete medium 
and split 1:10 into new flasks. 1 mg/ml of Geneticin, also known as G418, was supplemented 
to the cell cultures to remove cells that have lost the transfected expression construct. The 
tonsillar MNCs were cultured in RPMI 1640 medium, thus the TMLCs were adapted to this 
culture medium before used for luciferase assay. 
 
2.19.2 Luciferase assay 
Cell culture supernatant was collected from tonsillar MNCs stimulated with bacterial CCS at 
different time points (Day 2, 3, 4, 5, 6) for the detection of active TGF-b produced by MNCs. 
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Culture medium supplemented with 2-fold serial diluted recombinant TGF-b1 (1000, 500, 250, 
125, 62.5, 0 pg/ml) was used to test the functionality of the TMLCs and a standard curve 






Figure 2.3 Standard curve for the correlation of luciferase activity (RLU) in the TMLCs 
and the concentration of active TGF-b1 in the media 
 
TMLCs were suspended in complete DMEM, and the cell number was adjusted to 1 ´ 105 
cells/ml. In a 96-well white plate (Thermo Fisher), 2.5 ´ 104 cells/well (250 μl) of TMLCs were 
seeded and cultured at 37°C with 5% of CO2 in the incubator for 3 hours to allow the cells to 
attach. Once the cells were attached properly, the culture medium was carefully removed and 
replaced with the MNCs’ culture supernatant mixed with equal volume of fresh culture medium. 
Cells were placed back to the incubator and cultured for 24 hours. 
The Luciferase assay kit was purchased from Promega. Before detecting luciferase activity in 
TMLCs, the cell culture supernatant was completely removed, and the cells were carefully 
washed with DPBS in the culture plate. Then, 20 μl/well of 1 ´ lysis buffer (included in the kit) 
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was added to the cells and the cell culture plate was put into the FLUO STAR Omega 
Luminometer. A bottle containing Luciferase assay reagent was placed into the Luminometer, 
and the injector was set to add 100 μl/well of the reagent when reading the plate. 
In some experiments, pre-attached TMLCs (4 ´ 104) were co-cultured with 5 ´ 105 of tonsillar 
MNCs and stimulated with bacterial CCS. At 48 hours, the MNCs were resuspended by gentle 
pipetting and then removed, followed by detecting Luciferase activity of the TMLC as 
described above. 
 
2.20 Mouse nasal colonization model  
2.20.1 Preparation of fresh Sau culture 
An aliquot of Sau liquid stocks was removed from the -80°C	freezer and defrosted at RT. The 
bacterial stock was prepared with bacterial suspension having an OD600 of 0.5 that equals to 
1 ´ 108 CFU/ml approximately for the bacterial concentration.  
For HIP07930 strain (NonSAg-Sau), the bacteria (1 ´ 108 CFU/ml) was diluted 1:106 in 10 ml 
of fresh THB media and cultured on an orbital shaker with a shaking speed of 230 revs/min 
for 12 hours at 37°C. 1 ´ 108 CFU/ml of FRI913 strain (SAg-Sau) was diluted 1:1010 in 10 ml 
of THB and cultured at the same conditions as HIP07930 strain. 
Following culture, OD600 of the bacterial growth was measured to estimate the bacterial 
concentration. An approximately 1 ´ 109 CFU of bacteria was resuspended in 1 ml of sterile 
PBS for the intranasal infection in mice. 
 
2.20.2 Mouse infection and tissue dissection 
Female C57BL/6 mice aged 6-8 weeks were purchased from Charles River, UK. Mice were 
maintained in individually ventilated cages at 22 ± 1°C and 65% humidity with a 12hr light-
dark cycle. Prior to use, mice were acclimatised for one week with free access to food and 
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water. Mice were lightly anaesthetised with O2/isoflurane and were infected intranasally with 
107 CFU of Sau in 10μl PBS or PBS only for control group mice. 3 infected mice were 
sacrificed at day 12 post infection to confirm clearance of primary infection, following which 
mice were re-infected with Sau at the same dose at day 14 post primary infection. Mice were 
then culled at 24hrs post secondary infection to assess the nasopharyngeal bacteria load and 
CD4+ T cell responses in the cervical lymph nodes (CLNs). All experimental protocols were 
approved and performed in accordance with the regulations of the Home Office Scientific 
Procedures Act (1986), project licence P86De83DA and the University of Liverpool Ethical 
and Animal Welfare Committee. 
The nasopharyngeal tissue was removed and homogenised in 3ml of sterile PBS before 
plating out on blood agar for assessment of tissue CFU. The CLNs were dissected for the 
isolation of lymphocyte. 
 
2.21 Isolation of MNCs from murine cervical lymph nodes 
 Lymph nodes dissected from 3 mice were pooled together for MNC isolation. The lymph 
nodes were collected in HBSS and kept on the ice before the isolation procedure. A 70 μm 
cell strainer was inserted into the well of a 6-well plate filled with 8 ml of HBSS which should 
be sufficient to cover the mesh of the cell strainer. The lymph nodes were transferred onto the 
mesh and ground using the plunger of a 5 ml syringe to release MNCs. The cell strainer was 
then moved to an adjacent well, and the cell suspension was filtered again through the cell 
strainer and transferred to a Universal tube. Cell number of the isolated MNCs were 
determined, followed by centrifuging cells at 400 g for 5 min and resuspending in appropriate 
amount of separation buffer for magnetic cell sorting. 
CD4+ T cells were isolated from the MNCs as described in 2.8.1 and per manufacturer’s 
instructions (Mouse CD4 (L3T4) Microbeads, Miltenyi). The purity of isolated CD4+ T cells 




2.22 Statistical analysis 
Data distribution was tested using D'Agostino-Pearson or Shapiro-Wilk normality tests and 
results were then analysed accordingly with paired t-test (two-tailed) or unpaired t-test (two-
tailed). Data that were not normally distributed was log-transformed before performing 
parametric t-tests or analysed using Wilcoxon matched-pairs signed rank test (two-tailed). The 
association between fold increase in Th17 and Th17 inhibition by IL-35 was analysed using 
linear regression. All data were analysed in Prism 7 software. Data displayed are mean ± SEM 
for column bar graphs and grouped line plots. For data shown as box and whiskers, median 
(centre line), upper and lower quartile (box limits) and minimum to maximum range (whiskers) 
are displayed. Asterisks denote p-value (*p <0.05, **p <0.01, ***p <0.001, ****p <0.0001). p-value 











Staphylococcus aureus activates Th17 and Treg 





Staphylococcus aureus (Sau) is a frequently identified colonizer in human nasopharynx, and 
its colonization has been associated with relapse/exacerbation of inflammatory and 
autoimmune diseases. However, little is known about the site-specific T cell-mediated 
immunity in response to nasal colonization of Sau. Pro-inflammatory Th17 cells and anti-
inflammatory Foxp3+ Tregs are two critical CD4+ T cell subsets that are involved in the 
aetiology and pathogenesis of inflammatory/autoimmune conditions. By evaluating the local 
Th17 and Treg responses to Sau in nasopharynx-associated lymphoid tissue (NALT) in 
humans, it may help to identify underlying mechanisms for infection-induced autoimmunity.  
In this study, Sau, especially superantigenic Sau (SAg-Sau), was shown to activate a potent 
Th17 response in tonsillar MNCs which was substantially higher than Streptococcus 
pneumoniae (Spn) and other commonly identified bacteria in the nasopharynx. An inverse 
correlation between Th17 and Treg responses was observed in Spn-stimulated tonsillar MNCs, 
indicating Treg-mediated suppression on Th17 responses. However, this inverse correlation 
was not found in the context of Sau stimulation even though the Treg population was largely 
expanded. Interestingly, Sau stimulation promoted IL-17A expression in Foxp3+ Tregs which 
partially explained why Sau-activated Th17 and Tregs were not negatively associated. Further 
investigation on Treg-related suppression pathways demonstrated that despite increased 
production of active TGF-b and IL-10, the expression of CD39 on the Tregs was markedly 
downregulated by Sau. Human Tregs have been shown to require CD39 for their suppressive 
function against Th17 cells. This reduced proportion of CD39+ Tregs following Sau stimulation 
may result in a deficient regulation of Th17 activation.  
The results suggest Sau infection may impair Treg-mediated suppression on Th17 responses 
in the NALT, thus contributing to inflammatory/autoimmune pathogenesis through 





The tonsils (palatine tonsils) are secondary lymphoid tissues located at the rear of the pharynx. 
As a major component of the mucosa-associated lymphoid tissue (MALT), tonsil sits at the 
entrance of upper respiratory tract and helps to protect the host from exogenous pathogens 
inhaled through the nasopharynx105. Frequently exposed to foreign antigens, tonsils are 
important induction sites for adaptive immune responses and contain a substantial repertoire 
of memory T cells, including both central memory and effector memory cells106. A markedly 
higher proportion of CD4+ T cells (CD4/CD8 ratio > 5) is found in tonsils compared to the 
average CD4/CD8 ratio of around 2 in the peripheral blood and spleen107. The activation and 
regulation of CD4+ T cell responses are of significant importance in fighting against pathogen 
infection but also in mediating inflammatory pathologies in the nasopharynx. 
It has been shown that local immune responses have systemic effects and are able to 
influence specific organs at distal sites108. The gut segmented filamentous bacteria (SFB) 
induced Th17 cells are able to migrate into central nervous system, spleen and lung and 
provoke autoimmune pathogenesis in these organs as shown in animal models47,48,108. A 
clinical case report describing a patient of autoimmune Tourette syndrome with intermittent 
Sau nasopharyngeal carriage demonstrated that the local Sau colonization-induced immune 
activation cleared the bacterial infection but also induced a systemic autoimmune 
reactivation109.  
Sau-activated Th17 and Treg responses have been studied using human peripheral blood 
mononuclear cells (PBMCs)14,110. It is reported that SAg-Sau activates IL-17A production from 
memory T cells in PBMCs14. Sau-derived superantigen SEA is shown to induce CD25+Foxp3+ 
Tregs from CD25- cells in PBMCs, and these induced Tregs are capable of suppressing anti-
CD3 activated T cell proliferation111. Compared to the peripheral blood, the NALT (refers to 
palatine tonsils in this study) has a different composition of immune cells and contains 
significantly higher frequency of antigen-experienced T cells, which has shaped the distinct 
immune environment of nasopharynx. Understanding of host-microbe interaction in the 
nasopharynx can shed light on the pathogenesis of infection-related diseases and provide 
new strategies for vaccine design. In this study, I explored the impact of Sau-derived antigens 
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on nasopharyngeal T cell responses, which could help to understand the underlying 




Ø To examine the capacity of Sau in activating Th17 responses in human NALT 
comparing to other common bacterial colonizers. 
Ø To assess whether Sau stimulation affects the Foxp3+ Treg population in human 
NALT. 
Ø To evaluate Treg associated suppression pathways in Sau stimulated tonsillar MNCs. 
 
3.4 Results and Discussion 
T cell co-receptor CD3 is the cell surface marker to distinguish thymus-derived T cells from 
other lymphocytes. The helper T (Th) cells express anther co-receptor CD4 and can thereby 
be separated from the CD8+ cytotoxic T (Tc) cells. Monocytes and macrophages also express 
low level of CD4, but they are generally excluded from the typical lymphocyte gate due to 
larger size and more granulated cell surface. Within the lymphocyte gate, a single CD4+ cell 
population was identified in tonsillar MNCs, and this cell population also expressed CD3 
indicating these cells were Th cells (Figure 3.1 a). Thus, CD4 staining only is sufficient to 
separate CD4+ Th cells from tonsillar MNCs. 
IL-17A is the signature cytokine expressed by Th17 cells, and Foxp3 is the transcription factor 
that governs the suppressive function of Foxp3+ T regulatory cells (Tregs). In accordance with 
current knowledge, IL-17A and Foxp3 were primarily expressed by CD4+ T cells in human 
tonsillar MNCs (Figure 3.1 b, c). The Th17 cells and Tregs in this study were gated as IL-
17A+CD4+ and Foxp3+CD4+ cells respectively (Figure 3.1 d). The proportion of Th17 cells 
shown in this study indicates all IL-17A+CD4+ cells, including IL-17A+ Foxp3+CD4+ cells, unless 
otherwise stated. 
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Concentrated culture supernatant (CCS) was prepared from bacterial cultures as described 
in 2.2 and used to stimulate MNCs isolated from human tonsillar tissue. The bacterial culture 
media, Todd Hewitt Broth (THB) supplemented with 0.5% w/v of yeast extract, was 
concentrated the same way as bacterial culture supernatant and used to treat cells as media 





Figure 3.1 Gating strategies for Th17 cells and Foxp3+ Tregs 
 a) CD3 and CD4 double staining for tonsillar MNCs. Lymphocytes were gated out to show the Th cells 
which are CD3+CD4+ cells as indicated in the rectangular gate. b) IL-17A intracellular cytokine staining 
showing CD4+ T cells are the primary source of IL-17A. Numbers in top left and right quadrants indicate 
the percentages of IL-17A+CD4- cells and IL-17A+CD4+ cells (Th17 cells) in SAg-Sau stimulated tonsillar 
MNCs. c) Foxp3 intracellular nuclear transcription factor staining to identify Foxp3+CD4+ Treg population. 
Numbers in top left and right quadrants indicate the percentages of Foxp3+CD4- cells and Foxp3+CD4+ 
cells (Tregs) in tonsillar MNCs. d) Lymphocytes were gated by FSC and SSC. After excluding doublets 
from the lymphocytes, CD4+ T cells were gated to show IL-17A+CD4+ Th17 cells and Foxp3+CD4+ Tregs. 
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3.4.1 Sau activates a potent Th17 response in human NALT  
Th17 cells are pro-inflammatory CD4+ T cells that play a pivotal role in host defence against 
external microbes but also in the development of inflammatory disorders37. Spn and Sau are 
two commonly identified colonizers of human nasopharynx that drive inflammatory diseases, 
such as pneumonia and septicaemia. Extracted pneumococcal antigens from wild type D39 
strain were able to activate memory Th17 cells in tonsillar MNCs shown by colleagues in our 
group112. Consistent with their finding, a modest increase in Th17 cells was detected in Spn-
D39 stimulated MNCs, accompanied with enhanced production of IL-17A in the culture 
supernatant (Figure 3.2 a, b). I then examined whether pneumococcal carriage strains 
isolated from the nasal swabs were also capable of activating Th17 responses in tonsillar 
MNCs. As shown in Figure 3.2 c, 3 out of 4 pneumococcal carriages strains (C6, C7, C8, C9) 
were capable of stimulating a Th17 response. 
It has been reported that superantigen-producing Staphylococcus aureus (SAg-Sau) 
promotes IL-17 production from memory CD4+ T cell in human PBMCs14. Located at the entry 
of the upper airway, tonsils are exposed to a large number of foreign antigens, and therefore 
contains a substantial amount of effector and memory T cells106. As expected, SAg-Sau 
(positive for tsst, sea, sec and see) stimulation produced a potent Th17 response in tonsillar 
MNCs. Interestingly, the NonSAg-Sau (negative for tsst, sea, seb, sec, sed and see) also 
activated a Th17 response, although it was significantly less than SAg-Sau stimulation (Figure 
3.3 a). In line with the markedly increased proportion of Th17 cells, a high concentration of IL-
17A in the cell culture supernatant was detected by ELISA upon SAg-Sau stimulation (Figure 
3.3 b). To further assess the Th17 activation by clinical Sau strains, CCS prepared from 3 
carriage strains (C1, C2, C3) isolated from the nasal swabs was used to stimulate tonsillar 
MNCs. Strong Th17 responses were detected for all three strains (Figure 3.3 c). 
I have shown that superantigen-positive Sau strain activated a remarkably higher Th17 
response compared to superantigen-negative strain. To examine whether this also applies to 
isolated carriage strains, the total SE (A-E) level in culture supernatant of the 3 carriage strains 
were measured. As expected, the C3 strain, which activated stronger Th17 responses than 
the other 2 carriage strains (C1 and C2), and NonSAg-Sau also produced higher level of SE 
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(A-E) (Figure 3.3 d). The results indicate a strong promoting effect by staphylococcal 






Figure 3.2 Spn-activated Th17 responses in tonsillar MNCs 
Tonsillar MNCs were stimulated with 1 μg/ml of concentrated culture supernatant (CCS) from wild type 
D39 (serotype 2 Spn strain) for 48hrs, and the Th17 responses were analysed comparing to the media 
control (MC) cells. a) Dot plots were gated on CD4+ T cells, and numbers in top right quadrants indicate 
the percentage of Th17 cells. Data displayed in the bar graph is mean ± SEM, n = 29. b) IL-17A 
concentration in the culture supernatant of MNCs measured by ELISA, n = 10. c) The Th17 responses 
activated by 4 carriage Spn strains isolated from nasal swabs. Mean ± SEM with individual data points 





Figure 3.3 SAg-Sau activates a potent Th17 response in tonsillar MNCs 
Tonsillar MNCs were stimulated with 1 μg/ml of CCS from NonSAg-Sau and SAg-Sau respectively for 
48hrs, and Th17 responses were analysed. a) Dot plots were gated on CD4+ T cells, and the percentage 
of Th17 cells is shown in top right quadrants. Mean ± SEM is displayed in the bar graph, n = 30. b) IL-
17A concentration in the culture supernatant of CCS stimulated MNCs. Individual data points with mean 
± SEM are shown in the scatter plot, n = 16. c) The Th17 responses activated by 3 carriage Sau strains 
were compared to NonSAg-Sau stimulated tonsillar MNCs. The percentages of Th17 cells (mean ± SEM) 
from different stimulation groups are shown in the scatter plot with bars, n = 5. d) Staphylococcal 
enterotoxin A-E levels in the culture supernatant of Sau strains. PC, positive control; NC, negative control. 
All data was analysed using paired t-test (*p < 0.05, **p < 0.01, ****p < 0.0001). 
 
The Th17 activation by SAg-Sau was then compared with pneumococcal strains (D39, TIGR4) 
and other commensal colonizers, M. catarrhalis and coagulase-negative Staphylococcus 
(CNS-C4, C5), in individual MNCs. SAg-Sau stimulation consistently activated a remarkably 
higher Th17 response than the Spn strains, and no significant Th17 response was elicited by 






Figure 3.4 SAg-Sau activates a markedly higher Th17 responses than Spn 
 a) Tonsillar MNCs were stimulated with 1 μg/ml of CCS from Spn, Sau, coagulase negative 
staphylococcus (CNS) and M. catarrhalis respectively for 48hrs. The percentages of Th17 cells following 
stimulation were determined and shown as mean ± SEM in the scatter plot with bars, n = 8. b) IL-17A 
concentration in the culture supernatant of MNCs stimulated by Spn-D39 and SAg-Sau respectively. 
Mean ± SEM is displayed in the scatter plot, n = 9. All data was analysed using paired t-test (*p < 0.05, 
**p < 0.01, ***p < 0.001, ****p < 0.0001). 
 
The results demonstrate SAg-Sau is the major activator of Th17 responses in human NALT. 
Superantigen activates T cells through cross-linking MHC class II of the antigen-presenting 
cells with T cell receptor (TCR) Vb chains which is not restricted to antigen specificity24. The 
NonSAg-Sau strain used in this study also had the ability in activating effector and memory 
Th17 cells, suggesting the presence of staphylococcal antigen-specific memory Th17 cells in 
the NALT. However, it cannot be excluded that this NonSAg-Sau strain may produce some 
unknown toxins that have superantigenic properties. 
Simultaneous colonization of Spn and Sau in the nasopharynx is uncommon, and one of the 
suggested underlying mechanisms is competing growth of these two bacteria. Interestingly, 
this exclusive colonization was not observed in HIV-infected individuals indicating host 
immunity also plays a role. Th17 activation-induced neutrophil influx is critical for the clearance 
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of pneumococcal colonization in the nasopharynx53. Although Spn itself is able to activate a 
mild Th17 response, it may not be sufficient for an efficient clearance. While SAg-Sau is 
introduced, the potent Th17 activation could help to remove the pneumococcal carriage in the 
nasopharynx. 
SAg-Sau-activated Th17 responses in the host may also promote its own clearance. How 
strong the Th17 responses are activated can be individual-dependent, which may determine 
the duration of bacterial carriage. Notably, superantigen-activated T cell responses are shown 
to assist superantigenic Streptococcus pyogenes in the establishment of nasopharyngeal 
colonization at earliest stages by a recent study113. It is possible that SAg-Sau-activated Th17 
responses can also be used by the bacteria to initiate its own colonization.  
The biological effect of Th17 cells is largely attributed to its signature cytokine, IL-17A. IL-17A 
acts on structural cells, such as epithelia cells, fibroblasts and keratinocytes, to activate the 
NF-kB signalling pathway resulting in the production of inflammatory cytokines (e.g. IL-6 and 
G-CSF) and chemokines by these cells. Macrophages and neutrophils are recruited by the 
chemokines and further developed into pro-inflammatory phenotypes with enhanced ability in 
phagocytosis and generating highly active molecules including nitric oxide (NO) and reactive 
oxygen species (ROS), thereby clearing the invading pathogens and also initiating 
inflammatory pathologies. 
In the presence of SAg-Sau, the NALT elicits a potent Th17 response which may promote 
bacterial clearance thereby protecting host against infection. Whether this defensive immunity 
is manipulated by the bacteria to facilitate its initial infection is yet to be elucidated. However, 
it is likely that this strong Th17 activation, if not controlled, may cause inflammatory tissue 
damage and present as a major risk for the development of inflammatory diseases. 
 
3.4.2 Sau expands the Foxp3+ Treg population in human NALT  
Foxp3+ Tregs have been intensively studied for their central role in maintaining immune 
tolerance to auto-reactive immune responses and resolving inflammations114. By sharing the 
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common TGF-b-mediated signalling pathway during differentiation, the development of Th17 
cells and Foxp3+ Tregs are reciprocally regulated and their phenotypes remain 
interchangeable in effector stage. Disturbed balance between these two cell populations has 
been implicated in various inflammatory/autoimmune diseases115,116. The Th17 activation was 
elicited by both Spn and Sau in tonsillar MNCs (Figure 3.2, 3.3), it was therefore of interest 
to examine whether Foxp3+ Tregs in the NALT were responding to these colonizers. 
Following stimulation, a significantly increased Treg population was detected in Spn-D39 
treated tonsillar MNCs, as well as the other 4 carriage Spn strains (Figure 3.5). This result 
confirmed that Spn promotes Treg activation in order to persistently colonize the nasopharynx 




Figure 3.5 Spn promotes Foxp3+ Treg population 
Tonsillar MNCs were stimulated with Spn CCS (1 μg/ml) for 48hrs, and the Treg population was analysed. 
a) The contour plots were gated on CD4+ T cells, and numbers in top right quadrants indicate the 
percentage of Foxp3+CD4+ cells. Treg proportions were summarised in the bar graph, n = 29. b) Bar 
graph with individual data points showing percentages of Tregs within CD4+ T cells for tonsillar MNCs 
stimulated by 4 carriage Spn strains, n = 8. Data displayed is mean ± SEM. 
 
Interestingly, the Foxp3+ Treg cell population was largely expanded following Sau stimulation, 
and SAg-Sau was again more potent than NonSAg-Sau in expanding Tregs (Figure 3.6 a). 
This Treg expansion was also observed in MNCs activated by the 3 carriage strains. However, 
the superantigen-producing C3 strain was not the strongest one in stimulating Treg expansion 
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as it was shown for Th17 activation compared to the other 2 carriage strains that produced 
barely detectable enterotoxin A-E (Figure 3.6 b). 
The Treg expansion stimulated by SAg-Sau was markedly higher than Spn which may be a 
negative regulation to counteract the potent Th17 activation by the host (Figure 6c). The 
commensal colonizers, M. catarrhalis and CNS, were not able to activate either Th17 or Tregs 




Figure 3.6 The Treg population is largely expanded by SAg-Sau 
a) Tonsillar MNCs were stimulated with 1 μg/ml of NonSAg-Sau and SAg-Sau CCS respectively for 
48hrs. Contour plots showing Foxp3+ cells within CD4+ T cells with percentages of the Treg population 
displayed in top right quadrants. The Treg percentages were summarised in the bar graph with mean ± 
SEM, n = 29. b) Percentages of Tregs within CD4+ T cells in tonsillar MNCs stimulated by NonSAg-Sau, 
SAg-Sau and 3 carriage Sau strains. Mean ± SEM is displayed in the scatter plot with bars, n = 5. c) 
The Treg expansion in tonsillar MNCs stimulated with Spn, SAg-Sau, CNS and M. catarrhalis 
respectively. Percentages of Tregs (mean ± SEM) are shown in the scatter plot with bars, n = 8. 
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It has been reported that Foxp3+ Tregs derived from human PBMCs are anergic to anti-CD3 
stimulation but able to proliferate in response to staphylococcal superantigen110. Another study 
demonstrates that bacterial superantigens are able to induce Foxp3 expression in CD25-CD4+ 
T cells111. Therefore, the expanded Treg population following SAg-Sau stimulation is likely to 
contain both proliferated Tregs and freshly induced Tregs. Whether this expanded Treg 
population has retained suppressive functions requires further investigation. 
 
3.4.3 The correlation of Th17 and Treg responses stimulated by Spn and Sau strains  
An intriguing finding was revealed when I looked into the correlation of Th17 and Treg 
proportions stimulated by 5 Spn and 5 Sau strains respectively in two individual samples (S1 
and S2). As shown in the Figure 3.7, the MNCs stimulated by 5 Spn strains showed an inverse 
correlation between activated Th17 and Tregs which meant a Spn strain that was more potent 
in activating Tregs would have a lower Th17 response. This inverse correlation indicates 
suppression of Th17 responses by activated Tregs in Spn stimulated MNCs. In contrast to 
Spn stimulation, Th17 and Treg responses stimulated by 5 Sau strains were not negatively 
correlated but more towards a positive correlation, suggesting Sau-expanded Tregs were not 













Figure 3.7 The correlation of Th17 and Treg responses in tonsillar MNCs stimulated by 
Spn or Sau 
The tonsillar MNCs isolated from 2 individuals (S1 and S2) were stimulated with 5 Spn strains (D39WT, 
C6, C7, C8, C9) and 5 Sau strains (NonSAg-Sau, SAg-Sau, C1, C2, C3) respectively. At 48hrs, 
percentages of Tregs and Th17 cells within CD4+ T cells were determined, and associations between 
these two cell populations activated by different Spn or Sau strains was analysed using linear regression. 
Each dot represents a bacteria strain. R2 and p values are displayed. 
 
3.4.4 SAg-Sau promotes IL-17A expression in Foxp3+ Tregs 
In addition, an increased IL-17A expression was detected in the expanded Tregs following 
Sau stimulation, and this was more evident in SAg-Sau stimulated MNCs (Figure 3.8). Th17 
cells and Tregs share the common TGF-b signalling for their initial differentiation which results 
in the interchangeable phenotype between these two CD4+ T cell subsets at effector phase116. 
The existence of IL-17A-producing Tregs in human PBMCs and tonsillar MNCs has been 
reported by stimulating cells with PMA/ionomycin. However, it requires extra addition of 
certain cytokines, such as IL-2, IL-6 and IL-21, to induce IL-17A expression in these Tregs if 
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stimulated via TCR signalling (anti-CD3 and anti-CD28)118. Here, I show that SAg-Sau 
stimulation only was able to induce a substantial expression of IL-17A in Foxp3+ Tregs. SAg-
Sau stimulation enhanced the production of IL-6 and IL-2 in tonsillar MNCs (Figure 3.9), which 




Figure 3.8 SAg-Sau promotes IL-17A expression in Foxp3+ Tregs 
Tonsillar MNCs were stimulated for 48hrs by Spn and Sau CCS respectively. The dot plots were gated 
on CD4+ T cells showing IL-17A expression in Foxp3- and Foxp3+ cells with numbers in top right 
quadrants indicating the percentage of IL-17A+Foxp3+ cells. Data was summarised (mean ± SEM) in the 








Figure 3.9 Cytokine production in the tonsillar MNCs stimulated by NonSAg-Sau or 
SAg-Sau  
Tonsillar MNCs were stimulated by 1 µg/ml of NonSAg-Sau and SAg-Sau respectively for 48 hours. Cell 
culture supernatants were collected, and the cytokine production were detected by CBA. n=5. 
 
The plasticity of Tregs which enabling them to convert to Th17 cells is correlated with the 
development of inflammatory/autoimmune conditions119,120. In a murine model of collagen-
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induced-arthritis (CIA), the arthritogenic and autoreactive Th17 cells are shown to derive from 
Foxp3+CD4+ T cells, indicating the autoimmune potential of Foxp3+ Tregs should they convert 
to Th17 cells119. Our results suggest that certain tonsillar Foxp3+ Tregs may also acquire an 
autoimmune potential in the context of SAg-Sau stimulation. However, it is technically difficult 
to track a Th17 conversion from Foxp3+ Treg in experimental human studies. 
 
3.4.5 SAg-Sau induces production of active TGF-b and IL-10  
Sau-expanded Tregs seemed unable to suppress the Th17 activation and contributed to IL-
17A production in tonsillar MNCs. It is plausible that Sau may downregulate Treg-mediated 
suppression pathways. To evaluate the suppressive activity of Sau-expanded Tregs, I first 
examined the production of active TGF-b and IL-10, two signature cytokines that mediate 
Treg-dependent suppressions. 
TGF-b is secreted as latent precursor protein which requires further activation to exert its 
biological functions. The latent TGF-b is produced by many cell types, including immune cells. 
The activation of TGF-b is tightly controlled and can be mediated by activated Tregs121-123. In 
this study, transformed mink lung cells (TMLCs), which produce luciferase in response to TGF-
b signalling (as described in 2.19), were used to examine the production of active TGF-b in 
bacterial antigen stimulated tonsillar MNCs.  
By co-culturing tonsillar MNCs with TMLCs in the presence of Spn or Sau CCS, an enhanced 
luciferase activity was detected at 48hrs following Sau stimulation, indicating an increased 
production of active TGF-b in Sau-activated MNCs (Figure 3.10 a). The TMLCs were then 
cultured with MNC culture supernatant collected at day 2, 3, 4, 5 and 6 following stimulation. 
Sau stimulation promoted TGF-b activation, and this increased level of active TGF-b was 
maintained throughout the 6-day culture. In accordance with the higher proportion of Tregs, 
SAg-Sau also activated more TGF-b than NonSAg-Sau and Spn (Figure 3.10 b). 
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The active TGF-b was not increased by Spn stimulation, nor was IL-10 (Figure 3.10 a and 
Figure 3.11 a, b). In contrast, both active TGF-b and IL-10 production were enhanced by Sau, 




Figure 3.10 Production of active TGF-b is enhanced by Sau stimulation 
a) Tonsillar MNCs (5 ´ 105) were co-cultured with TMLCs (4 ´ 104) and stimulated with Spn and Sau 
respectively for 48hrs. The TMLCs were washed and lysed for the detection of luciferase signal (RLU, 
relative light unit). Data was analysed using paired t-test, n = 3. b) The cell culture supernatant was 
collected from Spn or Sau stimulated MNCs at different time points (D2, D3, D4, D5 and D6), and the 








Figure 3.11 SAg-Sau stimulation promotes IL-10 production in tonsillar MNCs 
Tonsillar MNCs were cultured in the presence of 1 μg/ml of Spn or Sau CCS for 48hrs. a) The percentage 
of IL-10+ cells within CD4+ T cells following Spn stimulation was summarised in the bar graph, n = 4. b) 
IL-10 concentration in the culture supernatant of Spn stimulated MNCs, n = 5. c) IL-10 concentration in 
the culture supernatant of MNCs stimulated by NonSAg-Sau and SAg-Sau respectively, n = 4. Data was 
analysed using paired t-test. 
 
IL-10 can be expressed by monocytes, B cells and T cells. Hence, intracellular cytokine 
staining was performed to determine whether SAg-Sau activated IL-10 production was from 
the Foxp3+ Tregs. As shown in Figure 3.12, Foxp3-CD4+ T cells were the primary source of 
IL-10 in SAg-Sau stimulated tonsillar MNCs, although an increase in IL-10 expression was 
detected in Foxp3+CD4+ T cells. 
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IL-10-producing CD4+ T cells that do not express Foxp3 have been described by previous 
studies and termed as type 1 regulatory T cells (Tr1). Tr1 cells are critical in controlling the 
activation of effector T cells during tissue inflammation, autoimmunity and graft-versus-host 
disease. The effect of IL-10 on SAg-Sau-activated Th1 and Th17 responses was examined in 
the next chapter. 
 
 
Figure 3.12 SAg-Sau induces IL-10 expression primarily in Foxp3-CD4+ T cells 
IL-10 expression in different immune cell populations was examined in SAg-Sau stimulated tonsillar 
MNCs. a) Dot plots showing IL-10 expression in CD4- lymphocytes and CD4+ T cells. Numbers in top 
left and right quadrants indicate percentages of IL-10+CD4-and IL-10+CD4+ cells respectively. Mean ± 
SEM is shown for both cell populations (%) in the stacked bar graph, n = 8. b) Percentages of IL-10+ 
cells in Foxp3+CD4+ and Foxp3-CD4+ T cell populations were summarised in the stacked bar graph, n = 
3. 
 
3.4.6 SAg-Sau upregulates CTLA4 but downregulates CD39 expression in Foxp3+ 
Tregs 
Cytotoxic T lymphocyte-associated protein 4 (CTLA4) and its structure relative CD28 are both 
expressed by T cells and interact with the same shared ligands CD80 and CD86 on antigen-
presenting cells (APC) but have opposing functions124. While CD28 binds to the ligands to 
provide co-stimulatory signal for T cell activation, CTLA4 signalling inhibits T cell responses. 
CTLA4 is constitutively expressed in Foxp3+ Tregs and induced in conventional T cells 
following activation. With higher affinity and avidity to both ligands, CTLA4 contributes to Treg-
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dependent suppression via outcompeting CD28 for ligand binding and thereby abrogating the 
co-stimulatory signal delivered by CD28125.  
The CTLA4 expression in CD4+ T cells was increased in Spn stimulated tonsillar MNCs. 
Matched with the potent activation of T cells, SAg-Sau induced CTLA4 expression in over 80% 
of CD4+ T cells (Figure 3.13 a). SAg-Sau-expanded Tregs also exhibited enhanced CTLA4 
expression comparing to Spn and NonSAg-Sau stimulation (Figure 3.13 b). Thus, SAg-Sau 
stimulation did not appear to affect Treg-mediated suppressions through CTLA4 route. 
CTLA4 is a well-recognized immune checkpoint that limits immune responses to self-tissues. 
CTLA4 deficiency caused by genetic mutation and immune checkpoint blockade therapy in 
cancer patients both lead to autoimmune reactions126,127. In Foxp3+ Tregs, CTLA4 signalling 
represents a critical suppressive pathway in containing effector T cell responses. However, 
Treg-specific CTLA4 deficiency is shown to enhance both Th1 and Th2 activation but not 
affect the Th17 frequency in the splenocytes of mice128. Further, it has been reported that the 
colon inflammation induced by adoptive transfer of in vitro differentiated Th17 cells can be 
augmented by co-transfer of induced Tregs, which is dependent on the CTLA4-mediated 
signalling of the Tregs129. Hence, the enhanced CTLA4 expression in SAg-Sau-expanded 







Figure 3.13 Increased CTLA4 expression in CD4+ T cells and Foxp3+ Tregs by Sau 
Tonsillar MNCs were stimulated with Spn and Sau CCS respectively for 48hrs, and the expression of 
CTLA4 was examined by intracellular staining. a) The percentage of CTLA4+ and CTLA4-cells within 
CD4+ T cells are shown in top and bottom right quadrants of the contour plots. b) Foxp3+CD4+ T cells 
were gated out to show CTLA4 expression in Foxp3+ Tregs. Results represent 3 independent 
experiments. 
 
CD39 is an ectonucleotidase that works with CD73 to convert extracellular ATP into 
immunosuppressive adenosine83,130. By engaging with the A2A receptor on effector T cells, 
adenosine downregulates NF-kB activation, thereby reducing the release of proinflammatory 
cytokines and chemokines83. 
In human PBMCs, both CD39+ and CD39- Tregs suppressed IFNg production and effector T 
cell proliferation but only CD39+ Tregs were capable of suppressing IL-17 production81,131. The 
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frequency of CD39+ Tregs was lower in patients with multiple sclerosis which may have led to 
Th17-driven autoimmune pathology in these patients81. In light of this study, I examined CD39 
expression on tonsillar Foxp3+ Tregs stimulated by Spn and Sau respectively. The results 
showed that Spn induced upregulation of CD39 on activated Tregs which was in contrast to 





Figure 3.14 SAg-Sau downregulates cell surface expression of CD39 on Foxp3+ Tregs 
Tonsillar MNCs were stimulated with Spn, NonSAg-Sau and SAg-Sau CCS respectively for 48hrs. 
Expression of CD39 was detected by cell surface staining and compared to media control (MC). a) 
Histogram plots were gated on Foxp3+CD4+ T cells, and the percentage of CD39+ cells in Tregs were 
summarised in the bar graphs (b), n = 6. Data displayed is mean ± SEM. 
 
Following SAg-Sau stimulation, the Foxp3+ population was expanded which was 
accompanied with increased level of active TGF-b and IL-10. The expanded Tregs also had 
enhanced expression of CTLA4. However, CD39 expression on SAg-Sau-activated Tregs was 
significantly downregulated which could lead to inefficient clearance of extracellular ATP and 
impaired suppression through adenosine/A2A signalling pathway. 
ATP is released from CD4+ T cells upon stimulation and acts in an autocrine manner through 
P2X receptors to further augment TCR-initiated activation of mitogen-activated protein 
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kinases (MAPKs) and IL-2 secretion132. It is demonstrated that accumulated ATP inhibits the 
suppressive potential of Tregs and induces their conversion to IL-17-producing Th17 cells133. 
SAg-Sau-expanded Tregs could therefore fail to suppress Th17 activation and further 
contribute to IL-17A production due to increased ATP level which was associated with low 
proportion of CD39+ Tregs. 
  
3.4.7 The association of SAg-Sau-activated T cell responses with age  
With PMA/ionomycin stimulation, an age-dependent increase in the tonsillar Th17 frequency 
was shown by our colleagues previously112. I examined whether SAg-Sau-activated Th17 and 
Treg responses in the NALT were associated with age. The age of patients recruited in this 
study ranges from 2 to 50 yrs old. SAg-Sau activated Th17 responses in tonsillar MNCs were 
observed from all age groups. The proportion of Th17 cells following SAg-Sau stimulation was 
increasing with age in children but not further increased in adults (> 16 yrs) (Figure 3.15 a). 
A trend of decline in the Th17 response was observed in individuals over 30-year-old which 
may relate to the decreasing of T cell responsiveness to antigen stimulation when grow older. 
However, the sample size of this age group was too small to make the conclusion. Overall, 
there was a lack of clear association between age and SAg-Sau-activated Th17 responses in 
the NALT (Figure 3.15 c).  
Interestingly, the proportion of the Tregs expanded by SAg-Sau showed a positive correlation 
with age (Figure 3.15 b, d). However, this expanded Treg population did not appear to 










Figure 3.15 The association of SAg-Sau-activated T cell responses with age 
Tonsillar MNCs were cultured with or without SAg-Sau CCS for 48hrs, and Th17 and Treg cell responses 
were analysed following stimulation. Percentages of Th17 cells (a) and Tregs (b) within CD4+ T cells are 
shown in the line plots as mean ± SEM for different age groups. Individual data points are displayed in 
(c) and (d) for Th17 and Tregs respectively, and their associations with age were analysed using linear 
regression. Sample size (n), R square (R2) and p values are indicated.  
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3.4.8 SAg-Sau activates significantly higher Th17 responses in tonsillar MNCs 
compare to PBMCs  
Since the nasopharynx is intensively exposed to foreign antigens, the NALT contains a 
markedly higher proportion of effector and memory T cells compared to peripheral blood. SAg-
Sau has been shown to activate IL-17 production from memory CD4+ T cells14. Indeed, I show 
here that SAg-Sau elicited a strong Th17 response in tonsillar MNCs, whereas only modest 
Th17 activation was detected in SAg-Sau stimulated PBMCs (Figure 3.16 a). In contrast, 
SAg-Sau induced more Tregs in PBMCs than tonsillar MNCs (Figure 3.16 b). It is possible 
that superantigen is more potent to induce naïve T cell proliferation, and this is followed by a 
phenotype switch to Foxp3+ Tregs111. 
My results suggest a high potency of SAg-Sau in activating effector and memory Th17 cells, 
and the nasopharynx provides a well-suited immune environment for SAg-Sau to elicit strong 
Th17 responses. It is of significant importance to investigate whether this potent Th17 











Figure 3.16 Comparison of SAg-Sau-activated Th17 and Treg responses in tonsillar 
MNCs and PBMCs 
Tonsillar MNCs or PBMCs were stimulated with 1 μg/ml of SAg-Sau CCS, and the Th17 and Treg cells 
were examined at 48hrs following stimulation. Percentages of IL-17A+ cells (a) and Foxp3+ cells (b) 
within CD4+ T cell population are shown in the scatter plots with mean ± SEM. The results represent 8 
(a, PBMCs group), 26 (a, TS-MNCs group), 9 (b, PBMCs group) and 28 (b, TS-MNCs group) 
independent samples. Data was analysed using unpaired t-test. 
 
3.5 Conclusions 
In this chapter, I have shown the activation of Th17 cells and Foxp3+ Tregs by Sau and Spn 
in human NALT. Treg-associated suppression pathways were also investigated to inform 
potential functional defects in Sau-activated Tregs. 
Sau-derived antigens activated a remarkably higher Th17 responses than Spn, and this strong 
Th17 activation was associated with high level of staphylococcal superantigens. Along with 
elevated Th17 responses, Sau also expanded the Foxp3+ Treg population. However, the 
proportion of Tregs and Th17 cells activated by Sau strains was not negatively associated as 
it was observed in Spn-stimulated tonsillar MNCs, indicating Sau-expanded Tregs were not 
able to suppress the potent Th17 responses. 
An increased level of active TGF-b and IL-10 was detected in MNC culture supernatant 
following SAg-Sau stimulation, although the enhanced IL-10 production was primarily derived 
from Foxp3-CD4+ T cells. SAg-Sau-expanded Tregs exhibited enhanced expression of CTLA4, 
suggesting these Tregs were able to efficiently antagonize CD28-mediated co-stimulatory 
 103 
signal, hereby suppressing T cell activation. However, the proportion of CD39+ cells within the 
Foxp3+ Treg population expanded by SAg-Sau was markedly reduced. It has been 
demonstrated that only CD39+ Tregs were capable of suppressing IL-17 production in human 
PBMCs, and a significantly lower frequency of CD39+ Tregs was found in the circulation of 
patients with multiple sclerosis which may contribute to the Th17-driven pathologies in these 
patients81. Thereby, SAg-Sau-expanded Tregs may be unable to suppress the Th17 activation 
due to downregulated CD39 expression. 
Further, SAg-Sau activated a remarkably stronger Th17 response in the nasopharynx 
compared to the peripheral blood, suggesting that the capacity of SAg-Sau in activating Th17 
responses is associated with high proportion of effector and memory T cells. Also, memory 
Th17 cells are more enriched at the mucosal site. This potent Th17 activation in SAg-Sau-
infected human nasopharynx is a potential risk for the development of 
inflammatory/autoimmune conditions. Hence, CD4+ T cell-mediated immune controls on SAg-
Sau-activated proinflammatory T cell responses were further investigated and demonstrated 















Foxp3+ Tregs and IL-10 play critical roles in suppressing pathological Th17 activation in 
murine models of autoimmune diseases. Staphylococcal superantigens have been shown to 
induce CD4+ T cell-mediated autoimmune pathologies. I have demonstrated that SAg-Sau 
was able to activate a potent Th17 response accompanied with largely expanded Treg 
population and significantly upregulated IL-10 production in tonsillar MNCs. It was therefore 
of interest to examine whether Tregs and IL-10 were able to suppress SAg-Sau-activated 
Th17 responses in human NALT.  
By depleting Foxp3+ Tregs, an enhanced proliferation of CD4+ T cells was detected in Spn 
stimulated tonsillar MNCs, whereas Sau-activated cell proliferation was not altered. Treg-
mediated suppression of IFNg-producing Th1 and IL-17A-producing Th17 responses was 
further evaluated in SAg-Sau stimulated MNCs. Interestingly, Treg removal enhanced the Th1, 
but not the Th17 activation, indicating that Foxp3+ Tregs were not competent in suppressing 
SAg-Sau-activated T cell responses, especially for Th17 cells. IL-10-mediated suppression of 
Th1 and Th17 activation in SAg-Sau stimulated MNCs was examined by neutralizing IL-10. 
Again, IL-10 depletion did not affect the strong Th17 responses, although it significantly 
augmented Th1 activation. Further, I found that addition of recombinant IL-10 enhanced the 
IL-17A expression in CD4+ T cells upon SAg-Sau stimulation and promoted GM-CSF 
expression in the activated Th17 cells, suggesting a potential pathogenic role of IL-10 in SAg-
Sau-infected nasopharynx.  
The results demonstrate that SAg-Sau-activated Th17 cells in the NALT are resistant to Tregs- 
and IL-10-mediated suppression. This aberrant immune regulation on proinflammatory Th17 






From suppressor T cells to regulatory T cells, the discovery and delineation of 
Foxp3+CD25+CD4+ regulatory T cell subset (Tregs) has gone through its own history of 
renaissance134-136. The existence of a specific suppressive T cell subpopulation was initially 
proposed in the early 1970s134. However, it was followed by decades of chaos in the field of 
suppression until this self-tolerance maintaining Treg cell population was characterised as 
CD25+CD4+ T cells by Sakaguchi in 1995137. Later in 2003, transcription factor Foxp3 was 
found to be a unique marker for CD25+CD4+ regulatory T cells. Foxp3 is specifically required 
for the thymic development of Tregs, and forced expression of Foxp3 in CD25-CD4+ cells 
confers suppressor activity on these cells138-140. 
It has been well described that Foxp3+ Treg depletion and Foxp3 gene mutations lead to the 
development of autoimmune and inflammatory diseases as a result of uncontrolled activation 
of CD4+ T cells139-144. Foxp3+ Tregs suppress effector T cell proliferation and Th1 activation. 
However, the suppression has been questioned when it comes to Th17 cells. Tregs and Th17 
cells share the common TGF-b signal for their initial differentiation, and Tregs can convert into 
IL-17-producing cells when they are exposed to certain cytokines, such as IL-6 and IL-23116,118. 
IL-10 is a well-established immune suppressive cytokine produced by a number of immune 
cells including Foxp3+ Tregs and Foxp3- type 1 regulatory cells (Tr1)145,146. IL-10 was originally 
termed as cytokine synthesis inhibitory factor (CSIF) that expressed by Th2 cells to inhibit 
proinflammatory cytokine production in Th1 cells147. Later studies demonstrate that IL-10 
inhibits production of a broad spectrum of inflammatory cytokines (IL-1, IL-6, GM-CSF, TNFa, 
IL-12, etc.) and chemokines (MCP1, MCP5, IL-8, IP-10, etc.) by macrophages/monocytes and 
subsequently suppresses the recruitment and activation of T cells and monocytes145. 
There is a large body of evidence to support the potent suppressive activity of IL-10 on both 
Th1 and Th17 activation in mice and humans78,85,148,149. IL-10 or IL-10 receptor knockout mice 
have significantly increased risk of developing autoimmune disorders, such as IBD and 
EAE87,150. Loss of function mutations in IL-10 and IL-10 receptor (IL-10R) in humans has also 
been linked to an early-onset of IBD88-90. Despite these findings, attempts to utilise 
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recombinant IL-10 clinically for treating autoimmune diseases have been unsuccessful91. 
Further studies to elucidate IL-10-mediated suppression in a wide range of immunological 
settings, including SAg-Sau-driven inflammations, are required to demystify the IL-10 paradox. 
 
4.3 Aims 
Ø To examine Treg-mediated suppression on SAg-Sau-activated CD4+ T cell responses, 
including cell proliferation and inflammatory cytokine production by Th1 and Th17 
cells. 
Ø To evaluate the role of IL-10 in suppressing SAg-Sau-activated Th1 and Th17 
responses in human NALT. 
Ø To test whether IL-10 affects the effector phenotype of SAg-Sau-activated Th17 cells. 
 
4.4 Results and Discussion 
 
4.4.1 SAg-Sau-activated CD4+ T cell proliferation is not inhibited by Foxp3+ Tregs 
It is shown in the previous chapter that activation of Th17 cells and Tregs upon SAg-Sau 
stimulation were not inversely correlated, and the expanded Tregs exhibited significantly 
reduced expression of CD39, suggesting the suppressive capacity of these Tregs may be 
compromised in terms of SAg-Sau stimulation. To characterise the function of Tregs in this 
specific inflammatory setting, I first examined their suppression against the T cell proliferation 
activated by Spn and Sau respectively.  
The proliferative response of CD4+ T cells following bacterial antigen stimulation was detected 
in the tonsillar MNCs with or without Tregs. Foxp3+ Tregs express high level of CD25 on the 
cell surface, making them distinguishable from other conventional CD4+ T cells. Magnetic cell 
sorting was used to deplete CD25+ cell from tonsillar MNCs which removed over 95% of 
Foxp3+ Tregs (Figure 4.1). The Treg-depleted MNCs and unfractionated MNCs were stained 
 108 
with CFSE, a fluorescent cell staining dye that is halved with cell division and can thereby be 
used to indicate dividing cycles of proliferated cells. CFSE-labelled cells were stimulated with 





Figure 4.1 CD25+ cell depletion removes Tregs in tonsillar MNCs 
Foxp3+ CD4+ cells (Tregs) were gated out in the rectangular boxes with numbers on top showing the 
percentage of Tregs within lymphocytes before and after CD25+ cell depletion. 
 
The CFSE fluorescence is halved within daughter cells following each cell division. As shown 
in the histogram of Figure 4.2, proliferated cells exhibited decreased fluorescent intensity, and 
peaks in the left compartment of the histogram represent cells undergone different dividing 
cycles. Following Spn stimulation, the proportion of proliferated CD4+ T cells was significantly 
increased in Treg-depleted MNCs, indicating suppression of Spn-activated T cell proliferation 
by the Tregs (Figure 4.2). 
Sau-derived antigens were extremely potent in inducing T cell proliferation with 70-80% of 
CD4+ T cells undergone at least one dividing cycle following stimulation. Different from 
pneumococcal stimulation, the CD4+ T cell proliferation following Sau stimulation was not 
changed by removing Tregs (Figure 4.3). The results indicate that Sau-activated proliferation 





Figure 4.2 Spn-activated CD4+ T cell proliferation is enhanced by removing Tregs 
CFSE stained tonsillar MNCs were stimulated with 1 μg/ml of Spn-TIGR4 CCS for 5 days, and CD4+ T 
cell proliferation was analysed by flow cytometry. The histogram plot was gated on CD4+ T cells showing 
median fluorescence intensity (MFI) of CFSE signals, and numbers in the top left corner indicate 
percentages of proliferated CD4+ T cells in unfractionated MNCs (black font) and Treg-depleted MNCs 
(red font). Data was summarised in the bar graph and analysed using paired t-test, ***p < 0.001. Mean 













Figure 4.3 Sau-activated CD4+ T cell proliferation is not altered by Treg removal 
CFSE labelled tonsillar MNCs were stimulated with 1 μg/ml of NonSAg-Sau and SAg-Sau CCS 
respectively, and cell proliferation was assessed at day 5. The histogram plots were gated on CD4+ T 
cells, and numbers in top left corner indicate percentages of CD4+ T cells that had undergone at least 
one dividing cycle in unfractionated MNCs (black font) and Treg-removed MNCs (red font) respectively. 
The percentages of proliferated CD4+ T cells were summarised in the grouped bar graph, n = 3. 
 
Ou et al. show that Foxp3+ Tregs derived from human PBMC were not able to suppress T cell 
proliferation following staphylococcal enterotoxin B (SEB) stimulation110. My results further 
demonstrate that human NALT-derived Tregs also lack suppressive activity for SAg-Sau-
stimulated proliferation of CD4+ T cells. Interestingly, this lack of suppression was also seen 
in NonSAg-Sau stimulated tonsillar MNCs. It is possible that the NonSAg-Sau strain may 
produce some unknown proteins that resemble the effects of superantigens. 
Another study demonstrates that staphylococcal enterotoxin A (SEA) and streptococcal 
pyrogenic enterotoxin K/L could induced Foxp3 expression in proliferated CD25- T cells, and 
these superantigen-induced Tregs exhibited suppressive activity comparable to naturally 
occurred Tregs for anti-CD3 stimulated T cell proliferation111. Since Foxp3+ Tregs were 
depleted before stimulation in my study, the effect of SAg-Sau-induced Tregs cannot be 
excluded. I showed in the previous chapter that SAg-Sau-expanded Tregs had enhanced 
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expression of CTLA4 but downregulated CD39, suggesting these Tregs may have retained 
certain suppressive activity. However, the potent proliferation of CD4+ T cells stimulated by 
SAg-Sau suggests limited suppressive effect, if there is any, by induced Tregs. 
It is notable that the suppression of T cell proliferation shown by previous studies was 
concluded from a single staphylococcal superantigen which cannot actually reflect the effects 
exerted by combined SAg-Sau antigens. The T cell responses and regulation examined using 
CCS containing secreted antigens from SAg-Sau are more likely to represent the host 
responses in SAg-Sau-infected nasopharynx. 
 
4.4.2 Foxp3+ Tregs suppress SAg-Sau-activated Th1, but not the Th17 responses 
Having shown the Foxp3+ Tregs exhibited no suppression on SAg-Sau stimulated CD4+ T cell 
proliferation, I then examined the suppressive activity of Tregs for SAg-Sau-activated IFNg 
and IL-17A expression. In the tonsillar MNCs without Tregs, a significantly increased IFNg 
expression was seen in both CD4- and CD4+ cells indicating enhanced cytotoxic T cell 
responses (IFNg-producing CD8+ T cells) and Th1 responses (IFNg-producing CD4+ T cells) 
(Figure 4.4). The results suggest that SAg-Sau stimulated Th1 activation can be efficiently 












Figure 4.4 Treg removal enhances IFNg expression in SAg-Sau stimulated tonsillar 
MNCs 
Unfractionated MNCs and Treg-depleted MNCs were stimulated with SAg-Sau CCS respectively. The 
expression of IFNg was examined at 48hrs following stimulation by intracellular staining. The zebra plots 
showing IFNg expression in CD4- lymphocytes and CD4+ T cells. Percentages of IFNg+ cells in these cell 
populations are shown in top left and right quadrants respectively and summarised in the grouped bar 
graph with mean ± SEM, n = 3. Data was analysed using paired t-test, *p < 0.05.  
 
In contrast to an enhanced IFNg expression, the expression of IL-17A in CD4+ T cells showed 
a trend to decrease although it did not reach significance in Treg-depleted MNCs (Figure 4.5). 
The results clearly demonstrate that NALT-derived Tregs have the ability to suppress Th1 











Figure 4.5 SAg-Sau-activated Th17 responses are not altered by removing Tregs 
Unfractionated tonsillar MNCs and Treg-depleted MNCs were stimulated with SAg-Sau for 48hrs, and 
IL-17A expression in CD4+ T cells was determined following stimulation. The zebra plots were gated on 
CD4+ T cells, and numbers in top right quadrants indicate percentages of Th17 cells. Data was 
summarised in the bar graph and analysed using paired t-test, n = 3. 
 
In order to determine whether this observation was distinct to the immune microenvironment 
of nasopharynx, I further examined the regulatory role of Foxp3+ Tregs in peripheral blood 
mononuclear cells (PBMCs). Consistent with the findings obtained from tonsillar MNCs, the 
Treg-depleted PBMCs also had an enhanced Th1, but reduced Th17 response upon SAg-
Sau stimulation (Figure 4.6). Thus, despite its critical role in maintaining immune tolerance, 
the Foxp3+ Tregs are unable to inhibit SAg-Sau-activated Th17 response in humans. 
The removal of Tregs resulted in decreased IL-17A expression provided further evidence to 
support that SAg-Sau was able to induce IL-17A expression in Foxp3+ Tregs shown in the 
previous chapter. The Treg depletion also removed those Tregs that had the potential to 








Figure 4.6 Treg depletion upregulates IFNg but not IL-17A expression in SAg-Sau 
stimulated PBMCs 
Unfractionated and Treg-depleted PBMCs were treated with 1 μg/ml of SAg-Sau CCS for 48hrs, and 
expression of IFNg and IL-17A was examined by intracellular staining. The top zebra plots are showing 
the percentages of IFNg+CD4- (numbers in top left quadrants) and IFNg+CD4+ cells (numbers in top right 
quadrants). The bottom zebra plots were gated on CD4+ T cells, and numbers in top right quadrant 
indicate the percentage of IL-17A+ cells. Results are representative of 3 individual samples. 
 
Annunziato et al. show that human Th17 cells have significantly lower susceptibility to 
autologous Tregs compared to Th1 and general proliferative response when stimulated with 
irradiated allogeneic PBMCs79. My results agree with their finding by showing SAg-Sau-
activated Th17 cells are highly resistant to Treg-mediated suppression, while the Th1 cells 
remained sensitive. However, it was shown in my study that the Tregs were also incapable of 
suppressing the T cell proliferation in response to SAg-Sau stimulation (Figure 4.3). 
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The differential regulation of the Th1 and Th17 responses by Tregs may be explained by the 
insensitivity of Th17 cells to Treg-mediated suppression pathways. Foxp3+ Tregs express high 
level of IL-2 receptor a (IL-2Ra), CD25, and IL-2 signalling is required for the induction and 
survival of Tregs151. By consuming large amount of IL-2, Tregs could suppress T cell 
responses through IL-2 deprivation152. However, Th17 differentiation is inhibited by IL-2, and 
activation of memory Th17 cells is shown to be independent of IL-2153,154. Further, it has been 
reported that CTLA4 expression in Tregs is required for the suppression of Th1 and Th2 
responses, whereas peripheral induced Tregs are shown to promote proinflammatory Th17 
response in CTLA4-dependent manner, suggesting increased CTLA4 expression in Tregs 
may results in enhanced Th17 responses128,129. 
Tregs also mediates suppression via producing inhibitory cytokines, such as TGF-b and IL-
10. It is known that TGF-b promotes Th17 development and activated/memory T cells are 
shown to be resistant to TGF-b-mediated suppression due to the downregulation of TGF-b 
receptor type II (TGF-bRII)155, thereby the TGF-b produced and activated by Tregs is unlikely 
to restrict SAg-Sau-activated Th17 responses. I have shown that SAg-Sau stimulation 
significantly enhanced IL-10 production primarily from Foxp3-CD4+ T cells, the Foxp3+ Tregs 
also exhibited increased IL-10 expression. Whether SAg-Sau-activated Th17 responses could 
be controlled by IL-10 was further examined. 
 
4.4.3 SAg-Sau-activated Th17 responses are not enhanced by IL-10 neutralization 
Tonsillar MNCs were stimulated with SAg-Sau CCS and treated with anti-human IL-10 
monoclonal antibody to neutralise the biological effects of secreted IL-10. The stimulation 
control MNCs were treated with the corresponding isotype control antibody. The activation of 
IFNg-producing Th1 cells and IL-17A-producing Th17 cells were examined using intracellular 
cytokine staining at 48hrs following stimulation.  
It is well known that IL-10 potently suppresses T cell activation in various inflammatory settings. 
Consistently, IL-10 neutralization resulted in significantly increased proportion of Th1 cells in 
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tonsillar MNCs upon SAg-Sau stimulation, indicating efficient suppression of SAg-Sau-




Figure 4.7 IL-10 neutralization enhances Th1 responses in SAg-Sau stimulated tonsillar 
MNCs 
Tonsillar MNCs were stimulated with SAg-Sau CCS in the presence of 1 μg/ml of anti-IL-10 or isotype 
control antibody. The IFNg expression in CD4+ T cells was determined at 48hrs. The zebra plots were 
gated on CD4+ T cells, and percentages of Th1 cells are shown in top right quadrants. Data was 
summarised in the bar graph, n = 7. Data was analysed using paired t-test and displayed in mean ± SEM 
with p value. 
 
However, when assessing the Th17 cell population following SAg-Sau stimulation, it was 
surprising to show that the proportion of Th17 cells were not altered by IL-10 neutralization 
(Figure 4.8). The results suggest that SAg-Sau-activated Th17 responses were not controlled 
by endogenous IL-10 despite that its expression was markedly upregulated by SAg-Sau. 
IL-10 suppresses T cell activation mainly through downregulating antigen presentation and 
cytokine production by accessory cells145. Superantigen elicited effector and memory Th17 
cell activation may require only minimum signals from accessory cells. Chaudhry et al. 
demonstrate that IL-10 activates the STAT3 signalling in Foxp3+ Tregs enabling them to 
suppress pathological Th17 responses which are responsible for the development of colitis78. 
Since I have shown that NALT-derived Foxp3+ Tregs are unable to suppress SAg-Sau-
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activated Th17 responses, it is possible that this IL-10/STAT3 signalling in the Tregs may be 




Figure 4.8 SAg-Sau-activated Th17 responses are not changed by neutralizing IL-10 
Tonsillar MNCs were stimulated with SAg-Sau CCS in the presence of 1 μg/ml of anti-IL-10 or isotype 
antibody, and the Th17 responses were analysed at 48hrs. Percentages of IL-17A+ cells within CD4+ T 
cells are shown in top right quadrants of the zebra plots and summarised in the bar graph (mean ± SEM) 
on the right, n = 7.  
 
4.4.4 Addition of IL-10 promotes Th17 activation by SAg-Sau 
The endogenous IL-10 showed no suppression on SAg-Sau elicited Th17 activation. To 
further examine the suppressive activity of IL-10, SAg-Sau stimulated tonsillar MNCs were 
treated with recombinant IL-10 and followed by detecting the Th1 and Th17 responses. 
As shown in Figure 4.9, IL-10-treated MNCs had markedly decreased proportion of activated 
Th1 cells which again proved that IL-10 could potently suppress the Th1 responses stimulated 
by SAg-Sau. 
Although it was anticipated that treatment of exogenous IL-10 may not affect the Th17 
responses, the following results were still striking to show that addition of IL-10 actually 
promoted SAg-Sau-stimulated Th17 responses (Figure 4.10). 
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Figure 4.9 Addition of IL-10 inhibits Th1 responses in SAg-Sau stimulated tonsillar 
MNCs 
Tonsillar MNCs were stimulated by SAg-Sau with or without 10 ng/ml of recombinant IL-10, and the Th1 
responses were analysed at 48hrs following stimulation. Percentages of IFNg+ cells within CD4+ T cells 
are indicated in top right quadrants of the zebra plots and summarised in the bar graph (mean ± SEM), 





Figure 4.10 Exogenous IL-10 promotes SAg-Sau-activated Th17 responses 
SAg-Sau stimulated tonsillar MNCs were treated with or without 10 ng/ml of recombinant IL-10 for 48hrs. 
The Th17 activation was analysed following stimulation. The zebra plots were gated on CD4+ T cells, 
and numbers in top right quadrants indicate the percentage of IL-17A+ cells. The symbols and lines plot 
on the right shows changes of Th17 proportions for each individual sample in the absence (Ctrl) and 
presence of IL-10, n = 8. Data was analysed using paired t-test, **p < 0.01. 
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The Th1 and Th17 cell populations were then divided into IL-17A+IFNg-, IL-17A+IFNg+, and IL-
17A-IFNg+ subpopulations to further define the opposing roles of IL-10 in the regulation of IFNg 
and IL-17A expression in SAg-Sau-activated tonsillar CD4+ T cells. IL-17A-IFNg+ cells were 
significantly reduced, and IL-17A+IFNg+ cells were also decreased although this did not reach 
significance. However, a marked increase in IL-17A+IFNg- cell population was observed in IL-
10 treated cells, providing further evidence that IL-10 could promote IL-17A expression in 


















Figure 4.11 IL-10 promotes IL-17A and suppresses IFNg expression in SAg-Sau-
activated CD4+ T cells 
SAg-Sau stimulated tonsillar MNCs were treated with or without recombinant IL-10, and expression of 
IL-17A and IFNg in CD4+ T cells were determined at 48hrs. The zebra plots were gated on CD4+ T cells. 
Percentages of IL-17A+IFNg-, IL-17A+IFNg+ and IL-17A-IFNg+ cells are shown in top left, top right and 
bottom right quadrants. The dots and lines plots showing percentage changes of these 3 cell populations 
for individual samples, n=5. Data was analysed using paired t-test, and p values were indicated. 
 
Th17 cells are able to acquire phenotypes of other Th cell subsets in response to different 
environmental cues156. It is possible that human NALT may contain Th1 cells originating from 
Th17 cells (ex-Th17), which is supported by the presence of IL-17A+IFNg+ (Th17/Th1) cells. 
 121 
IL-10 mediated Th1 suppression may downregulate T-bet expression in these ex-Th17 cells 
which removes the antagonizing effect of T-bet on RORgt function, thus reactivating the Th17 
phenotype79. Combined with the resistance to endogenous IL-10-mediated suppression in 
SAg-Sau-activated Th17 cells, this may provide a plausible explanation for the promoting 
effect of exogenous IL-10 on SAg-Sau stimulated Th17 activation. Further investigation to 
elucidate mechanisms involved in this unexpected effect of IL-10 for human Th17 activation 
is required to inform future development and optimization of IL-10-based therapy in clinical 
inflammatory/autoimmune conditions. 
 
4.4.5 IL-10 promotes GM-CSF expression in SAg-Sau-activated Th17 cells 
While IL-10 promoted IL-17A expression in SAg-Sau stimulated tonsillar CD4+ T cells, it 
appeared to reduce the cell population that co-expresses IL-17A and IFNg (Figure 4.11). It 
has been shown that IL-17A and IFNg double positive CD4+ T cells are a subset of pathological 
Th17 cells associated with autoimmune pathologies156. Therefore, it can be argued that if IL-
10 was able to suppress this specific Th17 cell subset, it remains a promising candidate to 
control autoimmune conditions. However, studies also reveal that granulocyte-macrophage 
colony-stimulating factor (GM-CSF)-producing Th17 cells are highly pathogenic, and 
autoreactive Th cells lacking GM-CSF fail to induce neuroinflammation despite expression of 
IL-17A and IFNg157,158. To further evaluate the influence of IL-10 on SAg-Sau-activated Th17 
cells, I next examined the effector phenotype of the activated Th17 cells with or without IL-10. 
SAg-Sau-stimulated MNCs were treated with recombinant IL-10 and the expression of GM-
CSF and IFNg in the activated Th17 cells was assessed. It was surprising to find that IL-10 
reduced IFNg expression in SAg-Sau-activated Th17 cells, but instead significantly enhanced 
the expression of GM-CSF. The proportion of Th17 cell subset that co-expresses GM-CSF 
and IFNg was not altered by exogenous IL-10 (Figure 4.12 a).  
To test whether the endogenously produced IL-10 also promoted GM-CSF-producing Th17 
cell, tonsillar MNCs were stimulated with SAg-Sau in the presence of anti-IL10 neutralizing 
antibody. As shown in Figure 4.12 b, IL-10 depletion resulted in a significant decrease in GM-
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CSF expression by SAg-Sau-activated Th17 cells, consistent with the positive effect of IL-10 
in inducing GM-CSF+ Th17 cells. 
GM-CSF was originally discovered as a growth factor capable of generating granulocytes and 
macrophages from myeloid precursor cells. However, it was later identified that GM-CSF is 
not essential for myelopoiesis in steady state and circulates at low and even undetectable 
levels159,160. Instead, increased concentration of GM-CSF is found at sites of inflammation and 
has been shown to drive autoimmune pathologies in murine models of arthritis and EAE160. In 
tissue inflammation, GM-CSF is prominently produced by Th cells. It has been reported that 
GM-CSF expression in the Th cells can be induced by RORgt, the dominant transcription factor 
of Th17 cells, and confers pathogenicity to Th17 cells157. Here, I show that IL-10 not only 
promoted SAg-Sau-activated Th17 responses, but also enhanced GM-CSF expression in 
these Th17 cells, which challenges the well-recognized anti-inflammatory role of IL-10 and 
provides new insights into pleiotropic effects of cytokines. 
Codarri et al. show that expression of GM-CSF in CD4+ T cells can be potently inhibited by 
blocking Th1 cytokines, IFNg and IL-12157. In my stimulating model, IL-10 effectively 
suppressed IFNg expression in the Th17 cells which may be associated with the upregulated 
GM-CSF in these cells. It is plausible to propose that IL-10 may promote GM-CSF-producing 
Th17 cells via downregulating IFNg/STAT1 signalling in the responding cells. 
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Figure 4.12 IL-10 promotes GM-CSF expression in SAg-Sau-activated Th17 cells 
Intracellular cytokine staining was performed to detect the expression of GM-CSF and IFNg in Th17 cells 
activated by SAg-Sau (1 µg/ml) in the presence of recombinant IL-10 (100 ng/ml) (a) or anti-IL-10 
neutralizing antibody (1 µg/ml) (b). Th17 (IL-17A+CD4+) cells were gated out. The contour plots show 
percentages of GM-CSF+IFNg-, GM-CSF+IFNg+ and GM-CSF-IFNg+ cells within the activated Th17 cells 
in the top left, top right and bottom right quadrants respectively. Individual data was plotted in the dots 
and lines graphs. a) IL-10-treated MNCs were compared to stimulation control (Ctrl), n = 5. b) SAg-Sau-
stimulated MNCs were treated with anti-IL-10 and isotype control antibody respectively, n = 3. Data was 
analysed using paired t-test with p values indicated.  
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4.4.6 GM-CSF-producing CD4+ T cells express high level of IL-23R  
IL-23 signalling is shown to be crucial for the stabilization of Th17 cells and their ability to 
induce autoimmune tissue inflammation161. In SAg-Sau-stimulated tonsillar CD4+ T cells, the 
expression of IL-23 receptor (IL-23R) was upregulated at both mRNA and protein levels 
(Figure 4.13 a-c), which is in line with the highly activated Th17 responses.  
By examining the IL-23R expression in effector CD4+ T cell subsets, it was revealed that GM-
CSF-producing CD4+ T cells expressed higher level of IL-23R than Th1 and Th17 cells (Figure 
4.13 d). SAg-Sau-activated CD4+ T cells were then further divided into 8 effector phenotypes 
depending on the expression of IL-17A, IFNg and GM-CSF in different combinations. Notably, 
the IL-17A+GM-CSF+IFNg- cell population (indicated by red-outlined rectangle in Figure 4.13 
e), which can be promoted by IL-10 as shown above, exhibited prominent expression of IL-
23R compared to other CD4+ T cell phenotypes. The lowest expression of IL-23R was seen 
in the CD4+ T cells expressing IFNg only (Figure 4.13 e). The results suggest that enhanced 
GM-CSF expression in human tonsillar Th17 cells is associated with upregulated expression 
of IL-23R. This is supported by a previous study showing expression of GM-CSF in the Th17 
cells is induced via IL-23 signalling in mice158. 
Using transgenic mice that express a TCR specific for myelin basic protein (MBP), it was 
demonstrated that GM-CSF-deficient Th17 cells had remarkably lowered ability to drive 
autoimmune neuroinflammation158. Other studies also show that both GM-CSF and IL-23R 
deficiency render resistance to autoimmune pathologies in mice162,163. GM-CSF and IL-23R 
are therefore suggested as molecular signature for pathological Th17 cells. My results suggest 
that IL-10 may drive the development of inflammatory/autoimmune pathologies in the context 





Figure 4.13 GM-CSF-producing CD4+ T cells express high level of IL-23R 
a) CD4+ T cells were isolated from SAg-Sau-stimulated tonsillar MNCs for RNA extraction. RT-qPCR 
was performed to measure the RNA expression of il23r in SAg-Sau-activated CD4+ T cells. The Cq value 
of il23r gene was normalised by housekeeping gene b-actin and shown as fold increase against media 
control (MC) in the bar graph, n = 3. b-e) Tonsillar MNCs were stimulated with SAg-Sau for 48hrs, and 
the expression of IL-23R was assessed by flow cytometry. b) CD4+ T cells were gated out to show the 
median fluorescent intensity (MFI) of IL-23R with or without SAg-Sau stimulation in the histogram plot. 
c) The MFI of IL-23R was normalised by isotype control and displayed in mean ± SEM in the bar graph, 
n = 3. d, e) Expression of IL-23R shown as normalised MFI in CD4+ T cell subsets, n =3. Data was 
analysed by paired t-test (c, d). *p < 0.05, **p < 0.01. 
 
4.5 Conclusions 
Foxp3+ Tregs and IL-10 are known to play pivotal roles in suppressing CD4+ T cell-mediated 
pro-inflammatory responses114,146. Although SAg-Sau stimulation was shown to induce Treg 
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expansion and enhance IL-10 production, I found that SAg-Sau-activated Th17 responses 
were not affected by increased Treg or IL-10 levels. 
It has been reported that human PBMC-derived Foxp3+ Tregs are able to proliferate in 
response to staphylococcal superantigen but cannot suppress superantigen-activated T cell 
proliferation110. My results support this published finding by showing human NALT-derived 
Tregs also failed to control the proliferative response of CD4+ T cells stimulated by secreted 
antigens of SAg-Sau. Further, I show that both PBMC- and NALT-derived Tregs were unable 
to suppress SAg-Sau-activated Th17 responses, although they retained the suppressive 
ability to control Th1 activation. Intriguingly, this differential regulation of Th1 and Th17 
responses was also found in IL-10-mediated suppression. Foxp3+ Treg- and IL-10-mediated 
immune regulation are the centre of peripheral tolerance that keep over-reactive inflammatory 
responses and auto-reactive T cells in check. These highly resistant Th17 cells activated by 
SAg-Sau infection could lead to an unresolvable inflammation resulting in pathological tissue 
damage. 
Intriguingly, addition of exogenous IL-10 was shown to further promote SAg-Sau-activated 
Th17 response and induce a potential pathological Th17 cell population which is IL-
23RhighGM-CSF+ in human NALT. To my knowledge, this is the first report to demonstrate that 
IL-10 may play a pathogenic role in certain inflammatory settings. It is conceivable that this 
promoting effect on pathological Th17 activation may underlie the failure of IL-10-based 
therapy for the treatment of clinical autoimmune diseases. Despite IL-10 has been reported 
to protect against Th17-mediated autoimmunity in mice, it is questioned that to what extent 
these experimental findings obtained from the murine studies can be translated to humans. 
Therefore, joint efforts should be made to clarify the potential divergent regulatory 
mechanisms that control human and mouse Th17 activation and illustrate the signalling 
pathways IL-10 has engaged with to promote the development of pathological Th17 cells in 
humans. 
Taken together, Foxp3+ Tregs and IL-10 are unable to control the potent Th17 responses 
activated by SAg-Sau in human NALT, suggesting an aberrant immune regulation of 
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superantigenic Th17 activation may present in the nasopharynx, which may potentially 






IL-35 is critical in suppressing superantigenic 





IL-35 has been identified as a novel suppressive cytokine that has therapeutic effects against 
autoimmune diseases by suppressing pathological Th17 cells in mice. However, the role of 
IL-35 in human Th17 activation and autoimmune disorders remains controversial. Whether 
human CD4+ T cells express IL-35 as their murine counterparts is also disputed.  
Here, I examined the expression of IL-35 in human tonsillar CD4+ T cells and its role in 
regulating SAg-Sau-activated Th17 responses. It shows that IL-35 was expressed by tonsillar 
CD4+ T cells and significantly downregulated upon SAg-Sau stimulation. Addition of IL-35 was 
able to suppress SAg-Sau elicited Th17 activation in high responders (fold increase in Th17 
response ³ 5-fold), while those low Th17 responders (fold increase in Th17 response < 5-fold) 
were not affected. The native form of IL-35 also suppressed SAg-Sau-activated Th17 
responses in a dose-dependent manner. Furthermore, IL-35 downregulated RORgt 
expression in CD4+ T cells and thereby inhibited SAg-Sau-induced Th17 differentiation. 
Additionally, in mice with nasal infection of SAg-Sau, the cervical lymph node (CLN)-derived 
CD4+ T cells showed markedly increased expression of IL-17A accompanied with 
downregulated IL-35 which was consistent with the in vitro findings from human NALT.  
The results suggest IL-35 is a key cytokine to suppress over-reactive Th17 responses while 
maintaining a proper Th17 activation against bacterial/fungal infections in humans and may 









IL-35 belongs to IL-12 family which is a unique heterodimeric cytokine family consisting of 
shared subunits. This cytokine family includes IL-12 (IL-12p40:IL-12p35), IL-23 (IL-12p40:IL-
23p19), IL-27 (EBI3:IL-27p28) and IL-35 (EBI3:IL-12p35) (Figure 5.1). Different from the other 
family members, IL-35 shows purely suppressive effects on T cell activation, while IL-12 and 





Figure 5.1 The IL-12 family of cytokines 
The subunits of IL-12 and IL-23 are linked by disulphide bond (S-S), whereas EBI3 subunit is 
heterodimerized with p28 or p35 by protein-protein interaction to form IL-27 or IL-35. 
 
Epstein-Barr virus-induced gene 3 (EBI3) is a homologue to IL-12 subunits, IL-12p40, which 
has led to the discovery of its association with another subunit of IL-12, IL-12p35 (also termed 
IL12A), in 1997165. It was postulated that the EBI3:IL-12p35 heterodimer (later named 
interleukin-35, IL-35 in 2007) may possess immune suppressive properties due to the 
following reasons. First, EBI3 is highly expressed in Epstein-Barr virus (EBV) transformed B 
lymphocytes and placental syncytial trophoblasts, two cell types that must survive in a 
potential hostile immunological environment with extensively activated NK and T cell 
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responses165,166. Second, due to the shared IL-12p35 subunit with IL-12, IL-35 is likely to 
antagonise IL-12’s biological effects via competing for the receptor binding165. 
Later in 2007, IL-35-mediated suppression on pathological immune responses was reported 
in murine models of collagen-induced arthritis and inflammatory bowel disease95,97. 
Interestingly, IL-35 was found to be expressed by murine Foxp3+ Tregs and contribute to their 
suppressive activities97. In the follow-up study done by the same group, a novel regulatory 
CD4+ T cell population that express IL-35 independent of Foxp3 was identified and termed as 
iTR35. The iTR35 can be induced by treating conventional T cells with IL-35 and exhibit potent 
suppressive properties by restoring homeostasis and preventing lethal autoimmunity in 
Foxp3-knockout mice94.  
However, it was demonstrated that IL-35 was not constitutively expressed by human Foxp3+ 
Tregs. Although activated human CD4+ T cells were shown to express both subunits at mRNA 
level, the protein expression of heterodimeric IL-35 protein was not demonstrated101. Seyerl 
et al. detected enhanced production of heterodimeric IL-35 by human peripheral blood-derived 
CD3+ T cells (including CD4+ and CD8+ cells) co-cultured with human rhinovirus-treated 
dendritic cells167. Nevertheless, whether IL-35 is expressed in human CD4+ T cells remains 
inconclusive. 
Murine studies have shown that IL-35 controls autoimmune pathogenesis at least partially 
through suppressing inflammatory Th17 responses95,96,100,168,169. In humans, reduced IL-35 
serum level was detected in autoimmune patients with rheumatoid arthritis, Sjogren’s 
syndrome and systemic lupus erythematosus (SLE)102-104,170. Since the biological activity of 
recombinant IL-35 is highly unstable, it has been difficult to study IL-35-mediated suppression 
on human Th17 cells, and further investigations to evaluate the therapeutic potential of IL-35 
in human autoimmune disorders are also hindered.  
I have shown in the previous chapter that both Foxp3+ Tregs and IL-10 cannot effectively 
suppress the Th17 responses activated by SAg-Sau. As a promising suppressive effect of IL-
35 against Th17-driven autoimmune pathologies have been demonstrated in previous studies, 
the regulatory role of IL-35 in human NALT was examined for SAg-Sau-activated Th17 
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Ø To detect IL-35 expression in human tonsillar CD4+ T cells and determine whether it 
is affected by SAg-Sau stimulation. 
Ø To examine the role of IL-35 in regulating SAg-Sau-activated Th17 responses in 
human NALT. 
Ø To examine in vivo activation of Th17 and IL-35-expressing CD4+ T cells in the 
cervical lymph nodes of mice infected intranasally with SAg-Sau. 
 
5.4 Results and Discussion 
 
5.4.1 SAg-Sau downregulates IL-35 in human tonsillar CD4+ T cells  
In the previous chapters, it has been demonstrated that SAg-Sau stimulation expands the 
Foxp3+ Tregs and activates IL-10-expressing Tr1 cells, indicating CD4+ T cell-mediated 
immune regulatory mechanisms were activated by SAg-Sau. However, the potent Th17 
responses activated by SAg-Sau were not suppressed by either of them, suggesting an 
aberrant immune suppression on SAg-Sau-activated Th17 responses. It therefore led to the 
question of what role IL-35-expressing iTR35 might play in human nasopharynx infected with 
SAg-Sau. To answer this intriguing question, the first step is to resolve the controversy of 
whether human CD4+ T cells express heterodimeric IL-35. 
In order to detect the expression of IL-35 in human tonsillar CD4+ T cells, CD4+ T cells were 
separated from tonsillar MNCs either unstimulated or stimulated with Sau-derived antigens 
and both mRNA and protein expression of IL-35 subunits, IL12A and EBI3, were examined. It 
has been reported that IL-12A was expressed constitutively by human CD4+ T cells but EBI3 
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was undetectable in any CD4+ T cell subset, including effector and regulatory T cells, without 
stimulation in peripheral blood101. However, I show here that both IL-12A and EBI3 were 
detected at mRNA and protein levels in unstimulated CD4+ T cells in tonsils (Figure 5.2 and 
5.3 a). Although the protein expression of EBI3 in unstimulated CD4+ T cells was relatively 
low, it was able to form heterodimer with IL-12A which can be detected by immunoprecipitation 
(Figure 5.3). 
Intriguingly, a significant reduction of both Il12a and Ebi3 mRNA was observed in SAg-Sau-
stimulated tonsillar CD4+ T cells (Figure 5.2). Although a slightly enhanced level of EBI3 
protein was detected in SAg-Sau-activated CD4+ T cells which may indicate a reduced 
secretion of EBI3 protein, the protein expression of IL-12A was remarkably decreased, 
consistent with the mRNA expression (Figure 5.3 a).  
 
 
Figure 5.2 SAg-Sau downregulates mRNA expression of IL-35 in human tonsillar CD4+ 
T cells 
Tonsillar MNCs were stimulated with 1 μg/ml of Sau for 24hrs followed by isolating CD4+ T cells to detect 
mRNA expression of il12a and ebi3 in the cells. The targeted gene expression was normalized to the 
expression of b-actin. The fold change in il12a (a) and ebi3 (b) mRNA expression compared to media 
control (MC) are shown in the bar graphs with mean ± SEM, n = 4. Data was analysed using paired t-
test, *p < 0.05, **p < 0.01, ***p < 0.001. 
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By performing immunoprecipitation, it was confirmed that SAg-Sau-stimulated downregulation 
of IL12A had resulted in a marked decrease of IL-35 heterodimer in tonsillar CD4+ T cells 




Figure 5.3 Protein expression of IL-35 in human tonsillar CD4+ T cells is inhibited by 
SAg-Sau 
Tonsillar CD4+ T cells were isolated from Sau stimulated MNCs at 48hrs. a) The protein expression of 
IL-12A and EBI3 subunits in NonSAg-Sau and SAg-Sau activated CD4+ T cells was detected by Western 
blot. b) CD4+ T cell lysates were immunoprecipitated using anti-human IL12A (anti-hIL12A) and blotted 
with anti-human EBI3 (anti-hEBI3) to detect heterodimeric IL-35 in the cells. The results represent 3 
independent experiments. 
 
Reciprocal expression of IL-35 and IL-10 in Foxp3+ Tregs has been demonstrated in murine 
studies, defining two separated effector Treg populations171,172. In humans, the expression of 
IL-35 is not dependent on Foxp3, and I have shown that SAg-Sau activated IL-10 expression 
primarily in Foxp3- Tr1 cells. However, the notion of segregated T cell population that produces 
IL-35 and IL-10 respectively may also apply and be presented as IL-35-producing iTR35 and 
IL-10-producing Tr1 cells in humans. 
The mRNA expression of Il12a was also reduced by NonSAg-Sau stimulation, but the 
reduction was less significant at protein level. It suggests that Sau-derived superantigens and 
other soluble antigens both contribute to the downregulation of IL-35 in tonsillar CD4+ T cells. 
To the best of my knowledge, this is the first study to show SAg-Sau-mediated alteration of 
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IL-35 expression in CD4+ T cells. With evidence provided by previous studies demonstrating 
suppression of inflammatory Th17 responses by IL-35, It was hypothesized that marked 
reduction of IL-35-expressing CD4+ T cells following SAg-Sau stimulation may underlie the 
potent Th17 activation. Further studies to identify specific staphylococcal antigens that 
modulate IL-35-expressing CD4+ T cell function may inform new strategies for novel vaccines 
targeting Sau-driven inflammatory diseases. 
 
5.4.2 IL-35 suppresses over-reactive Th17 responses in SAg-Sau stimulated tonsillar 
MNCs 
I next examined the hypothesis that SAg-Sau downregulated IL-35 expression was 
contributing to the strong Th17 responses by supplementing recombinant IL-35 to SAg-Sau 
stimulated tonsillar MNCs. Tonsillar MNCs were stimulated with SAg-Sau in the 
presence/absence of recombinant IL-35 followed by examining the Th17 responses. To better 
reflect the individual difference in the level of Th17 response activated by SAg-Sau, the 
activated Th17 responses were normalised and presented as fold increase against 
unstimulated media controls for each sample. Interestingly, the percentage of IL-35-mediated 
Th17 suppression was shown to be positively correlated with the level of Th17 activation 
(Figure 5.4 a).  
The average fold increase in Th17 cells following NonSAg-Sau and SAg-Sau stimulation was 
2.25 (range: 1.22-5.40) and 4.67 (range: 2.50-9.82) respectively (Figure 5.4 b). To further 
delineate IL-35-mediated Th17 suppression, the tonsillar samples were then divided into high 
responders (³ 5-fold increase) and low responders (< 5-fold increase) based on the average 
fold increase of the Th17 proportion within SAg-Sau-activated tonsillar CD4+ T cell population. 
As shown in Figure 5.5 a, the addition of IL-35 significantly reduced Th17 activation in the 
high responder group, whereas there was no effect on the low responders. Consistent with 
this, IL-17A production was also decreased in the culture supernatant of the high responders 
following IL-35 treatment (Figure 5.5 b). These results suggest that IL-35 is able to suppress 
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over-reactive Th17 responses while maintaining a low level of Th17 activation for the host 
defence in human NALT. 
 
 
Figure 5.4 Inhibition of SAg-Sau-activated Th17 responses by IL-35 is associated with 
the level of Th17 activation 
Tonsillar MNCs were stimulated with Sau CCS for 48hrs, and the Th17 responses were analysed as fold 
increase in percentage of Th17 cells against media control. a) The association between fold increase in 
Th17 proportion and Th17 inhibition by IL-35 (100 ng/ml) was analysed using linear regression. The R2 
and p values are displayed, n = 22. b) The Th17 fold increase in NonSAg-Sau and SAg-Sau stimulated 
MNCs are shown in mean with range, and individual data points are plotted. Mean values are indicated, 












Figure 5.5 IL-35 suppress SAg-Sau-activated Th17 responses in the high responders 
Tonsillar MNCs were treated with 100 ng/ml of IL-35 or Fc control protein and stimulated with SAg-Sau 
CCS. The Th17 responses were analysed at 48hrs. a) Suppression of SAg-Sau-activated Th17 
responses by IL-35 in high responder group (fold increase ³ 5-fold) and low responder group (fold 
increase < 5-fold) are shown, n = 8 per group. b) IL-17 concentration in the MNC culture supernatant of 
the high responders treated with IL-35 and the Fc control protein respectively, n = 8. Data was analysed 
using paired t-test with p values indicated. 
 
IL-10 was shown to suppress SAg-Sau-activated IFNg expression and in fact promoted IL-
17A expression in tonsillar CD4+ T cells (described in 4.4.4). To examine whether IL-10 and 
IL-35 were playing divergent roles in SAg-Sau-activated Th1 and Th17 responses, the 
suppressive effect of IL-35 was compared to that of IL-10 on the effector CD4+ T cell 
responses stimulated by SAg-Sau. Indeed, IL-35 was shown to suppress the IL-17A+IFNg- 
cells without affecting the IL-17A-IFNg+ CD4+ T cell population which was in contrast to IL-10-
mediated suppression (Figure 5.6), suggesting a reciprocal regulation of Th1 and Th17 






Figure 5.6 IL-35 and IL-10 have opposite effects on SAg-Sau-activated Th1 and Th17 
responses 
Tonsillar MNCs were treated with recombinant IL-35 or IL-10 and stimulated with SAg-Sau CCS for 
48hrs, and expression of IL-17A and IFNg in CD4+ T cells were determined by intracellular staining. The 
zebra plots on the top were gated on CD4+ T cells, and numbers in top left and bottom right quadrants 
indicate percentages of IL-17A+IFNg- and IL-17A-IFNg+ cells respectively. Individual data was plotted in 
the dots and lines graphs, n = 5. Data was analysed using paired t-test, *p < 0.05, **p < 0.01. 
 
The recombinant IL-35 used for the above experiments was an Fc fusion protein with linked 
EBI3 and IL-12A, which is widely used to study the biological function of IL-3595,173,174. 
Although an Fc control protein was used at all times to exclude possible biological effects from 
the human IgG1 Fc protein region included in the recombinant protein, the way that the protein 
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subunits were fused together may also have impact on the biological activity of the 
recombinant IL-35. To confirm that the IL-35 mediated suppression of SAg-Sau activated 
Th17 response in tonsillar MNCs was not due to artificial IL-35-Fc fusion protein, a transfected 
CHO cell line producing the native form of IL-35 was constructed by introducing IL-12A and 
EBI3 expressing plasmids into CHO cells respectively. As shown in Figure 5.7, both IL-12A 
and EBI3 proteins were expressed in 4 transfected CHO cell colonies selected (C7, C8, C14 
and C15), and the heterodimeric IL-12A/EBI3 protein secretion was confirmed by Co-IP 
Western Blot. The conditioned medium generated by C7 CHO cells, which produced the 
highest amount of the IL-35 heterodimer, was used to examine the suppressive activity of 
native IL-35 on SAg-Sau stimulated Th17 response.  
 
 
Figure 5.7 Secretion of native form IL-35 by IL-35-expressing CHO cells 
The CHO cells were transfected with plasmids encoding human EBI3 (pRP-Neo-hEBI3) and human IL-
12A (pRP-Puro-hIL12A). a) Protein expression of IL-12A and EBI3 in the transfected CHO cell clones 
(C7, C8, C14 and C15) and control CHO cells (CHO) were detected by Western blot (this image was 
kindly provided by Richard Ali and Dr. Xiaoqing Wei from Cardiff University). b) Measurement of 
heterodimeric IL-35 in the culture supernatant of transfected CHO cells by co-immunoprecipitation (Co-
IP). 
 
Tonsillar MNCs were cultured in medium containing C7 CHO cell or control CHO cell 
conditioned medium (either 1, 2 or 10%) and stimulated with SAg-Sau. The native IL-35 
showed inhibition of SAg-Sau activated Th17 proliferation in a dose-dependent manner 
(Figure 5.8). Thus, it was confirmed that both IL-35-Fc and the native form of IL-35 were 
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functionally capable of regulating SAg-Sau activated Th17 response in human tonsillar MNCs. 
Recombinant IL-35 with Fc fusion was used for all subsequent experiments. 
 
 
Figure 5.8 Native form IL-35 supresses SAg-Sau-activated Th17 proliferation 
Tonsillar MNCs were stimulated with SAg-Sau CCS (1µg/ml) in the presence of conditioned medium 
from CHO-C7 or control CHO cells at 1%, 2% and 10% respectively. a) Dot plots were gated on CD4+ T 
cells and numbers in top right quadrants indicate the percentage of IL-17A+ Ki67+ cells (Proliferating 
Th17 cells). b) Suppression (%) of Th17 proliferation was calculated against stimulated MNCs without 
conditioned medium. Data displayed is mean ± SEM, n = 5. Data was analysed using paired t-test, *p < 
0.05. 
 
IL-35 signals through interleukin-12 receptor subunit beta 2 (IL-12Rb2) and glycoprotein 130 
(gp130) to activate members of the Janus kinase (Jak) family followed by phosphorylation of  
signal transducer and activator of transcription (STAT1 and STAT4), thereby suppressing the 
proliferative responses of effector T cells in mice175. However, the downstream signalling 
pathways involved in IL-35-mediated suppression of Th17 responses are yet to be elucidated. 
Both IL-12 and IL-35 bind to IL-12Rb2 but modify downstream gene transcriptions distinctively. 
IL-12 is well known for its ability to promote Th1 development, while IL-35 acts on IL-
12Rb2/STAT4 pathway to suppress helper T cell responses. gp130 is a common co-receptor 
for IL-6 family cytokines and mediates phosphorylation of STAT1 and STAT3 upon ligand 
binding. Collison et al. show that IL-35 interacts with gp130 to activate STAT1 signalling which 
also leads to the suppression of effector T cells. They further demonstrate that induction of IL-
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35 expression in effector CD4+ T cells by IL-35 requires both receptors and through a unique 
and unconventional STAT1:STAT4 heterodimer175.  
In human tonsillar MNCs, IL-12Rb2 was primarily expressed in CD4+ T cells and markedly 
higher expression of gp130 was also detected in CD4+ T cell population compared to the CD4+ 
cell-depleted lymphocytes (Figure 5.9). It suggests that IL-35-mediated suppression of SAg-
Sau-activated Th17 responses is likely a direct suppression on the activated CD4+ T cells 
through JAK/STAT signalling. 
 
 
Figure 5.9 IL-35 receptors are primarily expressed in CD4+ T cells in human NALT 
mRNA expression of Il-12rb2 (a) and gp130 (b) was examined in freshly isolated tonsillar CD4+ T cells 
and CD4- MNCs. The targeted gene expression was normalized to the expression of b-actin. 
 
IL-10- and Treg-dependent mechanisms have been reported to play a role in IL-35-mediated 
Th17 suppression98,169. However, I have demonstrated that IL-10- and Treg-mediated 
suppression of the Th17 activation stimulated by SAg-Sau is impaired, which may explain why 
IL-35 was not able to suppress SAg-Sau-activated Th17 response in tonsillar MNCs from low 
responders. The mechanism used by IL-35 to suppress the Th17 response in high responders 
may require expression of the IL-12Rb2:gp130 heterodimer at high levels in activated Th17 
cells, thus allowing IL-35 to signal through an unconventional pathway to induce IL-35 
expression in the targeted Th17 cells. Similar to IL-10 expression in Th17 cells, which directs 
the cell towards a regulatory phenotype86, IL-35 expression in pathological Th17 cells may 
 142 
also elicit an anti-inflammatory gene expression profile to reverse the post-activation fate of 
pathogenicity. 
 
5.4.3 IL-35 downregulates SAg-Sau-induced RORgt expression and inhibits Th17 
differentiation  
IL-35 has been reported to suppress Th17 cell differentiation164,176. It is therefore interesting 
to examine the effect of IL-35 on SAg-Sau-induced Th17 differentiation from naïve tonsillar 
CD4+ T cells. CD45RO is expressed on the cell surface of memory but not naïve T cells. 
Depleting CD45RO+ cells using magnetic cell sorting can therefore remove the memory CD4+ 
T cells from the tonsillar MNCs. Over 99% of CD45RO+CD4+ T cells was removed following 
magnetic cell sorting (Figure 5.10). 
 
 
Figure 5.10 The efficiency of depleting CD45RO+ memory T cells using magnetic cell 
sorting 
Dot plots showing percentages of CD45RO+CD4+ cells (numbers in top right quadrants) in unfractionated 
tonsillar MNCs and CD45RO+ cell depleted MNCs. 
 
CD45RO+ cell-depleted MNCs were then stimulated with SAg-Sau in the presence of Th17 
polarizing cytokines (IL-1b, IL-21 and TGFb1) for 7 days either with or without IL-35. SAg-Sau 
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induced IL-17A production was significantly reduced by the addition of IL-35 (Figure 5.11 a). 
The expression of RORgt, the key transcription factor controlling the differentiation of Th17 
cells59, was also analysed. Along with reduced IL-17A production, SAg-Sau induced RORgt 
expression in CD4+ T cells was downregulated by IL-35 (Figure 5.11 b), suggesting that IL-




Figure 5.11 IL-35 inhibits SAg-Sau-induced RORgt expression and Th17 differentiation 
CD45RO+ cell depleted tonsillar MNCs were stimulated with SAg-Sau CCS (50ng/ml) for 7 days in the 
presence of recombinant IL-1b (50ng/ml), IL-21 (50ng/ml) and TGFb1 (2ng/ml). 10ng/ml of recombinant 
IL-35 or Fc control protein were added at day 0 and day 3. a) IL-17A concentration in the cell culture 
supernatants as measured by ELISA, n = 6. b) Line plot showing the percentage of RORgt+ CD4- 
lymphocytes and RORgt+ CD4+ T cells in SAg-Sau stimulated tonsillar MNCs with or without IL-35. Mean 
± SEM are shown, n = 4. 
 
Orphan nuclear receptor RORgt has long been known as a transcription factor expressed by 
CD4+CD8+ double-positive (DP) thymocytes and lymphoid-tissue-inducer (LTi) cells, which is 
required for the regulation of thymic development and lymphoid-tissue genesis177. Ivanov et 
al. discovered that RORgt was also expressed in a subpopulation of lamina propria T cells and 
directed the differentiation of Th17 cells59. Later studies have surged to provide accumulating 
evidence demonstrating that RORgt is the master transcription factor to drive the gene 
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transcription profile of Th17 lineage, and RORgt deficiency results in the lack of Th17 cells 
and thereby confers protection against autoimmune pathologies. Small molecules and 
proteins that block the activity of RORgt have been developed and show promising effects in 
clinical trials for autoimmune diseases, such as psoriasis and multiple sclerosis. Here, I show 
that IL-35 treatment was able to downregulate the expression of RORgt in the CD4+ T cells, 
thereby hampering the development of Th17 cells in the context of SAg-Sau stimulation. This 
may serve, at least partially, the mechanism of IL-35-mediated suppression of SAg-Sau-
activated Th17 responses. 
 
5.4.4 SAg-Sau-activated IL-23R expression in CD4+ T cells is not altered by IL-35 
The differentiation and activation of Th17 cells are facilitated by certain cytokines, such as 
TGFb, IL-1b, IL-6 and IL-23. It is shown in Chapter 4 and here that SAg-Sau stimulation 
enhanced the expression of IL-23R in CD4+ T cells (Figure 5.12). Although IL-23 signalling is 
not required for the initial development of Th17 lineage, it is essential for Th17 cells to maintain 
stable phenotype in the effector phase and contributes to the pathological features of Th17 
cells in inflammatory settings. IL-35 has been shown to inhibit the transcription factor RORgt 
during Th17 differentiation. It was tempting to know whether IL-35 suppressed the effector 
and memory Th17 cells activated by SAg-Sau through downregulating the IL-23 signalling in 
Th17 cells. To examine this hypothesis, SAg-Sau stimulated tonsillar MNCs were treated with 
recombinant IL-35 and the expression of IL-23R in CD4+ T cells were measured by RT-qPCR 
and flow cytometry. 
Both mRNA and protein expression of IL-23R in SAg-Sau-activated CD4+ T cells did not 
change following addition of IL-35, as shown in Figure 5.12. It indicates IL-35-mediated 
suppressive signals may not act on the pathway that regulates the expression of IL-23R in 
Th17 cells. However, If IL-35-mediated suppression of SAg-Sau-activated Th17 response was 
dependent on the cell surface expression of IL-12Rb2:gp130 heterodimer, it would mean that 
only a small proportion of Th17 cells are specifically targeted. Changes in IL-23R expression 
in these cells may be too subtle to be detected in the whole CD4+ T cell population. Further 
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studies using single-cell RNA sequencing may help to characterise these SAg-Sau-activated 
Th17 cells which could be specifically regulated by IL-35. 
 
 
Figure 5.12 Expression of IL-23R in SAg-Sau-activated CD4+ T cells is not altered by IL-
35 
a) Tonsillar MNCs were stimulated with SAg-Sau CCS for 24hrs in the presence of IL-35 or Fc control 
protein and followed by CD4+ T cell isolation. mRNA was extracted from isolated CD4+ T cells for RT-
qPCR. Il23r mRNA expression is shown as fold change against media control (MC) in the bar graph, n 
= 3. b) SAg-Sau-stimulated MNCs were treated with IL-35 for 48hrs and the protein expression of IL-
23R was examined by flow cytometry. The median fluorescent intensity (MFI) of the IL-23R-APC in the 
CD4+ T cells was normalized by the isotype control and shown as mean ± SEM in the bar graph, n=3. 
Data was analyzed using paired t-test, **p < 0.01, n.s. means not significant. 
 
5.4.5 IL-35 does not affect CD39 expression in SAg-Sau-expanded Tregs 
Although previous studies tend to support the notion that IL-35 acts directly on the effector T 
cells to suppress their activation, Treg-dependent mechanisms has been reported94,169,175. It 
was shown IL-35 suppressed Th17 cells and ameliorated pathological changes in murine 
models of collagen-induced arthritis (CIA) by promoting CD39+ Tregs, as well as Foxp3- 
CD39+CD4+ T cells169. The importance of CD39 expression in human Tregs for their 
suppressive effect against Th17 activation was discussed in chapter 3 and the Foxp3+ Treg 
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population expanded by SAg-Sau had a significantly lower proportion of CD39+ cells has been 
shown in 3.4.6. Hence, it would be interesting to examine whether IL-35 was able to enhance 
CD39 expression in SAg-Sau-expanded Tregs and thereby enabling these Tregs to effectively 
suppress the Th17 activation. 
As shown in Figure 5.13, high frequency of CD39+ cells were detected in the Foxp3+ Treg 
population without stimulation. However, the frequency of CD39+ cells dropped significantly in 
SAg-Sau-stimulated Tregs, and this downregulation of CD39 cannot be rescued by IL-35 
treatment. Therefore, IL-35 seems not to act through Foxp3+ Tregs for its suppression of Th17 
responses in human NALT activated with SAg-Sau.  
 
 
Figure 5.13 IL-35 does not affect CD39 expression in SAg-Sau-expanded Tregs 
MNCs were stimulated with SAg-Sau CCS in the presence of IL-35 or Fc control protein for 48hrs, and 
cell surface expression of CD39 on Foxp3+ Tregs was examined by flow cytometry. a) Histograms 
showing the MFI of CD39 bound by PE-conjugated antibody in Foxp3+CD4+ (top) and Foxp3-CD4+ 
(bottom) cells respectively, with CD39+ cells gated in the right compartments.  b) Percentages of CD39+ 
cells within Foxp3+ Tregs were summarised in the bar graph, n = 10. Data was analysed using paired t-
test and Wilcoxon matched-pairs signed rank test, ***p < 0.001. 
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5.4.6 SAg-Sau colonization of the mouse nasopharynx induces IL-17A expression 
and downregulates IL-12A in the cervical lymph node CD4+ T cells 
I have demonstrated a highly activated Th17 response in human tonsillar MNCs driven by 
SAg-Sau, which was associated with downregulated IL-35 expression in the CD4+ T cells in 
vitro. A mouse nasal colonization model was used to further examine the in vivo activation of 
NALT CD4+ T cells. C57BL/6 mice were intranasally infected with SAg-Sau and the Th17 
response in the cervical lymph nodes (CLN) was assessed after secondary infection. All mice 
infected with SAg-Sau carried the bacterium at 24hrs post-secondary infection (Figure 5.14 
a). Consistent with in vitro Th17 activation by SAg-Sau in human tonsillar MNCs, mice infected 
with SAg-Sau also had significantly higher Il17a mRNA expression in their CLN CD4+ T cells 
compared to their naïve counterparts (Figure 5.14 b). The mRNA expression of Il12a and 
Ebi3 were also determined. Although less significant than in human tonsillar CD4+ T cells, the 
expression of Il12a in the mouse CLN CD4+ T cells was also reduced by SAg-Sau colonization, 













Figure 5.14 Nasal colonization of SAg-Sau induces IL-17A expression in mouse cervical 
lymph node CD4+ T cells 
C57BL/6 mice were infected intranasally with 107 CFU of SAg-Sau at day 0 and day 14 respectively. 
Nasopharynx and cervical lymph nodes (CLN) were harvested at 24hrs post-secondary infection. a) 
Nasopharyngeal homogenates were plated on blood agar plates and colonies were counted after 
overnight culture. b) CLN from 3 mice were pooled for lymphocyte isolation and CD4+ T cell separation. 
mRNA was extracted from separated CD4+ T cells for RT-qPCR. The mRNA expression of Il17a are 
shown as fold change against control mice. Results represent 2 independent experiments, 9 mice per 
group were used in each experiment. Data was analysed using unpaired t-test and displayed as mean 











Figure 5.15 Il12a expression in mouse CLN CD4+ T cells was downregulated by SAg-
Sau colonization 
C57BL/6 mice were infected intranasally with 107 CFU of SAg-Sau at day 0 and day 14 respectively, 
and the CLN were harvested at 24hrs post-secondary infection. mRNA expression of il12a (a) and ebi3 
(b) was detected in the CD4+ T cells isolated from the CLN and shown as fold change against control 
mice. 
 
In humans, IL-35 is produced primarily by effector CD4+ T cells, however in mice, Foxp3+ 
Tregs constitutively express IL-35 and are the primary source of this cytokine97,101. SAg-Sau 
stimulation led to a more significant decrease in IL-35 expression in human CD4+ T cells, 
suggesting that it may primarily downregulate IL-35 expression in effector CD4+ T cells. 
Despite this, both human and mouse carriage models show that SAg-Sau downregulates IL-
35 expression in CD4+ T cells, which could contribute to an enhanced Th17 response. 
 
5.5 Conclusions 
In this chapter, immune suppressive cytokine IL-35 was identified to play a key role in 
controlling the pro-inflammatory Th17 responses activated by SAg-Sau in human NALT. 
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IL-35 is a heterodimeric protein consisting of IL-12A and EBI3 subunits. In mice, the 
expression of EBI3 subunit is found to be the downstream target of transcription factor Foxp3, 
therefore IL-35 is constitutively and primarily expressed by Foxp3+ Tregs97. Further study 
shows that IL-35 can be induced in effector CD4+ T cells and these IL-35-producing CD4+ T 
cells (iTR35) exhibit potent suppressive function94. However, it remains controversial whether 
IL-35 is expressed in human CD4+ T cells101. Here, I show that human tonsillar tissue-derived 
CD4+ T cells expressed heterodimeric IL-35 and its expression was inhibited by SAg-Sau, in 
contrast to the expanded Foxp3+ Tregs and enhanced IL-10 expression. It indicates that 
expression of IL-35 in human CD4+ T cells may be independent of Foxp3+ Tregs which is 
supported by a previous study showing EBI3 subunit is not constitutively expressed in human 
PBMC-derived Tregs101. Despite the potential discrepancy in human and mice CD4+ T cell 
subsets that express IL-35, mice with nasopharyngeal infection of SAg-Sau also showed 
reduced expression of IL-35 in the CD4+ T cells of cervical lymph nodes. 
Not only the expression of IL-35 was regulated by SAg-Sau in a way that is opposing to IL-10 
and Tregs, IL-35 also showed differential regulatory effects by suppressing the activation of 
IL-17A-producing Th17 cells but not the IFNg-producing Th1 cells. Interestingly, IL-35-
mediated Th17 suppression was shown to positively correlate with the level of Th17 activation, 
and IL-35 significantly reduced SAg-Sau-activated Th17 responses in those high responders 
(fold increase in Th17 response ³ 5-fold) only. Since appropriate Th17 activation is required 
to protect the host from fungal and bacterial infection, patients with autoimmune diseases 
treated by IL-17A/Th17 antagonists frequently develop chronic mucocutaneous candidiasis 
(CMC). IL-35 has the ability to suppresses over-reactive Th17 responses while maintaining a 
“physiological level” of Th17 activity against bacterial infection in human nasopharynx, making 
it potentially a promising treatment option for Th17-mediated inflammatory/autoimmune 
diseases. 
Further, addition of IL-35 was shown to downregulate RORgt expression in CD4+ T cells and 
thereby inhibiting SAg-Sau-induced Th17 differentiation. However, the IL-23R expression in 
CD4+ T cells which was enhanced by SAg-Sau was not affected by IL-35 treatment. Further 
studies are required to illustrate the signalling pathways used by IL-35 in suppressing the high 
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Th17 responses activated by SAg-Sau infection, as well as other inflammatory settings 
mediated by strong Th17 activation in humans. 
In summary, SAg-Sau infection is able to inhibit IL-35-expressing CD4+ T cells in human 
NALT which may contribute substantially to the over-reactive Th17 responses activated by 









General Discussion  
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In this project, the T cell activation and regulation in response to SAg-Sau in NALT were 
examined using human tonsillar tissue and murine nasopharyngeal infection model. The 
majority of data were acquired from in vitro re-stimulation of human tonsillar MNCs. Tonsils 
are organised lymphoid tissue and interaction between lymphocytes and epithelial cells of the 
tissue are important for the development of immune responses. In vitro-isolated tonsillar 
MNCs lack organised lymphocyte zones (e.g. germinal centres) and do not include tissue 
epithelial cells, therefore results obtained from this in vitro re-stimulation system require a 
careful interpretation. However, the simplicity of isolated tonsillar MNCs makes it possible to 
explore mechanisms by which Sau-activated inflammatory T cell responses are regulated and 
therefore inform new strategies in the management of Sau-associated inflammatory 
conditions. SAg-Sau was shown to activate not only pro-inflammatory Th1 and Th17 
responses, but also anti-inflammatory Foxp3+ Tregs and IL-10-producing Tr1 cells in human 
NALT. Interestingly, the expression of IL-35 in the tonsillar CD4+ T cells was markedly 
downregulated by SAg-Sau, indicating the development of iTR35 cells may be inhibited in SAg-
Sau-infected nasopharynx. The regulation of SAg-Sau-activated Th1 and Th17 responses by 
the Foxp3+ Tregs, IL-10 and IL-35 was demonstrated in the previous chapters and 
summarised in Figure 6.1.  
Based on these results, I would like to discuss a number of questions and hypotheses 
underlying the findings of this project. 1) SAg-Sau showed a potent ability in activating T cell 
responses. How do staphylococcal superantigens stimulate T cells in a way different from 
conventional antigen in terms of the three-signal model of T cell activation? 2) SAg-Sau 
activated a strong Th17 response and induced IL-17A expression in the Foxp3+ Tregs. Will 
this contribute to autoimmunity? 3) SAg-Sau-activated Th1 and Th17 responses were 
divergently regulated by Foxp3+ Tregs and IL-10. Is this related to the opposing role of 
CD28/B7 co-stimulatory signalling in Th1 and Th17 activation? 4) Exogenous IL-10 was 
shown to promote SAg-Sau-activated Th17 responses. Is this associated with the 
downregulation of endogenous IFNg by IL-10 which may act through lifting STAT1-mediated 
suppression of STAT3 signalling? 5) IL-35 was able to suppress the strong Th17 responses 
activated by SAg-Sau. What are the cellular mechanisms that mediate this suppressive effect? 




Figure 6.1 Schematic representation of T cell-mediated regulation of SAg-Sau-activated 
Th1 and Th17 responses in NALT 
SAg-Sau-derived antigens activates IFNg-producing Th1 cells, IL-17A-producing Th17 cells, Foxp3+ 
Tregs and IL-10-producing Tr1 cells but suppressed the IL-35-producing iTR35 cells. The Th1 responses 
are inhibited by the Tregs and IL-10, while IL-35 does not appear to affect the Th1 activation in SAg-Sau 
stimulated tonsillar MNCs. However, IL-35 is shown to inhibit the Th17 responses which in fact are 
promoted by exogenous IL-10. Some Tregs exhibit expression of IL-17A following SAg-Sau stimulation 
and removal of Tregs reduces the proportion of activated Th17 cells, indicating Tregs may also promote 








6.1 Staphylococcal superantigens activate T cells by circumventing 
the canonical TCR recognition of peptide/MHC complex 
The recorded history of Sau causing infection and diseases can be dated back to the 19th 
century178. Sau commonly colonizes skin and mucous of the upper respiratory tract and 
associates with infectious and inflammatory diseases which is mainly due to its capability of 
producing numerous virulence factors179,180. Staphylococcal enterotoxins (SEs) and TSST-1 
are an important group of protein toxins produced by Sau, and these toxins have attracted a 
large number of studies aiming to uncover their potent ability in activating antigen-presenting 
cells (APCs) and T cells and how this activation leads to inflammatory pathologies181. 
Those staphylococcal antigens stimulate T cells in a way that is similar to a group of 
endogenous antigens expressed by mice, named minor lymphocyte stimulating antigens (MIs), 
by interacting with a particular variable beta (Vb) chain of the TCR regardless of the 
composition of variable alpha (Va) chain23,182. By a process of somatic gene rearrangement, 
the two separately rearranged Va and Vb chains have resulted in the vast diversity of ab 
TCRs, and thereby allowing the T cells to recognize an even larger repertoire of foreign 
antigenic peptides presented by APCs183,184. However, T cells possess limited type of Vb 
elements with 54 and 35 TCR Vb genes expressed in humans and mice respectively183. Thus, 
SEs and the mice MIs are able to activate simultaneously a large proportion of total T cells 
through recognizing specific Vb chains, whereas only a very small fraction of T cells can be 
activated by conventional antigens which have to match the binding epitopes of both Va and 
Vb regions185 (Figure 6.2). Antigens that activate T cells depending on the Vb specificity only 
are termed “superantigens”186. 
Superantigen-producing Sau is common with up to 50% of Sau strains identified are positive 
for one or multiple superantigens10,33. The SAg-Sau used in this study produces TSST-1, SEA, 
SEC and SEE and exhibit potent ability in activating both proliferative response and production 
of inflammatory cytokines, such as IL-17A and IFNg, in human tonsillar CD4+ T cells. 
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TCR recognition by MHC class II loaded with foreign peptide which is presented on the cell 
surface of APCs is the primary signal required to initialize CD4+ T cell activation187. Normally, 
exogenous antigens can be taken by professional APCs, including dendritic cells (DCs), 
macrophages and B cells, through phagocytosis or endocytosis and are processed into small 
peptides. These peptides can then be loaded onto MHC class II molecules and displayed by 
the APCs188. Different from conventional antigens, superantigens are able to directly bind to 
the MHC class II molecules without prior processing24. It is notable that presentation of the 
conventional antigenic peptide is not inhibited by the association of superantigen with MHC 
class II because superantigens do not occupy the peptide-binding groove of MHC class II23 
(Figure 6.2).  
Here, I stimulated tonsillar MNCs with concentrated culture supernatant of SAg-Sau which 
was a mixed antigen pool containing not only superantigens, but also other conventional 
antigens secreted by the bacteria. Therefore, both superantigenic and antigen-specific T cell 
responses were activated. By comparing the CD4+ T cell responses activated by SAg-Sau 
with NonSAg-Sau and other common colonizers of the nasopharynx, including Spn, 
coagulase-negative staphylococcus and M. catarrhalis,  SAg-Sau and/or its superantigens 
were shown to activate highly  pro-inflammatory T cell responses (e.g. Th1 and Th17) in 












Figure 6.2 Superantigen activates T cells by directly binding to the TCR Vb, MHC class 
II and co-stimulatory molecules 
Schematic diagram of the two stimulatory signals for T cell activation. Left: The TCR complex of T cells 
consists of a chain, b chain, CD3 and z chain molecules. The TCR a and b chains are composed of two 
extracellular domains, variable region and constant region. The T cells recognize the peptide/MHC class 
II complex on the APCs by variable a and b chains which provides the first signal for T cell activation. 
The co-stimulatory molecules CD28 and ICOS are expressed by T cells which bind to the B7 and ICOS 
ligand (ICOSL) on the APCs respectively, acting as the secondary signal to assist T cell activation. 
Activated T cells upregulate the co-inhibitory molecule, CTLA4, which is homologous to CD28 and 
thereby could compete with CD28 for the binding of B7 proteins. Compare to the B7-2 which is 
constitutively expressed in APCs, the B7-1 is induced only following T cell activation and it has higher 
avidity to CTLA4. Thus, CTLA4 binds to the B7-1 more efficiently and transduce inhibitory signals to 
contain T cell activation. Right: Different from the conventional antigen which needs to be processed by 
the APCs and then be loaded onto the MHC class II for TCR recognition, superantigen can bind to the 
MHC class II and TCR Vb chain directly. Furthermore, superantigen can also bind directly to the co-
stimulatory molecules CD28/B7, providing strong co-stimulation signals for the activation of inflammatory 
cytokine production in the effector T cells. 
 
6.2 Staphylococcal superantigens may contribute to autoimmunity by 
activating self-reactive T cells  
It is worth noting that the random rearrangement of Va and Vb chain enables the TCR to 
recognize various antigens derived from external pathogens, but also generates TCR that 
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reacts to self-derived antigens which underlies the aetiology of autoimmunity73,189. To 
eliminate those self-reactive T cells, the thymus has developed a central tolerance mechanism 
described as negative selection by which T cell clones with high avidity to self-antigens are 
depleted during the selection process190,191. In addition to the negative selection, some self-
antigen specific T cells can differentiate into suppressive Foxp3+ Tregs via agonist selection 
and those thymic-derived Tregs (tTregs) are crucial for maintaining peripheral immune 
tolerance190. However, studies have shown that self-reactive Foxp3- T cells (conventional T 
cells, Tconvs) can sometime escape the thymic selection and exit to the periphery. This occurs 
especially when they express TCRs with high affinity for certain tissue-restricted peptides that 
are not expressed or have limited expression in the thymus192,193. These self-reactive T cells 
are normally ignored in the periphery because tissue-specific antigens are usually concealed 
behind the anatomical barrier in physiological context36. However, infection or other causes of 
tissue damage could lead to the exposure of sequestered self-antigens and therefore 
increasing the risk of activating auto-reactive T cells. Peripheral immune suppressive 
mechanisms, including regulatory T cell subsets (e.g. Foxp3+ Tregs, Tr1 and iTR35) and 
inhibitory molecules (e.g. CTLA4, PD-1), are important to control those auto-reactive T cells 
upon encountering autoantigens36. 
With the ability to activate T cells regardless of antigen specificity, staphylococcal 
superantigens could also activate those escaped autoreactive T cells. Superantigenic 
activation of naïve T cells are shown to result in clonal deletion and cell anergy which could 
be a tolerance mechanism to protect the host from massive T cell activation. However, it has 
been demonstrated that superantigen stimulation in mice pre-challenged by self-antigens 
could reactivate autoreactive T cells, leading to autoimmune pathologies26,27,31,34. Studies 
linking Sau and its superantigens with autoimmunity were reviewed in Chapter 1. In addition, 
pathogen-primed T cells may also be activated by staphylococcal superantigens and thereby 
mediating inflammatory tissue damage25. In my study, SAg-Sau showed potent ability of 
activating inflammatory Th17 responses which were more resistant to immune suppression 
than Th1 responses. Although the antigen specificity of these activated Th17 cells were not 
defined, it was possible that SAg-Sau-activated Th17 responses could underlie pathological 
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changes of certain inflammatory and autoimmune diseases, given the highly pathogenic 
property of Th17 cells shown by a large number of studies. 
 
6.3 SAg-Sau may break down immune tolerance by inducing Treg 
conversion into pro-inflammatory Th17 cells  
Furthermore, I found an aberrant expansion of Foxp3+ Tregs in SAg-Sau stimulated tonsillar 
MNCs and a significant proportion of these Treg showed expression of IL-17A, indicating SAg-
Sau may alter the anergic state of Tregs and promote their conversion into effector T cells. It 
is known that Foxp3+ Tregs do not respond to TCR-mediated activation and are capable of 
suppressing immune responses of effector T cells194-197. The unresponsiveness of Tregs is 
critical for the maintenance of immune tolerance against self-tissue, since natural Tregs 
(nTregs) developed in the thymus have a TCR repertoire biased towards self-peptides and 
exhibit greater avidity for self-peptide/MHC class II complexes than Tconvs198-200. In a model 
of autoimmune neuroinflammation induced by myelin oligodendrocyte glycoprotein (MOG), 
the functional avidity and encephalitogenic capacity of the MOG-specific TCRs derived from 
Tregs and Tconvs were compared. It shows that poly-clonal Tconvs engineered to express 
the Treg-derived TCRs show stronger reactivity to the MOG antigen and cause an earlier 
onset of EAE and more severe disease manifestation upon adoptive transfer in the recipient 
mice200. Another strong evidence to support the proposal of strong self-reactive Tregs comes 
from the transgenic mice harbouring autoimmune regulator (Aire) deficiency. The Aire is a 
transcription factor expressed by the medullary thymic epithelial cells (mTECs) controlling the 
promiscuous expression of tissue-restricted antigens in the thymus, its deficiency results in 
multi-organ autoimmunity in mice. By characterising TCR specificities of the Tconvs infiltrating 
the autoimmune lesions in Aire-/- mice, it reveals that the predominant TCR clonotypes 
expressed by these infiltrating Tconvs are primarily expressed by Tregs in Aire+/+ mice199. 
Thus, the removal of anergy and the subsequent phenotypic changes in Tregs, which has 
been observed following SAg-Sau stimulation, could lead to the expansion of auto-reactive 
Tconvs which may break down the immune tolerance and initiate autoimmune pathologies.  
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6.4 The possible role of CD28/B7 co-stimulations for Treg- and IL-10-
mediated differential regulation of SAg-Sau-activated Th1 and Th17 
responses 
Upon TCR engaging with the peptide/MHC class II complex, the interaction between co-
stimulatory receptors of T cells and the corresponding ligands on the APCs provides the 
second signal for T cell activation (Figure 6.2). The classical co-stimulation signal is 
represented by the CD28-B7 paradigm201. CD28 is the most well-known co-stimulatory 
receptor which is constitutively expressed on T cells and interacts with both B7 ligands, B7-1 
(also known as CD80) and B7-2 (also known as CD86)201,202. B7-2 is constitutively expressed 
on APCs, although at a low level, and rapidly upregulated within 6 hours of stimulation, 
whereas B7-1 is undetectable on resting APCs and it is not until 24 hours post stimulation that 
the B7-1 is induced to express202,203. The B7 ligands can also bind to CTLA4, a co-inhibitory 
receptor which is homologous to CD28, with high affinity. In Tconvs, CTLA4 is induced only 
by stimulation and peaks 48 hours following cell activation and negatively regulate the 
activated T cells202,204. The B7-1 binds 13-fold more strongly to CTLA4 than B7-2, therefore 
the delayed expression of B7-1 is timed to specifically enhance the co-inhibitory signal 
mediated by CTLA4204. Different from Tconvs, Foxp3+ Tregs constitutively express CTLA4 
and the suppression through the CTLA4 pathway plays an important role in Treg-dependent 
immune regulation and tolerance128. 
T cells activated in the absence of CD28 signalling acquire the state of functional 
unresponsiveness which means they cannot respond following stimulations for a certain 
period, and this is thought to be an immune tolerance mechanism against autoimmunity36. 
CD28 signalling is also involved in the T cell activation stimulated by superantigens205-207. 
Superantigens bind directly into the dimer interface of CD28 and B7 coligands (Figure 6.2), 
potently promoting their interaction and thereby eliciting strong production of inflammatory 
cytokines, including IFNg, TNF-a and IL-2208. Peptide mimetics that block binding sites of 
superanigens in CD28 and B7 both abrogate the inflammatory cytokine production and protect 
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mice from superantigen-induced lethal shock208-210. Furthermore, CD28-deficient mice are 
completely resistant to staphylococcal superantigen TSST-1-induced toxic shock syndrome205. 
The T cells derived from CD28-/- mice pre-challenged with SEB exhibit dramatically reduced 
proliferation and TNF-a production following secondary SEB stimulation, indicating T cell 
anergy is induced by the superantigen without CD28 signalling206. 
The lack of CD28 co-stimulatory signals inhibits production of IFNg and Th1 responses in both 
conventional and superantigenic T cells activation. However, studies have shown the 
activation of Th17 cells are not affected in the absence of CD28 signals and these activated 
Th17 cells respond normally to restimulations. Moreover, CD28 co-stimulation in fact 
suppresses Th17 differentiation in the initial induction period211,212. Instead, the accessory co-
stimulatory molecule, inducible co-stimulator (ICOS), is shown to mediate the development of 
Th17 cells213,214. Another study demonstrates that CD28-mediated increasing of metabolic 
activity which supports the proliferation and effector cytokine production of Th1 cells can be 
replaced by Th17-related cytokines IL-1b and IL-23 for Th17 activation212. The negative 
modulation of Th17 responses by CD28-B7 signalling explains why CTLA4-immunoglobin 
(CTLA4-Ig), which is supposed to inhibit T cell responses via blocking the interaction of CD28 
and B7, actually enhances Th17 responses and exacerbates Th17-mediated intestinal 
inflammations129. 
The CD28-B7 co-stimulations also play an opposing role in superantigen-activated Th1 and 
Th17 responses. In a murine model of arthritis induced by superantigen-producing 
Mycoplasma arthritidis (M. arthritidis), treatment of anti-B7-1 significantly enhances Th17 
responses whereas the Th1 responses are reduced, making mice more susceptible to the 
arthritogenic effects of M. arthritidis215. I’ve shown that Foxp3+ Tregs derived from both NALT 
and peripheral blood suppressed the activation of Th1 but not Th17 cells following SAg-Sau 
stimulation (Figure 4.4 and 4.5). In Treg-depleted MNCs, the proportion of activated Th17 
cells even showed a trend of decreasing, which was consistent with reduced IL-17A 
production in the culture supernatant (IL-17A concentration measurement was done after first 
draft thesis submission). Those SAg-Sau stimulated Tregs exhibited upregulated CTLA4 
expression indicating an enhanced regulatory pathway through CTLA4 signalling. Therefore, 
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it is plausible that the divergent regulation of SAg-Sau-activated Th1 and Th17 responses by 
Tregs is correlated with CTLA4-mediated immune modulations which antagonise CD28-
mediated costimulatory signals and selectively suppressed Th1 activation. 
Similar to Tregs, IL-10 also showed opposing effects in the superantigenic Th1 and Th17 
responses which may be explained by a previous study showing IL-10 acts directly on CD28 
co-stimulation pathways for its suppression of Th1 and Th2 responses. It demonstrates that 
IL-10 is able to inhibit the tyrosine phosphorylation of CD28 and its following association with 
phosphoinositide 3-kinase (PI3K) which is an essential step for the downstream activation of 
CD28 signalling pathway, and this IL-10-mediated suppression affects Th1/Th2-related 
cytokine production activated by both conventional antigens and superantigens148. However, 
if IL-10 suppresses superantigenic effector T cell responses through blocking CD28 signalling, 
it is possible that SAg-Sau-activated Th17 responses were not suppressed by IL-10 since 
CD28-mediated co-stimulations are not required for Th17 activation as discussed above. The 
differential regulation of Th1 and Th17 responses by co-stimulatory/co-inhibitory signals is 
summarised in Figure 6.3. 
 
6.5 Inflammatory cytokine milieu may be responsible for the 
reprogramming of Tregs into Th17 cells 
The third signal for T cell activation is the cytokine milieu in which the T cells are activated. It 
largely affects the T cell lineage commitment during differentiation and phenotypic changes in 
the effector phase which is described as T cell plasticity (Figure 6.3). In general, a pro-
inflammatory cytokine environment supports the development and activation of inflammatory 
T cell subsets, such as Th1 and Th17, whereas immune suppressive Tregs are developed in 
the absence of pro-inflammatory cytokines115,216. Interestingly, the differentiation of Foxp3+ 
Tregs and Th17 cells both require TGF-b signal115,120,217. Although TGF-b may not be 
necessary for the development of nTregs in the thymus, it is critical for the maintenance of 
nTregs in the periphery218. TGF-b induces the expression of both Foxp3 and RORgt nuclear 
factors in CD4+ T cells, which transcription factor is dominant depends on the cytokine 
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environment and determines whether the cells are programmed into Tregs (Foxp3-dominant) 
or Th17 cells (RORgt-dominant)116,217. Without inflammatory cytokines, such as IL-6 and IL-
21, the function of RORgt is repressed by the Foxp3 and thereby leading to the suppressive 
phenotype of Tregs. However, this inhibition of RORgt can be relieved once Foxp3 is 
downregulated which can be induced by inflammatory cytokine-mediated STAT3 activation219. 
SAg-Sau activated IL-17A expression in the Tregs suggesting a potential Treg conversion into 
Th17 cells, and this could be the results of enhanced inflammatory signals in SAg-Sau 
stimulated tonsillar MNCs, such as increased production of IL-6. IL-6-mediated activation of 
STAT3 signalling has been shown to induce the redifferentiation of both thymic-derived 
nTregs and peripheral-induced Tregs (iTregs) into effector Th17 cells. Functionally, Tregs that 
have been reprogrammed to express IL-17 exhibited markedly reduced suppressive 
activity220,221. This may partially explain why tonsillar Tregs were unable to suppress the 
proliferation and IL-17A production in CD4+ T cells upon SAg-Sau stimulation. Notably, 
another study demonstrates that IL-17-producing Tregs still have the ability to inhibit the 
proliferation of CD4+ responder T cells activated by anti-CD3 and anti-CD28118. In the context 
of SAg-Sau stimulation, the proliferative responses activated were not suppressed by Tregs. 
This may be explained by impaired suppressive function of SAg-Sau-stimulated Tregs or 
associate with high resistance of superantigen-activated T cells to Treg-mediated suppression. 
Whether SAg-Sau-activated IL-17A-producing Tregs retained the suppressive capability for 









Figure 6.3 Co-stimulatory signals and cytokine milieu that regulate the development of 
different CD4+ T cell subsets 
Schematic representation of how effector T cell subsets are regulated by the co-stimulatory/co-inhibitory 
signals and cytokine environment. The activation of Th1 cells requires CD28/B7 co-stimulation and the 
stimulation signals mediated by IFNg and IL-12 cytokines. IL-10 could thereby suppress the Th1 
responses by inhibiting the co-stimulatory signal delivered by CD28 and B7 interaction. IL-10 can also 
suppress IFNg production by Th1 cells and thereby blocking the positive feedback of IFNg signalling for 
Th1 activation. CTLA4 suppresses Th1 responses by displacing CD28 to bind the B7 proteins and 
transduce inhibitory signals. However, the co-stimulatory signal CD28/B7 which supports Th1 activation, 
in fact inhibits the development of Th17 cells. Rather, the co-stimulation that facilitate Th17 activation is 
provided by the interaction of ICOS and ICOSL. The co-inhibitory CTL4 also appears to assist Th17 
activation, in contrast to its general inhibitory role for the proliferative response of T cells and Th1 
responses. Cytokines that support Th17 activation include TGFb, IL-6, IL-1b, IL-21 and IL-23. The Th1 
cytokine IL-12 could induce Th17 conversion into Th1 cells. TGFb is also required for Foxp3+ Treg 
induction, and the Tregs could be reprogrammed to Th17 cell in the presence of inflammatory cytokines, 
such as IL-6. IFNg is the signature cytokine produced by Th1 cells, and its presence can inhibit Th17 
development.   
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It has been mentioned above that the TCR specificity of nTregs is self-antigen biased. The 
potential of these strong self-reactive Tregs to be reprogrammed into effector Th17 cells may 
contribute to the high pathogenicity of Th17 cell subset, although it remains controversial 
regarding the in vivo stability of nTregs222,223. Compared to nTregs, the iTregs are developed 
from peripheral naïve T cells and thereby their TCR repertoire is overlapped with conventional 
T cells, exhibiting low avidity to self-antigens. However, conversion of iTregs into Th17 cells 
also leads to autoimmunity. Komatsu et al. demonstrates in a murine model of collagen-
induced arthritis (CIA) that those arthritogenic IL-17-producing T cells originate from Foxp3+ 
Tregs which are transdifferentiated into Th17 cells in the inflamed joint containing high level 
of IL-6. These ex-Tregs have a gene expression profile matched with iTregs, distinguishable 
from Tconvs and nTregs119. Hence, despite the origin of the Tregs, their conversion into Th17 
cells could occur in response to environmental cues and this conversion has pathological 
implications for inflammatory and autoimmune diseases. SAg-Sau infection can therefore be 
a trigger of autoimmunity by promoting the Treg conversion into pathological Th17 cells. 
 
6.6 Dose endogenous IFNg affect the activation of committed Th17 
cells? 
For the regulation of SAg-Sau-activated Th17 responses in the nasopharynx, both Treg- and 
IL-10-mediated suppression were shown to be inefficient, in contrasting to their potent effects 
in controlling Th1 activation. Further, exogenous IL-10 was found to promote Th17 responses 
stimulated by SAg-Sau. This may be partially related to the inhibition of CD28 signalling by IL-
10 which removes the negative effects of CD28 co-stimulation on Th17 activation148. However, 
it is notable that CD28-induced suppression on Th17 cells mainly affects Th17 differentiation 
but does not appear to inhibit memory Th17 activation212.  
Different Th cell lineages are counter-regulated during differentiation but committed Th cells 
could exhibit heterogenous effector phenotypes. Following SAg-Sau stimulation, not only IL-
17A and Foxp3 double positive CD4+ T cells were activated, a CD4+ T cell population that co-
express IL-17A and IFNg (Th17/Th1 cells) was also detected. Along with highly activated Th17 
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responses, SAg-Sau also activated strong Th1 responses. It has been reported by two parallel 
studies that development of Th17 cells from naïve CD4+ T cells is strongly suppressed by 
IFNg, whereas committed effector and memory Th17 cells are resistant to exogeneous 
IFNg224,225. These two studies also examined whether blocking endogenously produced IFNg 
could enhance IL-17 expression by committed Th17 cells but generated contradicting results. 
The principal difference between their stimulations is one study used anti-CD3 stimulation only 
and the other stimulated the cells with anti-CD3 and anti-CD28. Depletion of endogenous IFNg 
enhanced the effector Th17 responses when anti-CD28 stimulation was present. The CD28-
mediated suppression of Th17 activation is shown to be dependent on the increased IFNg and 
IL-2 production, although this suppression seems to not apply to effector Th17 cells211. It is 
possible that depleting IFNg enhances the effector Th17 responses by removing certain 
suppressive effects mediated by CD28 co-stimulations but do not alter the responses 
activated by anti-CD3 only. Consistent with this notion, IFNg blockade has been shown to 
enhance IL-17 expression in human memory CD4+ T cells coming into contact with activated 
monocytes80. Activation signals via TCR and CD28 co-stimulatory molecules both were 
delivered by tonsillar monocytes and B cells in my stimulation model, exogenous IL-10 
significantly reduced IFNg production following SAg-Sau stimulation, this reduction of 
endogenously produced IFNg may contribute to the enhanced IL-17A expression in tonsillar 
CD4+ T cells. How IFNg-mediated signalling pathway in effector CD4+ T cells may affect the 
IL-17 expression and Th17 activation is discussed below. 
 
6.7 STAT3 activation by IL-6 and IL-10 could confer distinct effector 
phenotypes in CD4+ T cells 
A wide range of cytokines that regulate T cell responses signal through type I and type II 
receptors, including IL-2, IL-10, IFNg, IL-6 and IL-12 family cytokines. These cytokine 
receptors lack an intrinsic catalytic kinase activity and rely on Janus kinases (JAKs) to 
phosphorylate downstream signal proteins. The JAK family has 4 members, JAK1, JAK2, 
JAK3 and tyrosine kinase 2 (TYK2), each associates with the cytoplasmic domain of different 
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cytokine receptors226. Upon cytokine binding, the receptor goes through conformational 
changes which allows the adjacent JAKs to phosphorylate each other and followed by 
phosphorylation of the signal transducer and activator of transcription (STATs). 
Phosphorylated STATs (pSTATs) form homodimer or heterodimer and translocate to the 
nucleus where they bind DNAs and regulate the transcription of target genes (Figure 6.4). 
There are 7 STAT proteins that have been identified, STAT1, STAT2, STAT3, STAT4, 
STAT5A, STAT5B and STAT6227. The extracellular cytokine milieu shapes the effector 
responses of T cells through integrated JAK-STAT signalling. Although IL-17 do not signal via 
JAK-STAT pathway, the development of Th17 cells is dependent on the activation of STAT3 
which can be induced by IL-6 and IL-21. Dimerised STAT3 enters the nucleus  and induce the 
transcription of IL-17A, as well as other Th17-related protein targets like IL-23R and IL-21228. 
Staphylococcal superantigen SEA has been shown to activate STAT3 for its promoting effects 
on Th17 responses229. 
What has to be born in mind is that IL-10 also activates STAT3, although no evidence yet to 
show IL-10-induced STAT3 activation could lead to enhanced Th17 activation. Rather, studies 
demonstrate that the STAT3 activation by IL-10 directs the T cell towards a tolerogenic 
phenotype resembling Tr1230. Moreover, CD4+ T cells transfected with active form of STAT3 
cannot enhance IL-17 expression without TGF-b signalling, but rather promote the 
suppressive capacity of T cells, suggesting STAT3 per se induce a dominant suppressive 
gene expression profile in T cells228,231. However, when the master regulator of Th17 cells, 
RORgt, is induced by TGF-b and IL-6, activated STAT3 could work synergistically with RORgt 
to potently promote IL-17 expression and Th17 responses228. In contrast to IL-6-mediated 
STAT3 activation which enhance Th17 activation, IL-10/IL-10R-mediated STAT3 activation in 
T cells are shown to be necessary for the suppression of Th17 responses by Foxp3+ Tregs 
and IL-10-producing Tr1 cells in murine models of colitis78,85. Whether the superantigenic 
stimulation altered the commonly suppressive IL-10/STAT3 signalling and resulted in the 
promoting effect of exogenous IL-10 on Th17 activation shown in my study is yet to be 
elucidated. Here, I would like to discuss another possibility relating to IFNg-mediated STAT1 
activation which may help to decipher this interesting effect from the perspective that 
emphasise the counter-regulation between STAT proteins. 
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6.8 IL-10 may promote SAg-Sau-activated Th17 responses through 
inhibiting IFNg-STAT1 signalling 
The STAT proteins were initially thought to be positive transactivating factors until it was found 
that they also serve as repressors for a considerable number of genes232. Different STATs 
could target the same gene but exert opposing effects and thereby fine-tune the phenotype of 
the effector T cells activated in a complicated cytokine milieu, with both STAT1 and STAT5 
having been demonstrated to negatively regulate Th17 activation via interfering with the 
function of STAT3233-235 (Figure 6.4). Yang et al. shows IL-2-activated STAT5 bind the 
promoter and several distal sites of Il17a locus, which regions can also be bound by IL-6-
activated STAT3. Therefore, the STAT3 binding in the Il17a promoter as a strong enhancer 
can be displaced by STAT5 which results in reduced gene transcription and diminished IL-
17A expression233. 
Several mechanisms have been suggested for STAT1-mediated STAT3 inhibition. 1) STAT1 
may displace STAT3 binding to Il17a promoter like STAT5; 2) STAT1 may bind to distinct 
regions of Il17a locus acting as a repressor for the transcription. Although the mechanism is 
yet to be clarified, it is clear that enhanced STAT1 activation is able to suppress STAT3-
induced IL-17 expression and Th17 activation234-236. In patients carrying gain-of-function 
STAT1 mutation, a smaller proportion of IL-17-produing cells is found in the circulation 
compared to normal individuals236. The PBMCs derived from these patients express 
significantly lower Th17-related genes (IL-17A, RORgt and IL-22) following stimulation, and 
this decreased expression of IL-17A can be fully restored by inhibiting the phosphorylation of 
STAT1234.  
IFNg stimulates a predominant STAT1 activation, which can be further enhanced by IL-12-
activated STAT4 signalling, together they drive Th1 effector phenotype. Th17 cells are shown 
to express not only its own master regulator RORgt, but also T-bet, the master regulator of 
Th1 cell lineage79,237. The T-bet is the downstream target of STAT1, and its expression can 
be upregulated in the Th17 cells in response to IL-12 signalling leading to increased IFNg and 
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decreased IL-17A expression79. The plasticity of Th17 cells leads to the generation of a 
heterogenic T cell subset, IL-17A+IFNg+ Th17/Th1 cells, which has been observed in SAg-
Sau-activated tonsillar MNCs. The occurrence of Th17/Th1 phenotype means enhanced 
STAT1 activation in the cells which limits STAT3 activity and its downstream IL-17 expression. 
If the STAT1 signalling keeps pushing over and perturbs the delicate balance of STAT1 and 
STAT3 in the Th17/Th1 cells, these cells may lose the expression of Th17-related genes and 
become ex-Th17 cells238. However, inhibiting the STAT1 activation could remove its 
suppression over STAT3 and thereby revive the Th17 effector phenotype234. Hence, in SAg-
Sau stimulated tonsillar MNCs, exogenous IL-10 may promote the IL-17A expression in 
Th17/Th1 and ex-Th17 cells through downregulating IFNg and the STAT1 activation it 
mediates, therefore showing positive effects on SAg-Sau-activated Th17 responses. 
 
6.9 Possible cellular mechanisms underlie IL-35-mediated Th17 
suppression 
STAT1-dependent Th17 inhibition has also been demonstrated to play a role in IL-27-
mediated suppression of pro-inflammatory Th17 responses239,240. Although IL-27 (IL-
27p28:EBI3 heterodimer) shares the gp130-STAT3 signalling with IL-6, it has contrasting 
effects on Th17 responses which is associated with the unique IL-27 receptor (IL-27R)-
mediated activation of STAT1. In STAT1-/- CD4+ T cells, IL-27-induced substantial inhibition 
of IL-17 production was abrogated240. IL-35 and IL-27 both belong to IL-12 heterodimeric 
cytokine family and they share the EBI3 subunit164. It has been shown that IL-35 could signal 
through IL-12Rb2 homodimer, gp130 homodimer and IL-12Rb2:gp130 heterodimer, activating 
STAT1, STAT4 and a unique STAT1/STAT4 heterodimer signalling respectively175 (Figure 
6.4). The IL-35-mediated suppression of Th17 responses activated by SAg-Sau shown in this 
study may be partially related to the activation of STAT1. However, given the selective 
suppression of high Th17 responses by IL-35 and the ability of IL-35 to downregulate RORgt 
expression in CD4+ T cells shown in the context of SAg-Sau stimulation, I propose that IL-35-
activated STAT1/STAT4 heterodimer may be capable of regulating the transcription of RORgt 
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directly or indirectly through inducing IL-35 expression. Hence, only Th17 cells that express 
the IL-12Rb2/gp130 heterodimer receptor can be specifically regulated by IL-35 in SAg-Sau-
infected nasopharynx. 
 
Figure 6.4 Cytokines regulate T cell responses through JAK-STAT signalling 
Schematic diagram of the JAK-STAT signalling activated by cytokines through type I and type II 
receptors in CD4+ T cells. The intracellular domains of type I and type II receptors are associated with 
JAK proteins (JAK1, JAK2, JAK3 and TYK2). Upon cytokine binding, the STATs are phosphorylated by 
the JAKs and then form active homodimers (e.g. STAT3/STAT3) or heterodimers (e.g. STAT1/STAT4), 
these dimerised STATs translocate into the nucleus and modulate gene expression. IL-6 activates 
STAT3 which together with RORgt induces the expression of Th17-related genes. However, the STAT3 
signal activated by IL-10 is shown to induce a tolerogenic gene expression profile. The IL-6-mediated 
STAT3 activation can be inhibited by IFNg-activated STAT1 and IL-2-activated STAT5 at transcription 
level, IFNg and IL-2 may thereby suppress the activation of Th17 responses. IL-35 could signal through 
gp130 homodimer and IL-12Rb2 homodimer to activate STAT1 and STAT4 signalling, but only through 
the gp130/IL-12RB2 heterodimeric receptor which activates the unique STAT1/STAT4 heterodimer can 
it induce the expression of IL-35. 
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In addition to above discussed questions/hypotheses which may explain the potential 
underlying cellular mechanisms of my findings, the pathogenicity of Th17 cells and the 
therapeutic potential of IL-35 are also interesting topics closely related to my study. Compared 
to the Th1 responses, SAg-Sau-activated Th17 responses were more resistant to T cell-
mediated immune regulation. The highly pathogenic property of Th17 cells is discussed which 
could provide rationale for the autoimmune potential of SAg-Sau-activated Th17 responses. 
IL-35 may control inflammatory/autoimmune pathologies through suppressing superantigenic 
Th17 responses. Those milestone IL-35 studies have been reviewed in Chapter 1, here I 
would like to further discuss what my study has added to the understanding of IL-35 and 
current challenges for IL-35 research which should be addressed in future studies, in order to 
develop IL-35-based immune therapy for clinical diseases. 
 
6.10 The culprit of autoimmunity, Th1 or Th17? 
In the presence of SAg-Sau, both Th1 and Th17 were potently activated but only Th1 
responses were effectively controlled by Foxp3+ Treg and IL-10. Although IL-35 was shown 
to regulate the Th17 responses, the expression of IL-35 in the tonsillar CD4+ T cells were 
markedly suppressed by SAg-Sau stimulation. The Th17 responses in the nasopharynx are 
certainly important for the host defence against bacterial and fungal infections but they need 
to be tightly controlled. Th1 and Th17 cells both are implicated in the pathogenesis of 
inflammatory/autoimmune diseases. Since the development of these two CD4+ T cell subsets 
is counter-regulated, it has been a dilemma on which subset should be primarily targeted 
when treating inflammatory conditions. The current opinions tend to suggest that Th17 cells 
are more pathogenic which is supported by a large number of studies. 
Firstly, mice with IL-12p40-deficiency (Il12p40-/-) are resistant to EAE induced by MOG peptide, 
whereas Il12p35-/- mice are susceptible241. IL-12p40 and IL-12p35 can be linked by disulphide 
bond to form the heterodimeric IL-12 which has been mentioned above for its ability to activate 
Th1 responses. Interestingly, the IL-12p40 subunit is shared by IL-23 (IL-12p40:IL-23p19 
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heterodimer) which is known to promote Th17 responses. By depleting IL-12p40, both Th1 
and Th17 responses are limited due to IL-12 and IL-23 deficiency. In Il12p35-/- mice, only IL-
12 is removed resulting in defected Th1 activation but leaving the IL-23-driven Th17 responses 
unaffected which may underlie the susceptibility of mice in EAE induction. Indeed, later studies 
have clarified the central role of Th17 cells in the pathology of autoimmune neural 
inflammation58,60. Notably, IL-12p35 can also pair with EBI3 to generate IL-35 heterodimer 
which means the Il12p35-/- mice also lack IL-35 expression leading to impaired suppression 
of Th17 responses. Though the overall clinical scores of developed EAE are comparable 
between Il12p35-/- and wild type mice, IL-12p35-deficiency has led to a higher production of 
nitric oxide (NO) in MOG-stimulated MNCs and an increase in TNF-a expression by lesional 
macrophages, which may correlate with the enhanced Th17 activation241. 
Secondly, genetic deletion of IFNg cannot prevent the animal from developing EAE and 
increased mortality is observed in mice with IFN-gamma receptor (IFNGR) deficiency49,242. 
The paradoxical role of IFNg-producing Th1 cells in autoimmunity is also manifested in 
collagen-induced arthritis (CIA), a murine model of rheumatoid arthritis, in which IFNGR 
deficiency has resulted in an accelerated onset of disease and more severe clinical 
symptoms243,244. Moreover, the loss of T-bet, the transcription factor that drives the 
development of Th1 cells, leads to a severe autoimmune heart disease which is associated 
with markedly increased Th17 responses51. Th17 cells also express T-bet but the Th17-
mediated autoimmune inflammation is T-bet-independent, because T-bet-/- Th17 cells are still 
capable of inducing autoimmunity following adoptive transfer50,245.    
Finally, results obtained from clinical trials show biological agents that target IL-17A and IL-
17RA have better efficacy than IL-12p40 monoclonal antibody (mAb) which affects both Th1 
and Th17 in treating a wide range of autoimmune diseases, such as psoriasis, multiple 
sclerosis, rheumatoid arthritis and ankylosing spondylitis37. This suggests pro-inflammatory 
Th17 cells are at the centre of autoimmunity and Th1 responses may have certain beneficial 
effects through counteracting the development of Th17 cells. 
Collectively, all these experimental and clinical evidences support that an uncontrolled Th17 
response is likely to place the host at high risk of developing inflammatory/autoimmune 
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conditions. The SAg-Sau infection of nasopharynx has been shown in my study to activate 
potent Th17 responses in the NALT which cannot be effectively controlled by T cell-mediated 
immune suppression. My results therefore suggest SAg-Sau-mediated Th17 activation may 
underlie the mechanism of those inflammatory and autoimmune diseases associated with Sau 
infection.  
 
6.11 IL-35 may have therapeutic potential for the treatment of 
autoimmune diseases 
In this study, I have demonstrated that IL-35 is able to suppress highly activated Th17 
response upon SAg-Sau stimulation in human NALT. IL-35-mediated suppression of Th17 
activation and its therapeutic effects against CIA, IBD, EAE and uveitis have also been 
illustrated by previous studies in mice95,97,99,100. However, these IL-35-targeted murine studies 
cannot be fully translated into human studies due to the different expression profile of IL-35 in 
human T cells. In mice, IL-35 is primarily expressed by Foxp3+ Tregs and can be induced in 
Tconvs by IL-35 itself94,97. However, human Foxp3+ Tregs are not shown to express IL-35 with 
or without stimulation101. To induce IL-35 expression in Tconvs, longer period of stimulation is 
required by human Tconvs (9-day compared to the 3-day induction period in mice), and the 
protein expression and secretion of the heterodimeric IL-35 in human PBMC-derived Tconvs 
are not confirmed following induction94. I showed here that human tonsillar CD4+ T cells 
expressed heterodimeric IL-35 using immunoprecipitation, indicating that IL-12p35 and EBI3 
subunits expressed in human CD4+ T cells can be associated to form IL-35. Although the level 
of IL-35 expression was lower than expected, the efficacy of cytokine was not absolutely 
determined by its concentration that can be detected by current methods. 
The stability of IL-35 heterodimer affects its biological activity. Unlike IL-12 subunits, IL-12p40 
and IL-12p35, which are linked by disulphide bond to maintain a stable structure of the 
heterodimer, the subunits of IL-35, IL-12p35 and EBI3 are dimerised depending on pure 
protein-protein interactions164,246. Detection of IL-35 in human peripheral blood has been 
repeatedly reported by various studies. The stability of IL-35 may rely on an additional 
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unidentified protein subunit binding to it. Specific binding proteins and soluble receptors that 
could affect the biological activity of cytokines, such as IL-18 and IL-15, has been 
demonstrated previously247,248. Currently, the widely used IL-35 recombinant protein is 
constructed by covalently linking EBI3 with the IL-12p35-Fc fusion protein95. This Fc-linked 
recombinant IL-35 is used in most of the experiments of this study. However, a CHO cell line 
that express native form of human IL-35 was constructed by our collaborators from Cardiff 
University and the biological activity of the native IL-35 was tested in my study and confirmed 
that it suppressed SAg-Sau-activated Th17 responses similarly as the Fc-linked IL-35. The 
native IL-35 used was not in purified form but was applied to the cell cultures as conditioned 
medium harvested from the IL-35-producing CHO cells. Hence, whether the native IL-35 can 
be efficiently purified without compromising its biological activity remains unknown. IL-35 is a 
potential therapeutic cytokine for inflammatory/autoimmune diseases, therefore a more 
stabilised recombinant protein preparation needs to be developed by future studies through 
identifying the potential binding protein or a possible chemical cross linking of the two protein 
subunits. 
Studies have demonstrated the promising effects of IL-35 in controlling inflammatory and 
autoimmune pathologies, but how IL-35 expression is regulated in inflammatory conditions 
and what cellular and molecular mechanisms, particularly for those involved in IL-35-mediated 
suppression of Th17 responses need to be studied in detail. My key finding in this study was 
to show a significantly downregulated IL-35 expression in tonsillar CD4+ T cells by SAg-Sau 
stimulation in human NALT, which was a potential mechanism of the potently induced 
superantigenic Th17 response. Furthermore, this Th17 response could not be suppressed by 
Foxp3+ Tregs and IL-10, but were effectively controlled by exogenous IL-35, providing the 
rationale to further investigate the application of recombinant IL-35 in clinical diseases that 





My study highlights a critical cellular mechanism of Th17 activation in SAg-Sau-infected 
human nasopharynx, whereby IL-35 is identified as a key suppressive cytokine in controlling 
superantigen-driven Th17 responses. Foxp3+ Tregs and IL-10 are known to play pivotal roles 
in suppressing CD4+ T cell-mediated pro-inflammatory responses114,146. SAg-Sau was shown 
to induce Foxp3+ Treg expansion and promote IL-10-producing CD4+ T cells. SAg-Sau-
expanded Tregs exhibited enhanced expression of IL-17A and defective suppressive function 
that may contribute to inflammatory pathologies. Whist SAg-Sau-activated Th1 responses can 
be suppressed by increased Treg and IL-10 levels, the Th17 responses were not affected. 
Instead, IL-35 expression in tonsillar CD4+ T cells was markedly downregulated by SAg-Sau 
and addition of recombinant IL-35 suppressed highly activated Th17 responses. My data 
suggest that IL-10 and IL-35 have reciprocal regulatory effects on SAg-Sau-activated 
inflammatory Th1 and Th17 responses, thereby making them potential targets for therapy 
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Figure 7.2 Melting curve and DNA gel image (mouse genes) 







Figure 8 Purification of CD4+ T cells from human tonsillar MNCs and mouse CLN MNCs 
CD4+ T cells were separated by magnetic cell sorting as described in the 2.8. Dot plots showing 
percentages of CD3+CD4+ cells (numbers in top right quadrants) in unfractionated MNCs and CD4+ cell-








Figure 9 SAg-Sau stimulated cytokine production in unfractionated MNCs and CD4+ T 
cell-depleted MNCs 
Unfractionated MNCs and CD4+ T cells-depleted MNCs were stimulated by 1 µg/ml of SAg-Sau for 48 
hours. Cell culture supernatants were collected, and the cytokine production were detected by CBA. 
